indazoles has been researched along with pazopanib in 1030 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 26 (2.52) | 29.6817 |
| 2010's | 809 (78.54) | 24.3611 |
| 2020's | 195 (18.93) | 2.80 |
| Authors | Studies |
|---|---|
| Mancuso, A; Sternberg, CN | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Ishitsuka, K; Kumar, R; Kumar, S; Legouill, S; Pandite, LN; Podar, K; Sattler, M; Tai, YT; Tonon, G; Yasui, H | 1 |
| Hutson, TE; Sonpavde, G | 1 |
| Boloor, A; Cheung, M; Crosby, RM; Crouthamel, MC; Epperly, AH; Gilmer, TM; Harrington, LE; Hopper, TM; Johnson, JH; Knick, VB; Kumar, R; Luttrell, DK; Miller, CG; Mullin, RJ; Onori, JA; Rudolph, SK; Stafford, JA; Truesdale, AT | 1 |
| Kibble, A; Shumoogam, J; Walker, K | 1 |
| LaGerche, A; Toner, GC; Whitbourn, RJ; White, AJ | 1 |
| Hutson, TE; Sonpavde, G; Sternberg, CN | 2 |
| Kaye, SB | 1 |
| Boloor, A; Cheung, M; Crosby, RM; Davis-Ward, RG; Epperly, AH; Harris, PA; Hinkle, KW; Hunter, RN; Johnson, JH; Knick, VB; Kumar, R; Laudeman, CP; Luttrell, DK; Mook, RA; Nolte, RT; Rudolph, SK; Stafford, JA; Szewczyk, JR; Truesdale, AT; Veal, JM; Wang, L | 1 |
| Bukowski, RM; Vakkalanka, BK | 1 |
| Scheinfeld, NS; Sloan, B | 1 |
| Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B | 1 |
| Campochiaro, PA; King, AG; Levin, R; Saishin, Y; Takahashi, K | 1 |
| Rini, BI | 2 |
| Bahlis, N; Baker, KL; Bell, B; Benjamin Suttle, A; Demarini, DJ; Hönemann, D; Pandite, LN; Prince, HM; Rizzieri, DA; Roberts, AW; Spencer, A; Stadtmauer, EA; Tricot, G | 1 |
| Chen, TK; Kord, AS; Liu, DQ; McGuire, MA | 1 |
| Blay, JY; Collin, F; De Brauwer, A; Le Cesne, A; Marreaud, S; Pandite, L; Papai, Z; Ray-Coquard, I; Schöffski, P; Scurr, M; Sleijfer, S; van Glabbeke, M; Verweij, J | 1 |
| Dowlati, A; Gibson, DM; Hodge, JP; Hurwitz, HI; Merkle, EM; Pandite, L; Saini, S; Savage, S; Suttle, AB | 1 |
| Charlton, A; Chong, ML; Dar, M; Davids, M; Davids, MS; Goh, BC; Hodge, J; Laubscher, K; Ng, SS; Soong, R | 1 |
| Commo, F; Dessen, P; Kroemer, G; Lacroix, L; Lazar, V; Olaussen, KA; Raza, SQ; Richon, C; Soria, JC; Tailler, M; Vitale, I | 1 |
| Gee, J; Harrison, MR; Huang, W; Liu, G | 1 |
| Crouthamel, MC; Gontarek, RR; King, AG; Kumar, R; Levin, RA; Rominger, DH; Tummino, PJ | 1 |
| Castaneda, CA; Gomez, HL | 1 |
| Sherman, SI | 1 |
| Limvorasak, S; Posadas, EM | 1 |
| Baker, KL; Crofts, T; Davis, ID; De Souza, PL; Epstein, RJ; Figlin, RA; Hong, BF; Hutson, TE; Machiels, JP; McCann, L; Pandite, L; Rottey, S | 1 |
| Bukowski, RM; Kirkpatrick, P; Yasothan, U | 1 |
| Barrios, CH; Chen, M; Davis, ID; Gladkov, OA; Hawkins, RE; Kavina, A; Lee, E; Mardiak, J; McCann, L; Pandite, L; Roychowdhury, DF; Salman, P; Sternberg, CN; Szczylik, C; Wagstaff, J; Zarbá, JJ | 1 |
| Bhanushali, DS; Kord, AS; Li, Y; Liu, DQ; McGuire, MA; Sudini, R; Yang, S | 1 |
| Abrey, LE; Butowski, NA; Chang, SM; Deangelis, LM; Fine, HA; Iwamoto, FM; Lamborn, KR; Mehta, MP; Prados, MD; Robins, HI; Zhang, WT | 1 |
| Altorki, N; Bordogna, W; Heymach, JV; Nikolinakos, PG; Ottesen, LH; Rajagopalan, D; Tran, HT; Yan, S; Yankelevitz, D | 1 |
| Carroll, AR; Coleman, RL; Dumble, M; Jennings, N; Kamat, AA; Kumar, R; Lin, YG; Lu, C; Matsuo, K; Merritt, WM; Nick, AM; Shahzad, MM; Sood, AK; Spannuth, WA; Stone, RL; Zhang, S | 1 |
| Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P | 1 |
| Choueiri, TK | 1 |
| Baker, KL; Cardon, LR; Chen, EP; Chen, M; Ellens, HE; Huang, L; Mooser, VE; Pandite, L; Reck, BH; Spraggs, CF; Xu, CF; Xue, Z | 1 |
| LaPlant, KD; Louzon, PD | 1 |
| Choueiri, TK; Schutz, FA; Sternberg, CN | 1 |
| Bukowski, RM | 1 |
| Deville, JL; Duffaud, F; Huynh, T; Salas, S | 1 |
| Sternberg, CN | 1 |
| Böhm, S; Brändle, M; Gillessen, S; Hess, D | 1 |
| Hamberg, P; Sleijfer, S; Verweij, J | 1 |
| Betof, AS; Dewhirst, MW; Dreher, MR; Hanna, G; Nixon, AB; Spasojevic, I; Tailor, TD; Yarmolenko, PS | 1 |
| Ratain, MJ | 1 |
| Bible, KC; Burton, JK; Erlichman, C; Ivy, SP; Menefee, ME; Sideras, K | 1 |
| Altorki, N; Bauer, T; Felip, E; Grannis, FW; Guarino, MJ; Gurpide, A; Huff, A; Lane, ME; Lee, PC; Mitchell, JD; Ottesen, LH; Pass, H; Peylan-Ramu, N; Reeves, A; Roychowdhury, DF; Swann, RS; Tachdjian, S; Yankelevitz, DF | 1 |
| Jeldres, C; Karakiewicz, PI; Perrotte, P; Sun, M | 1 |
| Datta, J; Jacob, ST; Kutay, H; Motiwala, T; Roy, S | 1 |
| Erdfelder, F; Filipovich, A; Gandhirajan, RK; Gehrke, I; Hallek, M; Hertweck, M; Kreuzer, KA; Paesler, J; Poll-Wolbeck, SJ; Uhrmacher, S | 1 |
| Friedlander, M; Hancock, KC; Hodge, JP; Lager, JJ; Ma, B; Matthys, GM; Messing, MJ; Rischin, D; Stringer, CA | 1 |
| Figlin, RA; Pal, SK | 2 |
| Alber, JA; Ding, J; Mas Lopez, L; Monk, BJ; Oaknin, A; Pandite, LN; Stutts, MW; Tarpin, C; Termrungruanglert, W; Zarba, JJ | 1 |
| Chen, E; Coatney, RW; Davis, CB; Frazier, KS; French, KJ; Gales, TL; Hu, CX; McSurdy-Freed, J; Renninger, JP; Storck, LM; Zhao, S | 1 |
| Keating, GM; Sanford, M | 1 |
| Agulnik, M; Chia, S; Clemons, M; Dent, S; Grenci, P; Ivy, P; Leighl, NB; Oza, AM; Pritchard, KI; Taylor, SK; Wang, L | 1 |
| Gore, M; Larkin, J | 1 |
| Bible, KC; Bieber, C; Burton, JK; Erlichman, C; Flynn, PJ; Goh, BC; Ivy, SP; Maples, WJ; McIver, B; Menefee, ME; Molina, JR; Morris, JC; Rubin, J; Sideras, K; Smallridge, RC; Suman, VJ; Tang, H; Traynor, AM; Webster, KP | 1 |
| Schlumberger, M | 1 |
| Arumugham, T; Dandamudi, UB; Dar, MM; Goh, BC; Hodge, JP; Lager, J; Laubscher, KH; Lewis, LD; Peckham, T; Reddy, NJ; Suttle, AB; Xu, CF; Xu, Y | 1 |
| Ghazaly, E; Joel, S; Kitromilidou, C; McGrowder, EH; Perry, J; Powles, T | 1 |
| Arumugham, T; Chiorean, EG; Dar, MM; Forman, K; Gainer, SD; Heath, EI; Hodge, JP; Lager, JJ; LoRusso, P; Malburg, L; Suttle, AB; Sweeney, CJ | 1 |
| Stadler, WM; Ward, JE | 1 |
| Gril, B; Ileva, L; Liewehr, DJ; Palmieri, D; Qian, Y; Smart, D; Steeg, PS; Steinberg, SM | 1 |
| Biglietto, M; Buonerba, C; Cartenì, G; Chiurazzi, B; Di Lorenzo, G; Riccardi, F; Scognamiglio, F | 1 |
| Barnes, MR; Cardon, LR; Goodman, VL; Huang, L; Koshy, B; Mooser, VE; Pandite, LN; Reck, BH; Spraggs, CF; Xu, CF; Xue, Z | 1 |
| Arumugham, T; Burris, HA; Dar, MM; Dowlati, A; Fang, L; Gainer, SD; Hodge, JP; Infante, JR; Jones, SF; Lager, JJ; Nishioka, J; Suttle, AB; Tan, AR | 1 |
| Biró, K; Küronya, Z | 1 |
| Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
| Ding, H; Fan, PL; Gao, DM; Kong, LQ; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Balagula, Y; Feldman, DR; Lacouture, ME; Su, X; Wu, S | 1 |
| Keisner, SV; Shah, SR | 1 |
| Maráz, A | 1 |
| Al-Marrawi, MY; Rini, B | 1 |
| Rexer, H | 3 |
| Karakiewicz, PI; Maurin, C; Perrotte, P; Sun, M; Thuret, R | 1 |
| Griffiths, C; Hay, N; Stevens, A; Sutcliffe, F | 1 |
| Flaig, TW; Li, Y; Su, LJ; Yang, X | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Ball, HA; Bing, NX; Cardon, LR; de Souza, P; Hutson, TE; King, KS; McCann, L; Mooser, VE; Pandite, LN; Ragone, LJ; Rajagopalan, D; Spraggs, CF; Sternberg, CN; Whittaker, JC; Xu, CF; Xue, ZG | 1 |
| Eichler, W; King, AG; Lange, J; Niemeyer, M; Nishiwaki, A; Wiedemann, P; Yafai, Y; Yang, XM; Yasukawa, T | 1 |
| Antràs, L; Cella, D; Duh, MS; Guerin, A; Hodge, R; McCann, L; Mishagina, N; Neary, MP; Pickard, AS; Sternberg, CN | 1 |
| Chan, AL; Leung, HW | 1 |
| Chowbay, B; Gao, F; Goh, BC; Ivy, P; Koh, TS; Leong, SS; Lim, WT; Ng, QS; Singh, O; Tan, DS; Tan, EH; Thng, CH; Toh, CK | 1 |
| Bergmann, L; Gschwend, J; Keilholz, U; Miller, K | 1 |
| Atkinson, B; Choueiri, TK; Chowdhury, S; Matrana, MR; Tannir, NM; Tsang, C | 1 |
| Baruchel, S; Kerbel, RS; Kumar, S; Man, S; Mokhtari, RB; Oliveira, ID; Sheikh, R; Wu, B; Xu, P; Yeger, H; Zhang, L | 1 |
| Barranger, E; Camus, M; Eveno, C; le Maignan, C; Pocard, M; Soyer, P | 1 |
| Adams, L; Ball, H; Forman, K; Gainer, S; Heath, EI; LoRusso, P; Malburg, L; Suttle, AB | 1 |
| Lim, ZD; Matrana, MR; Ng, C; Rao, P; Tannir, NM | 1 |
| Chan, P; Chen, PJ; Curtis, CM; Dar, MM; Gauvin, J; Hodge, JP; Murphy, PS; Poon, RT; Suttle, AB; Yau, T | 1 |
| Canter, D; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Simhan, J; Uzzo, RG | 1 |
| Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K | 1 |
| Joly, F | 1 |
| Kompella, UB; Rao, VR; Scheinman, RI; Thakur, A | 1 |
| Bourdeanu, L; Pal, SK; Twardowski, P | 1 |
| Grünberger, B | 1 |
| Abadie, E; Borregaard, J; Ersbøll, J; Nieto, M; Pignatti, F; Schellens, JH; ten Bosch, GJ; van Zwieten-Boot, B | 1 |
| Canter, DJ; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Simhan, J; Sirohi, M; Street, R; Uzzo, RG | 1 |
| Anwar, T; Bernardo, M; Choyke, P; Gril, B; Ileva, L; Liewehr, DJ; Palmieri, D; Qian, Y; Steeg, PS; Steinberg, SM | 1 |
| Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V | 1 |
| Chatta, G; Hussain, M; Karrison, T; O'Donnell, PH; Posadas, EM; Shevrin, D; Stadler, WM; Szmulewitz, RZ; Ward, JE | 1 |
| Bischofs, E; Eichbaum, M; Eickhoff, R; Fehm, T; Fersis, N; Fricke, HC; Gebauer, G; Lenz, F; Mayer, C; Schmidt, M; Schneeweiss, A; Sohn, C; Solomayer, E; Wallwiener, M | 1 |
| Hohenberger, P; Kasper, B | 1 |
| Koc, G; Luo, Y; Wang, X | 1 |
| Houghton, PJ; Keir, ST; Kurmasheva, RT; Morton, CL; Smith, MA; Wu, J | 1 |
| Amiri-Kordestani, L; Swain, SM; Tan, AR | 1 |
| Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Curtis, LB; du Bois, A; Harter, P; Mitrica, I; Ray-Coquard, I; Vergote, I; Wimberger, P | 1 |
| Choueiri, TK; Je, Y; Richards, CJ; Schutz, FA | 1 |
| Buonerba, C; De Placido, S; Di Lorenzo, G | 1 |
| Nystrom, KK; Pick, AM | 1 |
| Gupta, GN; Singer, EA; Srinivasan, R | 1 |
| Chiba, K; Horiuchi, K; Hosaka, S; Morioka, H; Nakamura, M; Nakayama, R; Susa, M; Tohmonda, T; Toyama, Y; Yoda, M | 1 |
| Jonasch, E; Kim, BY; McCutcheon, IE | 1 |
| Becze, E | 2 |
| Döme, B; Török, S | 1 |
| Haddad, H; Rini, BI | 1 |
| Haritoglou, C; Hirneiss, C; Kampik, A; Kernt, M; Koenig, S; Neubauer, AS; Thiele, S; Ulbig, MW | 1 |
| Cooks, RG; Espy, RD; Manicke, NE; Ouyang, Z | 1 |
| Bramwell, VH | 1 |
| Aglietta, M; Araki, N; Beppu, Y; Blay, JY; Bui-Nguyen, B; Casali, PG; Chawla, SP; Coens, C; Dei Tos, AP; Demetri, GD; Dewji, MR; Fletcher, CD; Gelderblom, H; Hodge, R; Hohenberger, P; Judson, IR; Kim, DW; Le Cesne, A; Marreaud, S; Ouali, M; Schöffski, P; Staddon, AP; van der Graaf, WT | 1 |
| Ball, HA; Burris, HA; Dar, MM; Dowlati, A; Gainer, SD; Infante, JR; Jones, SF; Levinson, KT; Lindquist, D; Moss, RA; Spigel, DR; Suttle, AB; Tan, AR | 1 |
| Khurana, V; Minocha, M; Mitra, AK; Pal, D; Qin, B | 1 |
| Schöffski, P | 1 |
| Carta, F; Maresca, A; Scozzafava, A; Supuran, CT; Winum, JY | 1 |
| Beijnen, JH; Schellens, JH; van Geel, RM | 1 |
| Cleary, J; Howard, SA; Jagannathan, JP; Krajewski, KM; O'Regan, K; Ramaiya, N; Thornton, E | 1 |
| Khurana, V; Minocha, M; Mitra, AK | 1 |
| Ray-Coquard, I; Thomas, D | 1 |
| Shariat, SF; Xylinas, E | 1 |
| Amado, RG; Baker-Neblett, KL; Figlin, RA; Heymach, JV; Hutson, TE; Lin, Y; Liu, Y; Martin, AM; Pandite, LN; Sternberg, CN; Tran, HT; Zurita, AJ | 1 |
| Boleti, E; Chowdury, S; Crabb, SJ; Jones, R; Nathan, P; Powles, T; Protheroe, A; Rashid, S; Sarwar, N; Shamash, J; Stockdale, A; Wilson, P | 1 |
| Bible, KC; Bieber, C; Bossou, AR; Burton, JK; Erlichman, C; Goh, BC; Harris, P; Isham, CR; Karlin, NJ; Kukla, AK; Kumar, P; Lim, WT; Maples, WJ; Menefee, ME; Molina, JR; Smallridge, RC; Suman, VJ; Traynor, AM; Webster, KP | 1 |
| Halfdanarson, TR; Naraev, BG; Strosberg, JR | 1 |
| Atkins, MB; Choueiri, TK; Doyle, LA; Klempner, SJ; Schuppan, D; Yee, E | 1 |
| Blay, JY; Burger, H; Collin, F; Gorlia, T; Hohenberger, P; Lamers, C; Le Cesne, A; Marreaud, S; Pandite, L; Scurr, M; Sleijfer, S | 1 |
| Galsky, MD | 1 |
| Crippa, F; Daidone, MG; De Braud, F; Giannatempo, P; Gianni, AM; Lanocita, R; Mariani, L; Messina, C; Morosi, C; Necchi, A; Nicolai, N; Ortega, C; Pennati, M; Sacco, C; Salvioni, R; Sava, T; Schwartz, LH; Zaffaroni, N | 1 |
| Cerbone, L; Recine, F; Sternberg, CN; Zivi, A | 1 |
| Issels, RD; Lindner, LH | 1 |
| Ahmed, TT; Beijnen, JH; Muilwijk, EW; Schellens, JH; Sparidans, RW; Welzen, ME | 1 |
| Bing, N; de Souza, PL; Goodman, VL; King, KS; McCann, LA; Mooser, VE; Pandite, LN; Spraggs, CF; Xu, CF; Xue, Z | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Arumugham, T; de Jonge, MJ; Hamberg, P; Hodge, J; Hurwitz, HI; Pandite, LN; Savage, S; Suttle, AB; Verweij, J | 1 |
| Carmichael, C; Ferrell, B; Hsu, J; Lau, C; Liu, X; Pal, SK; Saikia, J; Sun, V; Wilson, T; Yuh, BE | 1 |
| Ball, HA; Botbyl, J; Gibson, DM; Jeffels, M; Madi, A; Nokay, B; Plummer, R; Richly, H; Rubin, S; Scheulen, ME; Weller, S | 1 |
| Deeks, ED | 1 |
| Araki, N; Itoh, K; Naka, N; Tanaka, T; Wakamatsu, T; Yoshikawa, H; Yoshioka, K; Yui, Y | 1 |
| Amarantidis, K; Chamalidou, E; Chelis, L; Christakidis, E; Dimopoulos, P; Kakolyris, S; Michailidis, P; Prassopoulos, P; Souftas, V; Xenidis, N | 1 |
| Chmielowski, B; Federman, N; Tap, WD | 1 |
| Backes, M; Bode-Erdmann, S; Greulich, S; Hebart, H; Kaufmann, M; Mahrholdt, H; Ong, P; Ott, G; Schumm, J | 1 |
| Adjei, AA; Burris, HA; Dy, GK; Eckhardt, SG; Huff, A; Infante, JR; Jones, SF; Ma, WW; Novello, S; Ottesen, LH; Suttle, AB; Wang, Q | 1 |
| Adamson, P; Campochiaro, PA; Gale, DC; Hashida, N; Iwase, T; Krauss, AH; Lima e Silva, R; Oveson, BC; Shen, J | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Adjei, AA; Allen, R; Bendell, JC; Burris, HA; Dy, GK; Huff, A; Infante, JR; Ma, WW; Novello, S; Ottesen, LH; Suttle, AB; Wang, Q; Xu, CF | 1 |
| Asaithambi, G; Hurliman, E; Khan, AS; Moran, BP; Peters, BR; Taylor, RA | 1 |
| Alfonso-Bartolozzi, B; Amparo, F; Chodosh, J; Ciolino, JB; Dana, R; Jin, Y; Jurkunas, U; Sadrai, Z; Schaumberg, DA; Shikari, H; Wang, H | 1 |
| Alvarez, RH; Blackwell, KL; Cristofanilli, M; Gladkov, O; Gomez, HL; Johnston, SR; Manikhas, A; Ranganathan, S; Redhu, S; Rubin, SD; Safina, S; Shao, Z; Trudeau, ME | 1 |
| Cappelleri, JC; Chen, C; Foley, G; Healey, PJ; Kroes, M; Larkin, J; Mitchell, S; Paine, A; Tumur, I | 1 |
| Borker, R; Fonseca, E; Hess, G | 1 |
| Pal, SK; Vogelzang, NJ | 1 |
| Bible, KC; Bossou, AR; Copland, JA; Fisher, KE; Isham, CR; Kumar, R; Lingle, WL; Marlow, L; Negron, V; Sherman, EJ; Smallridge, RC; Suman, VJ | 1 |
| Durante, M; Gómez, H; Goodman, V; Johnston, SR; Pandite, L; Richie, M; Slamon, D; Stemmer, SM | 1 |
| Arai, H; Fukasawa, N; Ueta, F | 1 |
| Alasker, A; Bianchi, M; Hanna, N; Hansen, J; Ismail, S; Karakiewicz, PI; Meskawi, M; Perrotte, P; Sun, M; Tian, Z | 1 |
| Brugarolas, J; Jacobs, C; Kim, DW; Straka, C; Timmerman, RD | 1 |
| Barrios, CH; Chen, M; Davis, ID; Gladkov, OA; Hawkins, RE; Lee, E; Mardiak, J; McCann, L; Rubin, SD; Salman, P; Sternberg, CN; Szczylik, C; Wagstaff, J; Zarba, JJ | 1 |
| Bissett, D; Elders, A; Fraser, C; Hislop, J; Kilonzo, M; McClinton, S; Mowatt, G; Vale, L | 1 |
| Ball, HA; Dar, MM; Heath, EI; Infante, J; Kasubhai, S; Kleha, JF; Lewis, LD; LoRusso, P; Luu, T; Ma, B; Stephenson, J; Suttle, AB; Tan, AR | 1 |
| Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY | 1 |
| Bowlin, SJ; Robinson, KD; Stanek, EJ; Wang, W; Xia, F | 1 |
| Arumugham, T; de Souza, P; Suttle, AB | 1 |
| Adamson, P; Bainbridge, JW; Coffey, P; Ju, M; King, AG; Lange, CA; Lee, D; Lundh von Leithner, P; Ng, YS; Robbie, SJ; Shima, DT; Sychterz, C | 1 |
| Arndt, C; Ecke, TH; Eimer, C; Georgas, E; Gerullis, H; Otto, T | 1 |
| Jones, R | 1 |
| Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS | 1 |
| Cohen, JE; Cohen, Y; Doviner, V; Goldshmidt, H; Katz, D; Orevi, M; Peylan-Ramu, N; Rubinstein, R; Zick, A | 1 |
| Sleijfer, S; Verweij, J | 1 |
| Eibl, K; Haritoglou, C; Kampik, A; Kernt, M; König, S; Langer, J; Liegl, RG; Siedlecki, J; Thiele, S | 1 |
| Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E | 1 |
| Bershas, D; Chen, EP; Dar, MM; Deng, Y; Gorycki, PD; Ho, MY; Negash, K; Qian, Y; Suttle, AB; Sychterz, C | 1 |
| Hunt, CM; Spraggs, CF; Xu, CF | 1 |
| Robert, C; Sibaud, V | 1 |
| Berney, D; Bex, A; Blank, C; Boleti, E; Chowdhury, S; Haanen, J; Jones, R; Kayani, I; Lim, L; Peters, J; Powles, T; Reynolds, AR; Sahdev, A; Shamash, J; Sharpe, K; Stewart, GD | 1 |
| Andreu, Z; Anwar, T; Fernández, P; Gril, B; Liewehr, DJ; Masana, D; Palmieri, D; Qian, Y; Steeg, PS; Steinberg, SM; Vidal-Vanaclocha, F | 1 |
| Choueiri, TK; Hapani, S; Kapadia, S; Wu, S | 1 |
| Büchler, T; Finek, J; Hájek, J; Kocák, I; Kubácková, K; Lakomý, R; Melichar, B; Petruzelka, L; Poprach, A; Siffnerová, M; Tomásek, J; Vyzula, R; Zemanová, M | 1 |
| Caulfield, TR; Cooper, SJ; Copland, JA; Marlow, LA; Tan, WW; Tun, HW; von Roemeling, CA; Wei, JJ; Wu, K | 1 |
| Botbyl, J; Edenfield, JW; Gibbon, DG; Gregory, C; Lindquist, D; Martin, JC; Stein, MN; Stephenson, JJ; Suttle, AB; Tada, H; Tan, AR | 1 |
| Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T | 1 |
| Belani, CP; Chung, V; Dowlati, A; Gandhi, L; Hamilton, AL; Harvey, RD; Ivy, SP; Kummar, S; Lau, SC; Lenz, HJ; Longmate, JA; LoRusso, P; Mulkerin, DL; Newman, EM; O'Neil, BH; Ottesen, LH; Rudek, MA; Sarantopoulos, J; Shibata, SI; Suttle, AB; Synold, TW | 1 |
| Arrowsmith, ER; Crane, EJ; Franco, LA; Hainsworth, JD; Khatcheressian, J; Rubin, MS | 1 |
| Meyer, CF; Trent, JC; Wilky, BA | 1 |
| Christensen, S; Dutia, MP; Eddings, C; Lara, PN; Semrad, TJ | 1 |
| Bonate, PL; Suttle, AB | 1 |
| Bono, P; Joensuu, H; Peltola, K; Rautiola, J; Utriainen, T | 1 |
| De Tursi, M; Felici, A; Lo Re, G; Milella, M; Ricotta, R; Ruggeri, EM; Sabbatini, R; Santini, D; Santoni, M; Vaccaro, V | 1 |
| Beauchamp, EM; Getz, G; Gray, NS; Haddad, RI; Hammerman, PS; Hayes, DN; Jung, J; Liao, RG; Liu, Q; Meyerson, M; Pedamallu, CS; Pugh, TJ; Sivachenko, A; Tchaicha, J; Wilkerson, MD; Wong, KK | 1 |
| Atkinson, BJ; Charnsangave, C; Corn, P; Duran, C; Jonasch, E; Matrana, MR; Millikan, RE; Pagliaro, LC; Shetty, A; Tannir, NM; Xiao, L | 1 |
| Ahern, CH; Baruchel, S; Blaney, SM; Glade Bender, JL; Harris, P; Ingle, AM; Lee, A; Reid, JM; Roberts, T; Voss, SD; Weigel, BJ; Wu, B | 1 |
| Bahamon, B; Baker-Neblett, KL; Brown, V; Carpenter, C; Choueiri, TK; Fay, AP; Gagnon, R; Hutson, TE; Lin, Y; Liu, Y; Pandite, L; Rosenberg, JE; Signoretti, S | 1 |
| Amantini, C; Berardi, R; Bonfili, L; Burattini, L; Cascinu, S; Eleuteri, AM; Farfariello, V; Liberati, S; Morelli, MB; Mozzicafreddo, M; Nabissi, M; Santoni, G; Santoni, M | 1 |
| Bozzi, F; Casali, PG; Cominetti, D; Gronchi, A; Libertini, M; Messina, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S; Tamborini, E; Tortoreto, M; Zaffaroni, N | 1 |
| Erlichman, C; Flynn, PJ; Ho, WM; Miles, KM; Millward, M; Picus, J; Pili, R; Pitot, H; Qin, R; Tan, W; Vaishampayan, U | 1 |
| Soulières, D | 1 |
| Barney, BM; Bauer, HJ; Laack, NN; Macdonald, OK; Markovic, SN; Miller, RC; Olivier, KR; Sarkaria, JN | 1 |
| Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Casanovas, O; Condom, E; Del Muro, XG; Germà, JR; Graupera, M; Juliachs, M; Piulats, JM; Vidal, A; Villanueva, A; Viñals, F | 1 |
| Manson, SC; Penel, N; Powell, S; Sharma, S; Takyar, S | 1 |
| Füessl, HS; Stiefelhagen, P | 1 |
| Boleti, E; Cella, D; Choueiri, TK; Crescenzo, R; De Giorgi, U; de Souza, P; Deen, K; Fife, K; Guo, J; Hackshaw, MD; Harmenberg, U; Hawkins, R; Hutson, TE; Jin, J; Jones, R; McCann, L; Merchan, JR; Motzer, RJ; Nathan, P; Pandite, LN; Reeves, J; Staehler, M; Sternberg, CN; Uemura, H; Wang, J | 1 |
| Heng, DY; Molina, AM; Motzer, RJ | 1 |
| Garcia-Donas, J; Jonasch, E; Rodriguez-Antona, C | 1 |
| Ahn, HK; Choi, JY; Choi, SH; Kang, WK; Kim, H; Kim, KM; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Hernández-Pastor, LJ; Villa, G | 1 |
| Harstead, KE; Stewart, CF; Throm, SL; Tillmanns, TD; Turner, DC | 1 |
| Broom, RJ; Dranitsaris, G; Schmitz, S | 1 |
| Ammendola, M; Citraro, R; De Sarro, G; Donato Di Paola, E; Gadaleta, CD; Gallelli, L; Mammì, M; Marech, I; Ranieri, G; Russo, E | 1 |
| Alesini, D; Cascinu, S; Cortesi, E; De Marchis, L; Iacovelli, R; Naso, G; Palazzo, A; Santoni, M; Trenta, P | 1 |
| Chauhan, VS; Kadam, RS; Kompella, UB; Panda, JJ; Yandrapu, S | 1 |
| Carpenter, C; Choueiri, TK; Deen, KC; Johnson, T; Motzer, RJ; Pandite, LN; Xu, CF; Xue, Z | 1 |
| Bodoky, G; Bodrogi, I; Csejtei, A; Dank, M; Géczi, L; Küronya, Z; Mangel, L; Maráz, A; Petrányi, A; Szûcs, M | 1 |
| Kim, RY; McLaughlin, MM; Paglione, MG; Slakter, J; Suttle, AB; Tolentino, M; Xu, CF; Ye, L | 1 |
| Feng, J; Jia, Y; Pan, H; Xu, F; Xu, W; Zhang, J | 1 |
| Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M | 1 |
| Linehan, WM; Srinivasan, R | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Abe, K; Asai, M; Koike, Y; Ogawa, F; Tanioka, M; Tomita, H; Utani, A | 1 |
| Azad, A; Maddison, C; Stewart, J | 1 |
| Danis, R; Johnson, MW; Kim, RY; McLaughlin, MM; Staurenghi, G; Tolentino, M; Xu, CF; Ye, L | 1 |
| Crippa, F; Daidone, MG; De Braud, FG; Farè, E; Giannatempo, P; Gianni, AM; Landoni, E; Lanocita, R; Mariani, L; Messina, C; Morosi, C; Necchi, A; Nicolai, N; Ortega, C; Pennati, M; Raggi, D; Sacco, C; Salvioni, R; Sava, T; Schwartz, LH; Zaffaroni, N | 1 |
| Afsar, B; Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Deger, SM; Gonul, II; Gumusay, O; Ozet, A | 1 |
| Chow, WA; Eroglu, Z; Kim, J; Wilczynski, S | 1 |
| Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T | 1 |
| Butrynski, JE; D'Adamo, D; Demetri, GD; Fisher, GA; Ganjoo, KN; George, S; Kamaya, A; McMillan, A; Morgan, JA; Villalobos, VM; Wagner, AJ | 1 |
| Boers-Sonderen, MJ; de Bruijn, P; Eskens, FA; Hamberg, P; Sleijfer, S; Suttle, AB; van der Graaf, WT; van Herpen, CM; Verweij, J | 1 |
| Besse, B; Bosquee, L; Chouaid, C; Felip, E; Lechevalier, T; Lianes-Barragán, P; Mellemgaard, A; Ottesen, LH; Paul, EM; Reck, M; Ruiz-Soto, R; Scagliotti, GV; Sigal, E; von Pawel, J | 1 |
| Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L | 1 |
| Chen, L; Liu, B; Liu, D; Long, L; Qi, H; Wang, X | 1 |
| Ando, Y; Araki, K; Inada-Inoue, M; Ishida, H; Kawada, K; Mitsuma, A; Mizuno, K; Nagamatsu, K; Nagashima, F; Sasaki, Y; Sawaki, M; Sunakawa, Y; Takekura, A; Yamashita, K; Yokoyama, T | 1 |
| Bauer, S; Hodge, RA; Kasper, B; Kerst, JM; Litière, S; Marreaud, S; Sleijfer, S; van der Graaf, WTA; Verweij, J | 1 |
| Colecchia, M; De Braud, F; Garanzini, E; Grassi, P; Iacovelli, R; Procopio, G; Testa, I; Torelli, T; Verzoni, E | 1 |
| Attia, S; Caracciollo, JT; Conley, AP; Koplin, S; Reed, DR; Webber, NP | 1 |
| Adkins, J; Aldrich, J; Asmann, Y; Baker, A; Barr Fritcher, EG; Barrett, MT; Bhavsar, JD; Bible, KC; Block, M; Borad, MJ; Bryce, AH; Carpten, JD; Champion, MD; Cherni, I; Christoforides, A; Collins, JM; Condjella, RM; Craig, DW; Egan, JB; Fonseca, R; Han, H; Harris, P; Hunt, K; Izatt, T; Kipp, BR; Klee, EW; Kocher, JP; Kurdoglu, A; Lazaridis, KN; Liang, WS; Lobello, J; Mastrian, SD; McCullough, AE; McDonald, J; McWilliams, RR; Middha, S; Nair, AA; Nasser, S; Oliver, GR; Patel, MD; Phillips, L; Placek, P; Reiman, R; Schahl, K; Silva, AC; Stewart, AK; Von Hoff, D; Watanabe, AT; Young, SW | 1 |
| Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S | 1 |
| Atkinson, BJ; Flaherty, AL; Jonasch, E; Matrana, MR; Shetty, AV; Tannir, NM | 1 |
| Banville, M; Collins, C; Cruz-Muñoz, W; Di Desidero, T; Hashimoto, K; Jaramillo, ML; Kerbel, RS; Man, S; O'Connor-McCourt, MD; Xu, P | 1 |
| Dayer, LE; Hutchins, LF; Johnson, JT | 1 |
| Antonysamy, MA; Bliss, RL; Dudek, AZ; Fischer, JH; Ganesan, C; Jha, G; Obulareddy, SJ | 1 |
| Brady, WE; Campos, SM; DiSilvestro, PA; Hanjani, P; Hensley, ML; Lee, PS; Moxley, KM; O'Cearbhaill, RE; O'Malley, DM; Rose, PG; Rotmensch, J; Thaker, PH; Zuna, RE | 1 |
| Bible, KC; Bieber, C; Burton, JK; Cher Goh, B; Erlichman, C; Fatourechi, V; Flynn, PJ; Harris, P; Hay, I; Isham, CR; Karlin, N; Maples, WJ; McIver, B; Menefee, ME; Molina, JR; Morris, JC; Rubin, J; Sideras, K; Smallridge, RC; Suman, VJ; Traynor, AM; Webster, KP | 1 |
| Choueiri, TK; Cleary, JM; Elfiky, AA; Gabriel, SB; Gandhi, L; Garraway, LA; Grabiner, BC; Hodis, E; Jacobus, S; Kantoff, PW; Lander, ES; Loda, M; Rosenberg, JE; Sabatini, DM; Shapiro, GI; Signoretti, S; Stack, EC; Stewart, M; Supko, JG; Taplin, ME; Van Allen, EM; Wagle, N | 1 |
| Bible, KC; Bossou, AR; Cradic, KW; Grebe, SK; Isham, CR; Milosevic, D; Netzel, BC | 1 |
| Ae, K; Gokita, T; Inagaki, L; Matsumoto, S; Motoi, N; Nakano, K; Shimoji, T; Takahashi, S; Tanizawa, T; Tomomatsu, J | 2 |
| Broom, RJ; Hadden, P; Jebb, A | 1 |
| Ferrari, S; Paioli, A; Palmerini, E | 1 |
| Bono, P; Cella, D; De Giorgi, U; Diaz, J; Eisen, T; Escudier, B; Gschwend, JE; Hawkins, R; Khan, S; Mehmud, F; Négrier, S; Parikh, O; Porta, C; Powles, T; Redhu, S; Sevin, E; Sternberg, CN | 1 |
| Garnick, MB | 1 |
| Blanc, E; Cassier, P; Chatelut, E; Escudier, B; Hollebecque, A; Imbs, DC; Lafont, T; Négrier, S; Pérol, D; Soria, JC; Varga, A | 1 |
| Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D | 1 |
| Heinzlmeir, S; Helm, D; Ku, X; Kuster, B; Médard, G | 1 |
| Liang, H | 1 |
| Choueiri, TK; Deen, K; Hutson, TE; McCann, L; Motzer, RJ | 1 |
| Bellmunt, J; Bracarda, S; Cerbone, L; Choueiri, TK; Fay, AP; Foreshew, A; Hutson, TE; Lampron, ME; Pons, F; Porta, C; Powles, T; Sternberg, CN | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Hackshaw, MD; Miller, LA; Nagar, SP; Parks, DC | 1 |
| Berkers, J; Beuselinck, B; De Wever, L; Dumez, H; Joniau, S; Lerut, E; Oyen, R; Paridaens, R; Schöffski, P; Strijbos, M; Van Poppel, H; Wolter, P | 1 |
| Bozcuk, H; Coskun, HS; Gunduz, S; Mutlu, H; Uysal, M | 1 |
| Elkord, E; Gilham, DE; Hawkins, RE; Shablak, A | 1 |
| Henderson, L; Hossain, M; Kelly, DS; Singh, R; Trivedi, T; Wurzelmann, JI; Ye, L | 1 |
| Cornillie, J; Hompes, D; Li, H; Schöffski, P; Wozniak, A | 1 |
| Blomqvist, LK; Farnebo, J; Grybäck, P; Harmenberg, U; Laurell, A; Sandström, P; Ullén, A; Wersäll, P | 1 |
| Beato-Merino, M; Casado-Verrier, B; Delgado-Mucientes, C; Pérez-Santos, S | 1 |
| McCormack, PL | 1 |
| Bonner, JA; Buchsbaum, DJ; Grizzle, WE; Li, Y; Meredith, RF; Raisch, KP; Spencer, SA | 1 |
| Araki, N; Hamada, K; Imura, Y; Itoh, K; Naka, N; Outani, H; Tanaka, T; Wakamatsu, T; Yoshikawa, H | 1 |
| Bay, JO; Brotelle, T | 1 |
| Cuesta, M; Guix, M; Hernández-Pastor, LJ; Lavernia, J; Villa, G | 1 |
| Booth, CM; Chi, KN; Golubovic, J; Gregg, R; Harris, P; Joshua, AM; Murray, N; Sridhar, SS; Wang, L | 1 |
| Minami, T; Nozawa, M; Shimizu, N; Uemura, H; Yamamoto, Y; Yoshimura, K | 1 |
| Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E | 1 |
| Escudero-Ortiz, V; Pérez-Ruixo, JJ; Valenzuela, B | 1 |
| Bernal-Becerra, I; Cabezas-Camarero, S; Corona, JA; Díaz-Rubio, E; González-Larriba, JL; Manzano, A; Puente, J; Sotelo, M | 1 |
| Aldabagh, B; Joo, J; Yu, SS | 1 |
| Acharyya, S; Chopra, A; Fay, AP; Haaland, B; Lopes, Gde L | 1 |
| Hasegawa, T; Hashimoto, A; Hayashi, T; Hirayama, Y; Horiguchi, H; Iyama, S; Kato, J; Kitamura, H; Kobune, M; Masumori, N; Miyanishi, K; Murase, K; Nakanishi, K; Ono, K; Sato, T; Sato, Y; Takada, K; Takimoto, R; Tatekoshi, A | 1 |
| Boysen, A; Lücke, A; Rossen, P; Safwat, A | 1 |
| Pattison, S; Zalcberg, JR | 1 |
| Dhruva, N; Grilley-Olson, J; Ivanova, A; Socinski, MA; Stinchcombe, TE; Villaruz, LC; Weiss, JM | 1 |
| Craveiro, RB; Dilloo, D; Ehrhardt, M; Holst, MI; Pietsch, T | 1 |
| McGuire, WP; Oliver, KE | 1 |
| Baumann, KH; Calvert, P; Canzler, U; Colombo, N; Crescenzo, R; del Campo, JM; Diaz-Padilla, I; du Bois, A; Floquet, A; Friedlander, M; Fujiwara, K; Harter, P; Herzog, TJ; Kim, BG; Kim, JH; Kim, JW; Kimmig, R; Kurzeder, C; Lesoin, A; Marth, C; Mirza, MR; Mitrica, I; Monk, BJ; Mouret-Reynier, MA; Pignata, S; Pujade-Lauraine, E; Rau, J; Ray-Coquard, I; Scambia, G; Schade-Brittinger, C; Shimada, M; Vasey, P; Vergote, I; Wang, Q; Zang, R | 1 |
| Bourlon, MT; Kessler, ER | 1 |
| Davis, ID; Deen, KC; Hawkins, RE; Sigal, E; Sternberg, CN | 1 |
| Bennouna, J; Botbyl, J; de Labareyre, C; Delord, JP; Deslandres, M; Ruiz-Soto, R; Senellart, H; Suttle, AB; Wixon, C | 1 |
| Cho, J; Choi, YL; Jang, HL; Kang, WK; Kim, KM; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yashiro, M | 1 |
| Badalamenti, G; Baldi, GG; Casali, PG; Cominetti, D; Dagrada, GP; Dei Tos, AP; Festinese, F; Fumagalli, E; Grignani, G; Gronchi, A; Morosi, C; Negri, T; Pennacchioli, E; Pilotti, S; Provenzano, S; Spagnuolo, RD; Stacchiotti, S; Tortoreto, M; Toss, A; Zaffaroni, N | 1 |
| de Wit, D; den Hartigh, J; den Hollander-van Deursen, M; Gelderblom, H; Guchelaar, HJ; Labots, M; van Erp, NP; Verheul, HM; Wolterbeek, R | 1 |
| Carmichael, C; Frankel, PH; Hossain, DM; Jones, JO; Kortylewski, M; Lau, C; Pal, SK; Ruel, C; Zhang, Q | 1 |
| Ames, E; Borys, D; Canter, RJ; Chen, M; Grossenbacher, SK; Li, CS; Mac, S; Monjazeb, AM; Murphy, WJ; Sayers, TJ; Smith, RC; Tellez, J | 1 |
| Ahmed, M; Coleman, CN; Curran, WJ; Dicker, AP; Finkelstein, SE; Houghton, P; Kirsch, DG; Machtay, M; Monjazeb, AM; Teicher, BA; Vikram, B; Wang, D; Wong, P; Xu-Welliver, M | 1 |
| Raj, N; Reidy-Lagunes, D | 1 |
| Alcindor, T | 1 |
| Kawai, A; Kawashima, M; Kobayashi, E; Kobayashi, K; Koyama, T; Setsu, N | 1 |
| Aihara, M; Fujita, H; Oda, K; Sato, M; Wada, H | 1 |
| Amado, R; Ball, HA; Carpenter, C; Hutson, TE; Lin, Y; Molimard, M; Pandite, L; Rajagopalan, D; Suttle, AB; Swann, S | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Bing, N; Cardon, LR; Cheng, YC; Cox, NJ; Das, S; Gamazon, ER; Karrison, TG; Kistner-Griffin, E; Levine, MR; Liu, Y; Maitland, ML; Mitchell, BD; O'Connell, JR; Pandite, LN; Ratain, MJ; Ryan, KA; Shuldiner, AR; Thomeas, V; Torgerson, D; Wilson, PA; Xu, CF | 1 |
| Galanis, A; Levis, M | 1 |
| Csaky, KG; Danis, RP; Dugel, PU; Fries, MA; Hossain, M; Kelly, DS; Pierce, AJ; Trivedi, T; Wurzelmann, JI; Xu, CF | 1 |
| Barrett, C; Calvert, P; Colombo, N; Crescenzo, RJ; del Campo, JM; du Bois, A; Fiane, B; Floquet, A; Friedlander, M; Herzog, TJ; Isonishi, S; Kim, JW; Meier, W; Mitrica, I; Monk, BJ; Pisano, C; Reinthaller, A; Vergote, I; Wang, K | 1 |
| Albiges, L; Escudier, B; Fizazi, K; Iacovelli, R; Loriot, Y; Massard, C; Massari, F | 1 |
| Bhowmik, D; Hackshaw, MD; Hutson, TE; Jonasch, E; Rembert, D; Vogelzang, NJ; Yap, M | 1 |
| Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P | 1 |
| Compton, N; Kendra, KL; O'Brien, ME; Ottesen, LH; Paul, EM; Plummer, R; Salgia, R; Suttle, AB; Villalona-Calero, MA; Xu, CF | 1 |
| Atkinson, BJ; Cauley, DH; Chen, AH; Land, JD; Tannir, NM | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Sawyer, MB | 1 |
| de Bruijn, P; de Jonge, MJ; Eskens, FA; Hamberg, P; Leonowens, C; Mathijssen, RH; Sleijfer, S; van der Biessen, D; Verweij, J | 1 |
| Benson, P; Carpenter, C; Choueiri, TK; de Souza, P; Deen, K; Fay, AP; Figueroa, DJ; Gagnon, R; Ho, TH; Liu, Y; Motzer, RJ; Pandite, L; Powles, T; Signoretti, S | 1 |
| Bhatt, K; Bury, MJ; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Goel, R; Jacobs, SA; Johannes, H; Julian, TB; Mamounas, EP; Provencher, L; Rastogi, P; Robidoux, A; Stella, PJ; Swain, SM; Tan, AR; Thirlwell, MP; Wolmark, N | 1 |
| Chryssidis, S; Cohen, L; Kotasek, D; Neuhaus, S | 1 |
| Arondekar, B; Deen, KC; Hackshaw, MD; Hansen, RN; Nagar, SP; Ramsey, SD; Sullivan, SD | 1 |
| Amdahl, J; Delea, TE; Diaz, J; Hackshaw, MD; Nakhaipour, HR | 1 |
| Ito, T; Kutikov, A | 1 |
| Rahman, A | 1 |
| Chua, CC; Earwood, CB; Firdaus, ID; Hainsworth, JD | 1 |
| He, CS; Huang, JK; Lin, QZ; Xie, M | 1 |
| Azijli, K; Broxterman, HJ; de Haas, RR; Dekker, H; Gotink, KJ; Honeywell, RJ; Peters, GJ; Poel, D; Rovithi, M; Verheul, HM | 1 |
| Araujo, D; Fu, S; Hess, K; Hong, D; Hou, MM; Hwu, P; Janku, F; Karp, D; Kee, B; Kurzrock, R; Meric-Bernstam, F; Naing, A; Piha-Paul, S; Subbiah, V; Tsimberidou, A; Wheler, J; Wolff, R; Zinner, R | 1 |
| Agarwal, N; Beard, C; Bhayani, S; Bolger, GB; Chang, SS; Choueiri, TK; Costello, BA; Derweesh, IH; Dwyer, M; Gupta, S; Hancock, SL; Jonasch, E; Kim, JJ; Kumar, R; Kuzel, TM; Lam, ET; Lau, C; Levine, EG; Lin, DW; Michaelson, MD; Motzer, RJ; Olencki, T; Pili, R; Plimack, ER; Rampersaud, EN; Redman, BG; Ryan, CJ; Sheinfeld, J; Shuch, B; Sircar, K; Somer, B; Wilder, RB | 1 |
| Bing, N; Choueiri, TK; Davis, ID; Deen, KC; Esteban, E; Garcia-Donas, J; Johnson, T; McCann, L; Motzer, RJ; Pandite, LN; Rodríguez-Antona, C; Spraggs, CF; Sternberg, CN; Whittaker, JC; Xu, CF; Xue, Z | 1 |
| Han, S; Hyun, C; Jo, J; Kim, JH; Kim, JY; Kim, W; Kwon, J; Rhee, J | 1 |
| van der Graaf, WT; van Erp, NP; Vlenterie, M | 1 |
| Liu, XJ; Lu, H; Mo, YS; Shi, BK; Sun, JX; Wang, SR; Yang, XS | 1 |
| Abrishami, P; Bucsics, A; Di Bidino, R; Goettsch, WG; Happonen, P; Kleijnen, S; Montilla, S; Muscolo, LA; Pasternack, I; Pulis, IZ; Rannanheimo, P; Sacchini, D; Sammut, SM; Van de Casteele, M; Vuola, JM | 1 |
| Miura, H; Shirai, H | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Ali, SM; Morris, JC; Pal, SK; Palma, N; Ross, JS | 1 |
| Climent-Durán, MÁ; Iborra, I; Ramírez-Backhaus, M; Rubio-Briones, J; Solsona-Narbón, E; Valverde-Martínez, S | 1 |
| Fukumoto, Y; Kubota, S; Morii, M; Nakayama, Y; Yamaguchi, N | 1 |
| Campbell, SC; Chen, DY; Dreicer, R; Elson, P; Fergany, A; Garcia, J; Gilligan, T; Kaouk, J; Klein, EA; Krishnamurthi, V; Plimack, ER; Rini, BI; Stephenson, AJ; Takagi, T; Uzzo, RG; Wood, LS; Zhang, Z | 1 |
| Haga, N; Hata, H; Homma, E; Imafuku, K; Kitamura, S; Shimizu, H | 1 |
| Dainichi, T; Kabashima, K; Kaku, Y; Otsuka, A; Usui, S | 1 |
| Fife, K; Welsh, SJ | 1 |
| Bjarnason, GA; Bocci, G; Di Desidero, T; Jedeszko, C; Kerbel, RS; Lee, CR; Man, S; Paez-Ribes, M; Xu, P | 1 |
| Booth, L; Cruz-Luna, T; Cycon, KA; Dent, P; Doern, CD; Fidanza, A; Nourbakhsh, A; Plamondon, P; Roberts, JL; Siembida, P; Smith, E; Tavallai, M | 1 |
| Arcangeli, V; Brandes, AA; Cecere, SC; Cinieri, S; Daniele, G; Di Maio, M; Di Napoli, M; Gallo, C; Lorusso, D; Maltese, G; Mosconi, AM; Orditura, M; Panici, PB; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Ricci, C; Salutari, V; Sambataro, D; Scambia, G; Tamberi, S | 1 |
| Cho, YJ; Kim, HS; Kim, SH; Kim, SJ; La Choi, Y; Lee, J; Lee, SJ; Park, SH; Rha, SY; Shin, KH; Yoo, KH | 1 |
| Abarzúa, Á; Giesen, L; González, S; Molgó, M | 1 |
| Bracarda, S; Carpenter, C; Chen, M; Compton, N; Harter, P; Heise, M; Hutson, T; Kaplowitz, N; Norry, E; Pandite, L; Powles, T | 1 |
| Bellido, J; Falchook, G; Fu, S; Hong, D; Janku, F; Karp, D; Ke, D; Kurzrock, R; Lim, J; Naing, A; Piha-Paul, S; Rodrigues, HV; Stephen, B; Subbiah, V; Tsimberidou, A; Wheler, J; Zinner, R | 1 |
| Borst, G; de Pree, I; Dewit, L; Gelderblom, H; Haas, RL; Hartgrink, HH; Kerst, JM; Nout, RA; Scholten, A; Sleijfer, S; Steeghs, N; van Boven, HH; van Coevorden, F; van der Hage, J; Verhoef, C | 1 |
| Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF | 1 |
| Abdallah, AO; Kunthur, A; Vallurupalli, S | 1 |
| Chan, JA; Fogelman, DR; Halperin, DM; Hess, KR; Kulke, MH; Malinowski, P; Ng, CS; Phan, AT; Regan, E; Yao, JC | 1 |
| Akkar, OB; Cetin, A; Kacan, SB; Kacan, T; Karakus, S; Ozer, H; Yildiz, C | 1 |
| D'Onofrio, L; Guida, FM; Ratta, R; Russano, M; Santini, D; Tonini, G; Venditti, O; Vincenzi, B | 1 |
| Bar-Sela, G; Keidar, Z; Naroditsky, I; Semenisty, V | 1 |
| Bennett, KL; Bigenzahn, JW; Bruckner, M; Colinge, J; Fauster, A; Gridling, M; Huber, KV; Krautwald, S; Kubicek, S; Lardeau, CH; Linkermann, A; Parapatics, K; Rebsamen, M; Scorzoni, S; Stukalov, A; Superti-Furga, G | 1 |
| Flaherty, C; Holland, J | 1 |
| Burton, TM; Byfield, SA; Hackshaw, MD; McPheeters, JT; Nagar, SP | 1 |
| Di Bella, S; Facchetti, R; Giannattasio, C; Giganti, MO; Maloberti, A; Mancia, G; Meani, P; Moreo, A; Musca, F; Pozzi, M; Ricotta, R; Sartore-Bianchi, A; Siena, S; Stucchi, M; Vallerio, P | 1 |
| de Wit, D; den Hartigh, J; den Hollander, M; Gelderblom, H; Guchelaar, HJ; Qian, Y; van Erp, NP; Verheul, H | 1 |
| Atkinson, BJ; Corn, PG; Jonasch, E; Kalra, S; Karam, JA; Matin, SF; Matrana, MR; Rao, P; Sircar, K; Tamboli, P; Tannir, NM; Wood, CG | 1 |
| Blay, JY; Bottomley, A; Chawla, SP; Coens, C; Hodge, RA; Judson, I; Litière, S; Lugowska, I; Manson, SC; Marreaud, S; Prins, JB; Sanfilippo, R; van der Graaf, WT | 1 |
| Akihama, S; Habuchi, T; Inoue, T; Koizumi, A; Narita, S; Numakura, K; Saito, M; Satoh, S; Takahashi, M; Takayama, K; Tsuchiya, N; Tsuruta, H | 1 |
| Alonso-Gordoa, T; Apellaniz-Ruiz, M; Capdevila, J; Carrato, A; Casanovas, O; Castellano, D; Díez, JJ; Durán, I; Earl, J; Escudero, P; Fuster, J; García-Carbonero, R; García-Donas, J; Grande, E; Ortega, L; Rodriguez-Antona, C; Sastre, J; Sevilla, I; Teulé, A | 1 |
| Behzadigohar, R; Rosenthal, MA; Tran, B | 1 |
| Baas, P; Blackhall, F; Cufer, T; Gaafar, R; Georgoulias, V; Hasan, B; Hennig, I; Menis, J; Montes, A; O'Brien, ME; Popat, S; Schmid-Bindert, G; Surmont, V; Woll, PJ | 1 |
| Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM | 1 |
| Bhatt, K; Kattan, MW; McCann, L; Mehmud, F; Motzer, RJ; Sternberg, CN | 1 |
| Bex, A; Blank, CU; Broeks, A; de Gruijl, TD; Gadiot, J; Guislain, A; Haanen, JB; Jordanova, ES; Kaiser, A; Sanders, J; van Boven, H | 1 |
| Schmidinger, M; Wittes, J | 1 |
| Cogle, CR; Drusbosky, L; Gars, E; McGee, C; Meacham, A; Scott, EW; Trujillo, A; Wise, E | 1 |
| Fu, S; George, GC; Henary, H; Hong, DS; Kurzrock, R; Mistry, R; Naing, A; Piha-Paul, S; Wheler, J; Zinner, R | 1 |
| Huang, J; Shan, L; Song, Y; Zhang, HT | 1 |
| Bouvet, M; Chishima, T; Endo, I; Hiroshima, Y; Hoffman, RM; Ichikawa, Y; Maawy, A; Matsuyama, R; Mii, S; Miwa, S; Momiyama, M; Mori, R; Murakami, T; Tanaka, K; Uehara, F; Yamamoto, M; Yano, S; Zhang, N; Zhang, Y; Zhao, M | 1 |
| Abu-Elsaad, N; El-Karef, A; Elshal, M; Ibrahim, TM | 1 |
| Asai, K; Eguchi, Y; Hirata, K; Kawaguchi, T; Kojima, K; Ohsawa, M; Sugitani, A | 1 |
| Kato, S | 1 |
| Agulnik, M; Mohindra, N | 1 |
| Devriese, LA; Giantonio, BJ; Kerklaan, BM; Lane, S; Langenberg, M; Legenne, P; Lolkema, MP; Mergui-Roelvink, M; Mykulowycz, K; Nol-Boekel, A; Schellens, JH; Smith, DA; Stoebenau, J; Voest, EE; Wissel, P; Witteveen, PO | 1 |
| Banerjee, S; McLachlan, J | 1 |
| Dahmani, B; De Boer, A; Fathallah, M; Goettsch, WG; Kleijnen, S; Leufkens, HG; Timoney, A; van der Linden, MW; Vancraeynest, P | 1 |
| Aliper, A; Borisov, N; Buzdin, A; Kholodenko, R; Malakhova, G; Roumiantsev, S; Shepelin, D; Suntsova, M; Vasilov, R; Venkova, L; Zhavoronkov, A | 1 |
| Chawla, SP; Dewji, R; Duffaud, F; Judson, I; Le Cesne, A; Litière, S; Marreaud, S; Papai, Z; Ray-Coquard, I; Schöffski, P; Sleijfer, S; van der Graaf, WT; Verweij, J | 1 |
| Ahmed, SR; Ball, DW; Bhan, S; Clark, DP; Jin, N; Nelkin, BD; Rosen, DM; Schayowitz, A; Xue, P | 1 |
| Abernethy, AP; George, DJ; Harrison, MR; Hirsch, BR; Mitchell, AP; Walker, MS | 1 |
| Covell, LL; Ganti, AK | 1 |
| Ledoux, B; Petit, B; Seront, E; van Marcke, C | 1 |
| Gananadhamu, S; Garg, P; Kalariya, PD; Patel, PN; Sharma, M; Srinivas, R; Talluri, MV | 1 |
| Racsa, PN; Whisman, TR; Worley, K | 1 |
| Berger, MF; Canevari, S; Colecchia, M; De Braud, FG; Giannatempo, P; Iyer, G; Necchi, A; Pierotti, MA; Pinciroli, P; Raggi, D; Rosenberg, JE; Solit, DB; Won, H | 1 |
| Ceelen, W; De Wever, O; Descamps, B; Gremonprez, F; Izmer, A; Vanhaecke, F; Vanhove, C | 1 |
| Fujihara, I; Fujita, K; Hiroma, T; Katsuyama, Y; Kitamura, R; Komori, K; Kondo, Y; Nakamura, T; Noguchi, M; Ogiso, Y; Sakashita, K; Sano, K; Yanagisawa, R | 1 |
| Kim, D; Kwon, A; Lee, BY; Min, KH; Nguyen, HK; Song, J; Suh, W; Yoo, J | 1 |
| Bokemeyer, C; Oechsle, K; Oing, C; Rink, M; Seidel, C; von Amsberg, G | 1 |
| Burns, K; Knights, KM; Mackenzie, PI; Miners, JO; Nair, PC; Rowland, A | 1 |
| Agulnik, M; Carvajal, RD; Chi, P; Chmielowski, B; Crago, AM; D'Angelo, SP; Dickson, MA; Ezeoke, MO; Gounder, MM; Hameed, M; Healey, JH; Keohan, ML; Landa, J; Luke, JJ; Munhoz, RR; Qin, LX; Schwartz, GK; Singer, S; Singh, AS; Tap, WD; Van Tine, BA | 1 |
| Beaumont, JL; Cella, D; Diaz, J; Khan, S; Lai, JS | 1 |
| Giri, S; Hahn, AW; Martin, MG; Patel, D; Sluder, H; Vanderwalde, A | 1 |
| Bahl, A; Brown, J; Buchan, S; Hawkins, R; Jones, R; Pickering, L; Porfiri, E; Wagstaff, J | 1 |
| Dietrich, PY; Haller, S; Koka, A; Leemann, B; Merkler, D; Migliorini, D; Pugliesi-Rinaldi, A; Schaller, K | 1 |
| Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W | 1 |
| Briley, LP; Carpenter, C; du Bois, A; Fraser, DJ; Graves, AP; Johnson, T; Kaplowitz, N; King, KS; Mitrica, I; Nelson, MR; Pandite, LN; Powles, T; Spraggs, CF; Stinnett, S; Tada, H; Wang, X; Warren, L; Xu, CF; Xue, Z | 1 |
| Grünwald, V; Ivanyi, P | 1 |
| Chatelut, E; Imbs, DC; Lafont, T; Négrier, S; Paludetto, MN; Powell, H; Thomas, F; White-Koning, M | 1 |
| Atkinson, B; Bathala, T; Campbell, MT; Corn, P; Duran, C; Jonasch, E; Kalra, S; Matrana, MR; Shetty, A; Tannir, NM; Teegavarapu, P; Xiao, L | 1 |
| Cox, CJ; Crescenzo, R; du Bois, A; Harter, P; Kim, BG; Kim, JW; Kong, BH; Liu, JH; Mahner, S; Mitrica, I; Ngan, HY; Park, SY; Shoji, T; Takano, T; Wang, KL; Wang, Q; Wei, LH; Wu, LY; Wu, Q; Zhang, P; Zhu, JQ | 1 |
| Abdollahi, A; Alves, F; Chiblak, S; Fuchs, B; Jannasch, K; Kleeff, J; Lindner, T; Matzke-Ogi, A; Mier, W; Morton, J; Orian-Rousseau, V; Ponta, H; Sansom, O; Schwager, C; Shatirishvili, M; Tawk, B; Warth, A | 1 |
| Cartenì, G; Vitale, MG | 1 |
| Gillessen, S; Hader, C; Rothermundt, C | 1 |
| Bocci, G; Di Desidero, T; Kerbel, RS; Man, S; Xu, P | 1 |
| Chen, JL; Koehler, K; Liebner, D | 1 |
| Beijnen, JH; Bins, S; Huitema, AD; Lolkema, MP; Mathijssen, RH; Nan, L; Rosing, H; Schellens, JH; Steeghs, N; Thijssen, B; Verheijen, RB | 1 |
| Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ | 1 |
| Arranz Arija, JA; Basterretxea Badiola, L; Borrega García, P; Castellano Gaunas, DE; Chirivella González, I; Fernández Parra, EM; Gajate Borau, P; García Carbonero, I; García Domínguez, R; García Marrero, RD; González del Alba, A; González Larriba, JL; Jiménez Gallego, P; Juan Fita, MJ; Jurado García, JM; Lambea Sorrosal, JJ; Lázaro Quintela, M; León-Mateos, L; López Brea, M; Maximiano Alonso, C; Meana García, JA; Méndez Vidal, MJ; Molins Palau, C; Pérez-Valderrama, B; Pinto Marín, A; Puertas Álvarez, JL; Reig Torras, O; Rodríguez Sánchez, A; Rubio Romero, G; Santander Lobera, C; Suárez Rodríguez, C; Vázquez Estévez, S; Vélez de Mendizábal, E; Villa Guzmán, JC | 1 |
| Ha, SY; Heo, JS; Kim, HC; Kim, KM; Kim, ST; Lauwers, G; Lee, J; Park, C; Park, YS | 1 |
| Kichenadasse, G; Mangoni, AA; Rowland, A; Sorich, MJ; Woodman, RJ | 2 |
| Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D | 1 |
| Carpenter, C; Figlin, RA; Goldstein, D; McCann, L; Pandite, L; Rosenberg, JE; Townsend, RR | 1 |
| Koo, V; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ | 1 |
| Berendes, BJ; Everaert, H; Lefesvre, P; Schallier, D | 1 |
| Enoch, IV; Indiraleka, M; Premnath, D; Selvakumar, PM; Vennila, JJ | 1 |
| Attenberger, U; Derigs, HG; Dimitrakopoulou-Strauss, A; Egerer, G; Fröhling, S; Gaiser, T; Hohenberger, P; Jakob, J; Kasper, B; Nowak, K; Pilz, LR; Ronellenfitsch, U; Schwarzbach, M | 1 |
| Barrett, C; Berton-Rigaud, D; Chan, JK; Colombo, N; Del Campo, JM; du Bois, A; Forget, F; Friedlander, M; Harter, P; Heitz, F; Herzog, TJ; Imhof, M; Jobanputra, M; Johnson, T; King, K; Mirza, MR; O'Donnell, D; Park, SY; Shimada, M; Stinnett, S; Xu, CF; Zamagni, C | 1 |
| Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ; Yang, C | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M | 1 |
| Bersanelli, M; Buti, S; Facchinetti, F; Maiorana, M; Tiseo, M | 1 |
| Bachelot, T; Campone, M; Chatelut, E; Diéras, V; Imbs, DC; Isambert, N; Jimenez, M; Joly, F; Lafont, T | 1 |
| Granovetter, M | 1 |
| Araki, N; Esaki, T; Fukasawa, N; Hiraga, H; Ishii, T; Kawai, A; Machida, M; Matsumine, A; Ozaki, T; Sugiura, H; Ueda, T | 1 |
| Gooch, ME; Kubicek, GJ; Nader, K; Somer, RA | 1 |
| Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
| Bertino, E; Haglund, K; Haraldsdottir, S; Kaffenberger, B; Shah, MH | 1 |
| Albers, T; Booth, L; Bottaro, D; Chen, CS; Dent, P; Ecroyd, H; Lebedyeva, IO; Proniuk, S; Roberts, JL; Shuch, B; Tavallai, M; Wang, D; Zukiwski, A | 1 |
| Delea, TE; Diaz, J; Latimer, N; Mehmud, F; Motzer, RJ; Pandite, L; Sternberg, CN | 1 |
| Epskamp, C; Hamberg, P; Snels, DG; Yo, GL; Zuetenhorst, HJ | 1 |
| Bissinger, R; Bossi, E; Castagna, M; Lang, F; Signoretto, E; Zierle, J | 1 |
| Araki, N; Boku, S; Goto, T; Hiraga, H; Honoki, K; Kawai, A; Matsumine, A; Nakamura, T; Nishida, Y; Sudo, A; Sugiura, H; Ueda, T; Yasuda, T; Yonemoto, T | 1 |
| Bodnar, L; Chrom, P; Semeniuk-Wojtas, A; Spencer, NJ; Stec, R; Szczylik, C | 1 |
| Ahn, S; Kang, WK; Kim, KM; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Beaumont, JL; Cella, D; Deen, KC; Diaz, J; Hackshaw, MD; McCann, L; Motzer, RJ; Powles, T; Salsman, JM | 1 |
| Borgel, S; Bottaro, DP; Doroshow, JH; Evrard, YA; Hollingshead, MG; Ji, JJ; Khin, SA; Kinders, RJ; Linehan, WM; Navas, T; Parchment, RE; Pfister, TD; Srivastava, AK; Tomaszewski, JE; Weiner, J; Zhang, Y | 1 |
| Jung, SH; Kang, WK; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Benson, C; Blay, JY; Chawla, S; Dewji, MR; Gil, T; Judson, I; Le Cesne, A; Litière, S; Marréaud, S; Papai, Z; Piperno-Neumann, S; Ray-Coquard, I; Schöffski, P; Sleijfer, S; van der Graaf, WTA | 1 |
| Kononenko, OA; Stakhovskiy, EO; Stakhovskiy, OE; Vitruk, YV; Voylenko, OA; Vukalovych, PS | 1 |
| Bergmann, L; Maute, L | 1 |
| Afshar-Kharghan, V; Armaiz-Pena, GN; Bottsford-Miller, J; Burns, AR; Cho, MS; Choi, HJ; Dalton, HJ; Gharpure, KM; Gutschner, T; Haemmerle, M; Han, HD; Hansen, JM; Lopez-Berestein, G; Mangala, LS; Nagaraja, AS; Nick, AM; Pecot, CV; Pradeep, S; Rupaimoole, R; Sood, AK; Stone, RL; Taylor, ML; Wu, SY; Zand, B | 1 |
| Nakamura, T; Okada, S; Shinji, A | 1 |
| Fan, A; Haas, D; Harshman, L; Lam, A; Li, S; Narayanan, S; Pachynski, R; Poushnejad, S; Srinivas, S; Vaishampayan, U | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bompas, E; Bouché, O; Cassier, P; Cesne, AL; Chauzit, E; Cropet, C; Duffaud, F; Gautier, J; Isambert, N; Italiano, A; Mir, O; Molimard, M; Pérol, D; Ray-Coquard, I; Rios, M; Toulmonde, M | 1 |
| Doi, T; Nishida, T | 1 |
| Lee, NR; Lee, SY | 1 |
| Hira, D; Jo, F; Kageyama, S; Kawauchi, A; Morita, SY; Noda, S; Terada, T; Wada, A; Yoshida, T | 1 |
| Keck, B; Lieb, V; Lüdecke, G; Sikic, D | 1 |
| Carbini, M; Maki, RG; Pang, A | 1 |
| Ali, SM; Futreal, A; Miller, VA; Patel, S; Ramesh, N; Ravi, V; Ross, JS; Sanford, EM; Stephens, PJ; Wang, WL | 1 |
| Kondakova, IV; Slonimskaya, EM; Spirina, LV; Usynin, EA; Yurmazov, ZA | 1 |
| Cheng, PF; Dummer, R; Goldinger, SM; Guenova, E; Jaberg-Bentele, N; Kunz, M; Levesque, MP; Mangana, J; Nagel, HW; Nägeli, M; Thurneysen, S; Ziegler, M | 1 |
| Andrikou, K; Bianconi, M; Bittoni, A; Burattini, L; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Montironi, R; Scartozzi, M; Zizzi, A | 1 |
| Chatelut, E; Delmas, C; Deluche, T; Hennebelle, I; Imbs, DC; Sauzay, C; Thomas, F; White-Koning, M | 1 |
| Eaddy, M; Hackshaw, MD; Holmes, M; Lankford, M; Ogbonnaya, A; Thomas, M | 1 |
| Goto, H; Kiyohara, Y; Niwakawa, M; Omodaka, T; Otsuka, M; Yoshikawa, S; Yoshimi, K | 1 |
| Kaneko, T; Shinkai, M; Watanabe, K | 1 |
| Ackerman, C; Aitchison, M; Beltran, L; Boleti, E; Chowdhury, S; Crabb, S; Harvey-Jones, E; Jones, R; Michel, C; O'Brien, T; Oades, G; Peters, J; Powles, T; Protheroe, A; Sahdev, A; Sarker, SJ; Sarwar, N; Smith, K; Stockdale, A; Sullivan, M; Trevisan, G; Wimalasingham, A; Worth, D | 1 |
| Azvolinsky, A | 1 |
| Albers, T; Booth, L; Dent, P; Lebedyeva, IO; Poklepovic, A; Roberts, JL; Tavallai, M | 1 |
| Abe, K; Hayashi, K; Higuchi, T; Inatani, H; Miwa, S; Takeuchi, A; Taniguchi, Y; Tsuchiya, H; Yamamoto, N | 1 |
| Bedke, J; Gauler, T; Grünwald, V; Hegele, A; Herrmann, E; Hinz, S; Janssen, J; Miller, K; Schmitz, S; Schostak, M; Tesch, H; Zastrow, S | 1 |
| De Groot, S; Haanen, JB; Kiemeney, LA; Oosterwijk, E; Redekop, WK; Sleijfer, S; Uyl-de Groot, CA | 1 |
| Chuman, H; Hayashi, Y; Iwase, H; Kawai, A; Kobayashi, E; Makino, Y; Nakatani, F; Sano, T; Tanzawa, Y | 1 |
| Annala, M; Azad, AA; Chi, KN; Fazli, L; Mo, F; Nappi, L; Wyatt, AW | 1 |
| Kim, JH; Lee, JL; Park, I | 1 |
| Kok, VC; Kuo, JT | 1 |
| Grünwald, V; Karch, A; Koch, A | 1 |
| Chagin, K; Djousse, L; Fraeman, KH; Gagnon, DR; Hall, SA; Nelson, J; Nordstrom, BL; Shantakumar, S; van Herk-Sukel, M | 1 |
| Cisar, LA; Harnett, J; Hoang, CJ; MacLean, E; Mardekian, J | 1 |
| Chung, J; Joo, J; Joung, JY; Kim, S; Kim, SH; Lee, KH; Seo, HK | 1 |
| Kim, MJ; Lee, JL; Lee, SH; Lee, SJ; Lim, HY; Park, SH | 1 |
| Beuselinck, B; Bjarnason, GA; Choueiri, TK; Donskov, F; Fraccon, AP; Heng, DY; Lee, JL; Pasini, F; Pezaro, C; Ptak-Chmielewska, A; Rini, BI; Ruiz-Morales, JM; Sim, HW; Sliwczynsk, A; Swierkowski, M; Szczylik, C; Teter, Z; Wells, JC; Wood, LA; Yuasa, T | 1 |
| Azraq, Y; Eleyan, F; Gill, S; Katz, D; Merimsky, O; Peretz, T | 1 |
| Golčić, M; Petković, M | 1 |
| Asakura, T; Fujimoto, K; Funatsu, Y; Hirayama, M; Inaki, S; Murata, Y; Oyamada, Y; Satomi, R; Shiraishi, J; Wakaki, M; Yamada, E | 1 |
| Demizu, Y; Futani, H; Mohri, T; Okimoto, T; Sakagami, M; Terada, T; Tsukamoto, Y; Uwa, N | 1 |
| Beijnen, JH; Bins, S; Huitema, AD; Mathijssen, RH; Schellens, JH; Steeghs, N; van Erp, N; Yu, H | 1 |
| Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yagisawa, T | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Goldwasser, F; Huillard, O; Jouinot, A; Thomas-Schoemann, A; Tlemsani, C; Vidal, M | 1 |
| Agrafiotis, AC; Grosdidier, G; Prieto, M; Rios, M; Siat, J; Verhaeghe, JL | 1 |
| Alamri, S; Atkinson, B; Baiomy, A; Campbell, M; Corn, P; Elsayes, KM; Jonasch, E; Kalra, S; Matrana, MR; Shetty, A; Tannir, NM; Teegavarapu, P; Xiao, L | 1 |
| Hata, H; Imafuku, K; Inamura, Y; Kitamura, S; Shimizu, H; Yanagi, T; Yoshino, K | 1 |
| Ebina, Y; Miyamoto, T; Nagamata, S; Nishijima, M; Yamada, H; Yamano, Y | 1 |
| Fukao, A; Horikawa, S; Ikeue, T; Noguchi, S; Ohi, I; Sugita, T; Terashita, S | 1 |
| Maltezou, M; Miaris, N; Papaxoinis, G; Samantas, E; Visvikis, A | 1 |
| Oashi, K; Ogata, D; Suzuki, K; Tsuchida, T; Yamazaki, N; Yanagisawa, H | 1 |
| Allman, K; Beach, J; Elson, P; Garcia, JA; Gilligan, T; Martin, A; Ornstein, MC; Rini, BI; Wood, L | 1 |
| Fishkin, P; Karczmar, GS; Karrison, T; Medved, M; O'Donnell, PH; Oto, A; Stadler, WM; Sweis, RF; Szmulewitz, RZ; Towey, S | 1 |
| Basso, E; Bergamaschi, L; Carta, R; Casanova, M; Chiaravalli, S; Fagioli, F; Ferrari, A; Magni, C; Massimino, M; Tirtei, E | 1 |
| Chi, Y; Cui, CX; Du, CX; Song, Y; Sun, Y; Sun, YK; Wang, JW; Yang, L; Zhang, W; Zhou, AP | 1 |
| Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M | 1 |
| Hirabayashi, M; Hoashi, T; Nakajima, R; Saeki, H; Takahashi, N | 1 |
| Camille, N; Dang, RP; Genden, EM; Le, VH; McFarland, D; Miles, BA; Misiukiewicz, KJ; Teng, MS | 1 |
| Aurilio, G; Cossu Rocca, M; Cullurà, D; de Cobelli, O; Iacovelli, R; Nolè, F; Verri, E | 1 |
| Ali, SM; Amini, B; Elvin, JA; Erlich, RL; Gowen, K; Holmes, O; Meric-Bernstam, F; Miller, V; Piha-Paul, S; Ross, JS; Schrock, AB; Spritz, D; Stephens, PJ; Stockman, DL; Subbiah, V; Suh, JH; Vergilio, JA; Wang, WL; Zarzour, M; Zinner, R | 1 |
| Broncel, M; Crosier, S; Daley, F; Finetti, MA; Holmes, K; Huang, PH; Jenks, A; Luczynski, MT; McCarthy, F; Natrajan, RC; Payne, LS; Ryall, KA; Tan, AC; Tanos, B; Todd, JR; Vyse, S; Wai, P; Williamson, D; Wong, JP | 1 |
| Duffaud, F; Gelderblom, H; Grignani, G; Gronchi, A; Guida, M; Jones, RL; Kasper, B; Katz, D; Kollár, A; Litière, S; Marreaud, S; Safwat, A; Sleijfer, S; Stacchiotti, S; Steeghs, N; Touati, N; van der Graaf, WT | 1 |
| de Waal, YR; Leenders, W; Ottevanger, PB; Tops, B; van der Steen, MJ; Westermann, A | 1 |
| Aarts, MJ; Beerepoot, LV; Cirkel, GA; Dercksen, MW; Groenewegen, G; Haanen, JBAG; Hamberg, P; Klümpen, HJ; Lolkema, MP; Loosveld, OJL; Los, M; Peters, FPJ; Polee, MB; Portielje, JEA; Sleijfer, S; Tascilar, M; van den Berkmortel, F; van der Noort, V; Voest, EE | 1 |
| Bedke, J; Stühler, V | 1 |
| Huang, X; Li, W; Tan, Z; Wang, H; Wang, J; Yu, R; Zhang, L; Zhang, Y; Zhong, J | 1 |
| Li, J | 1 |
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
| Fujiwara, K; Hasegawa, K; Kozawa, E; Nishikawa, T; Yabuno, A; Yasuda, M; Yoshida, H | 1 |
| Broutin, S; Le Cesne, A; Mir, O; Paci, A; Perret, A | 1 |
| Huitema, AD; Steeghs, N; Verheijen, RB | 1 |
| Carter, JJ; Fretwell, LV; Woolard, J | 1 |
| Fujita, H; Kadono, T; Kimura, T; Masui, Y; Miyagaki, T; Miyagawa, T; Saigusa, R; Sato, S; Yamada, D; Yoshizaki, A | 1 |
| Abdulfatah, E; Kukreja, G; Nagasaka, M; Sukari, A; Vaishampayan, U | 1 |
| Abe, K; Funakoshi, Y; Ito, N; Kawata, S; Moriuchi, H; Okada, M | 1 |
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
| Kaneko, T; Koike, K; Kurata, T; Motobayashi, M; Nakazawa, Y; Sano, K; Shigemura, T; Sumi, T; Suzuki, S; Watanabe, T | 1 |
| Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A | 1 |
| Bono, P; Peltola, K; Penttilä, P; Poussa, T; Rautiola, J | 1 |
| Benson, C; Hatcher, H; Jones, RL; Judson, I; Messiou, C; Miah, A; Szucs, Z; van der Graaf, WT; Wong, HH; Zaidi, S | 1 |
| Bersanelli, M; Buti, S; Caffo, O; De Giorgi, U; Facchini, G; Fornarini, G; Fraccon, AP; Gelsomino, F; Leonardi, F; Librici, C; Maines, F; Maruzzo, M; Masini, C; Morelli, F; Prati, G; Santoni, M; Sava, T; Verri, E; Vitale, MG; Zustovich, F | 1 |
| Choudhury, Y; Kanesvaran, R; Li, H; Poh, J; Qu, Y; Tan, HS; Tan, MH; Toh, YC; Xing, J; Yu, H | 1 |
| Agarwal, N; Ghate, SR; Li, N; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML | 1 |
| Afriansyah, A; Hamid, AR; Mochtar, CA; Umbas, R | 1 |
| Booth, L; Dent, P; Kirkwood, JM; Lee, J; Poklepovic, A; Roberts, JL; Sander, C | 1 |
| Blay, JY; Clippe, S; Collard, O; Ducimetiere, F; Ladarre, N; Laramas, M; Manson, S; Mercier, F; Ray-Coquard, I; Stefani, L; Suchaud, JP; Tehard, B | 1 |
| Beijnen, JH; Huitema, ADR; Schellens, JHM; Steeghs, N; Verheijen, RB | 1 |
| Capri, S; Delea, TE; Porta, C | 1 |
| Abdel-Rahman, O; Elhalawani, H; Heiba, M | 1 |
| Laguna, MP | 2 |
| Fader, AN; Ricci, S; Stone, RL | 1 |
| Aggarwal, R; Bartelink, I; Cripps, A; Grabowsky, J; Harb, A; Jahan, T; Leng, J; Mastroserio, I; Munster, PN; Pawlowska, N; Reinert, A; Ryan, CJ; Thomas, S; Truong, TG | 1 |
| Kishikawa, H; Nakagawa, M; Nakazawa, S; Nishimura, K; Sekii, Y; Yoshinaga, M | 1 |
| Ghate, SR; Li, N; Liu, Z; Pal, SK; Perez, JR; Signorovitch, JE; Vogelzang, NJ; Zichlin, ML | 1 |
| Stone, L | 1 |
| Albiges, L; Ficarra, V; Heng, DY; Hsieh, JJ; Larkin, J; Purdue, MP; Schmidinger, M; Signoretti, S; Swanton, C | 1 |
| Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M | 1 |
| Barlesi, F; Bennouna, J; Berard, H; Besse, B; Debieuvre, D; Gervais, R; Jacquot, S; Lacas, B; Lena, H; Mazières, J; Milleron, B; Molinier, O; Moreau, L; Morin, F; Moro-Sibilot, D; Petit, L; Pignon, JP; Ribassin-Majed, L; Soria, JC; Souquet, PJ; Zalcman, G | 1 |
| Choe, SW; Kim, MJ; Kim, YH; Lee, YJ; P Oh, S; Sprecher, D | 1 |
| Endo, M; Fukushi, JI; Fukushima, S; Hatano, M; Iwamoto, Y; Matsumoto, Y; Matsunobu, T; Nabeshima, A; Okada, S; Yokoyama, N | 1 |
| Busico, A; Calareso, G; Colecchia, M; Crippa, F; Giannatempo, P; Lo Vullo, S; Mariani, L; Necchi, A; Nicolai, N; Pennati, M; Perrone, F; Raggi, D; Salvioni, R; Togliardi, E; Zaffaroni, N | 1 |
| Freeman, ML; Gibney, GT; Knepper, TC; McLeod, HL; Russell, JS | 1 |
| Ambert, V; Cambon-Thomsen, A; Castellano, D; Diekstra, MHM; Eisen, T; Fritsch, A; Garcia Donas, J; Guarch Troyas, R; Guchelaar, HJ; Hartmann, A; Hulsbergen-van de Kaa, C; Jaehde, U; Junker, K; Kiemeney, LALM; Martinez-Cardus, A; Masson, G; Maurits, JSF; Oosterwijk, E; Oosterwijk-Wakka, J; Oskarsdottir, A; Radu, MT; Rafnar, T; Rodriguez-Antona, C; Roessler, M; Ruijtenbeek, R; Stefansson, K; van der Zanden, LFM; Vermeulen, SH; Warren, A; Wessels, L | 1 |
| Alexander, L; Bahl, A; Birtle, A; Chakraborti, P; Crabb, SJ; Dixon-Hughes, J; Huddart, RA; Hussain, SA; Jagdev, S; Jones, RJ; Kelly, C; Morris, A; Paul, J; Powles, T; Protheroe, AS; Stobo, J; Stockdale, A; Sundar, S | 1 |
| Gandhi, S; George, S; Pandey, M | 1 |
| Fehnel, CR; Miller-Patterson, C | 1 |
| Chagin, K; Djousse, L; Fraeman, KH; Gagnon, DR; Hall, SA; Nelson, JJ; Nordstrom, BL; Shantakumar, S; van Herk-Sukel, MPP | 1 |
| Azad, NS; Gallagher, D; O'Connor, A; Ohaji, C; Rosner, G; Sartorius-Mergenthaler, S; Shroff, RT; Subbiah, V; Yarchoan, M; Zahurak, ML; Zinner, R | 1 |
| Duan, P; Fan, L; Gao, Q; Qu, W; Ren, M; Shen, Y; Silwal, BM | 1 |
| Burger, DM; Desar, IME; Kweekel, DM; Lankheet, NAG; Mulder, SF; van der Graaf, WTA; van Erp, NP; van Herpen, CML | 1 |
| Araki, K; Fujikura, M; Koshikawa, H; Kurita, A; Suzuki, M; Tsukie, T | 1 |
| Agelaki, S; Fountzilas, G; Georgoulias, V; Hartabilas, E; Karavassilis, V; Katsaounis, P; Kentepozidis, N; Koinis, F; Kotsakis, A; Messaritakis, I; Peroukidis, S; Samantas, E; Varthalitis, II | 1 |
| Araki, N; Hamada, K; Imura, Y; Itoh, K; Kaneko, K; Myoui, A; Naka, N; Nakai, S; Nakai, T; Outani, H; Takenaka, S; Ueda, T; Yamada, S; Yasuda, N; Yoshikawa, H | 1 |
| Doehn, C; Ehneß, R; Goebell, PJ; Grüllich, C; Grünwald, V; Steiner, T; Welslau, M | 1 |
| Dinkic, C; Eichbaum, M; Fricke, HC; Gebauer, G; Grischke, EM; Lenz, F; Marme, F; Rom, J; Schmidt, M; Schneeweiss, A; Sohn, C; Wallwiener, M | 1 |
| Desar, IME; Kaal, SEJ; Soomers, VLMN; van der Graaf, WTA; van Erp, NP; Verwiel, J | 1 |
| Jung, KS; Kang, JH; Kim, HY; Lee, JL; Lee, KH; Lee, S; Lee, SH; Lee, SJ; Lim, HY; Lim, JY; Park, SH; Rha, SY | 1 |
| Araki, N; Kawai, A; Takahashi, S; Ueda, T; Yonemori, K | 1 |
| Ardizzoni, A; Berardi, R; Bersanelli, M; Biasco, E; Buti, S; Cossu Rocca, M; De Giorgi, U; Fornarini, G; Galli, L; Guida, A; Iacovelli, R; Lolli, C; Masini, C; Massari, F; Mosca, A; Nolè, F; Pastorino, A; Pinto, C; Sabbatini, R; Santoni, M; Terrone, C; Tortora, G | 1 |
| Cook, G; Goh, V; Kelly-Morland, C; Mallett, S; Montana, G; Nathan, P; Rudman, S | 1 |
| Amdahl, J; Chandiwana, D; Delea, TE; Diaz, J; Park, J; Sharma, A | 1 |
| Anderson, LN; Chow, LQ; Doot, R; Failor, A; Mankoff, D; Pantel, A; Roth, M; Santana-Davila, R | 1 |
| Frampton, JE | 1 |
| Altman, RB; Klein, TE; Sharma, MR; Thorn, CF | 1 |
| Aiello, N; Barra, F; Bogani, G; Ditto, A; Ferrero, S; Leone Roberti Maggiore, U; Lorusso, D; Raspagliesi, F | 1 |
| D'Amelio, AM; Figlin, RA; Gagnon, RC; Heymach, JV; Hutson, TE; Liu, Y; Pandite, LN; Sternberg, CN; Tran, HT; Zurita, AJ | 1 |
| Auchus, RJ; Bible, KC; Burton, JK; Harris, P; Jasim, S; Jimenez, C; Sideras, K; Suman, VJ; Worden, FP | 1 |
| Adachi, S; Kato, I; Okamoto, T; Saida, S; Umeda, K | 1 |
| Brands, RC; De Donno, F; Hartmann, S; Knierim, LM; Kübler, AC; Müller-Richter, UDA; Seher, A; Steinacker, V | 1 |
| Bortlicek, Z; Buchler, T; Chloupková, R; Dusek, L; Fiala, O; Finek, J; Hornova, J; Kiss, I; Kopeckova, K; Kopecky, J; Lakomy, R; Melichar, B; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M | 1 |
| Benson, C; Freivogel, KW; Gelderblom, H; Grignani, G; Jobanputra, M; Judson, IR; Katz, D; Manson, SC; Merimsky, O; Mungul, A; Sanfilippo, R; Stein, D | 1 |
| Craven, C; Grossniklaus, HE; Kompella, U; Matter, B; Olsen, TW; Schmit, J; Tran, J; Wabner, K | 1 |
| Dalhaug, A; Nieder, C; Norum, J; Pawinski, A; Syed, MA | 1 |
| Durand-Zaleski, I; Fleury, L; Maroun, R; Maunoury, F; Nachbaur, G; Vanhille, JL | 1 |
| Blay, JY; Boye, K; Brahmi, M; Casali, PG; Duffaud, F; Fedenko, A; Gelderblom, H; Hindi, N; Italiano, A; Kawai, A; Kobayashi, E; Kosela, H; Le Cesne, A; Maki, RG; Martin-Broto, J; Mir, O; Patel, S; Provenzano, S; Rutkowski, P; Somaiah, N; Stacchiotti, S; Sundby Hall, K; Vincenzi, B | 1 |
| Penel, N | 1 |
| Fife, K; Warren, A | 1 |
| Kelly, C; Paul, J; Powles, T; Stobo, J | 1 |
| Horiguchi, M; Uno, H; Wei, LJ | 1 |
| Joussen, AM; Zeitz, O | 1 |
| Calareso, G; de Braud, F; Grassi, P; Mennitto, A; Porcu, L; Prisciandaro, M; Procopio, G; Ratta, R; Verzoni, E | 1 |
| Bahleda, R; Blanc, E; Boyle, H; Cassier, P; Chatelut, E; Escudier, B; Hollebecque, A; Metzger, S; Négrier, S; Pérol, D; Soria, JC | 1 |
| Chandramohan, J; George, AA; Georgy, JT; Mathuram, AJ | 1 |
| Chawla, SP; Kaiser, PE; Milhem, MM; Portnoy, DC; Priebat, DA; Samuels, BL; Skubitz, KM; Somaiah, N; Staddon, AP; Stepanski, EJ; Walker, MS | 1 |
| Bhamra, A; Broncel, M; Huang, PH; McCarthy, F; Paul, A; Vyse, S; Wong, JP | 1 |
| Gilbert, JA | 1 |
| Brock, P; Dillhoff, M; Espinosa, A; Kirschner, LS; Konda, B; Owen, D; Patel, S; Phay, J; Schmidt, CR; Shah, MH; Shirley, L | 1 |
| Davidson, D; Jones, RL; Katz, D; Loggers, ET; Pollack, SM; Rodler, ET | 1 |
| Hebron, ML; Javidnia, M; Kinney, NG; Moussa, CE; Xin, Y | 1 |
| Aimone, P; Bao, W; Carrasco-Alfonso, MJ; Choueiri, TK; Chowdhury, S; Doehn, C; Donskov, F; Gross-Goupil, M; Haas, NB; Kopyltsov, E; Lee, JL; Lim, HY; McDermott, R; Melichar, B; Michael, A; Motzer, RJ; Reaume, MN; Rini, BI; Russo, P; Stenzl, A; Sternberg, CN; Varlamov, S; Voi, M; Wood, LA; Zemanova, M | 1 |
| De Lobel, L; De Maeseneer, D; De Meerleer, G; De Wolf, K; Decaestecker, K; Fonteyne, V; Goetghebeur, E; Lumen, N; Ost, P; Rottey, S; Sundahl, N; Vermaelen, K | 1 |
| Akaike, K; Hayashi, T; Hosoya, M; Kaneko, K; Kim, Y; Kobayashi, E; Kohsaka, S; Kubota, D; Mogushi, K; Mukaihara, K; Okubo, T; Saito, T; Sato, S; Suehara, Y; Tanabe, Y | 1 |
| Fukuda, R; Gotoh, N; Hashida, M; Hashida, Y; Murakami, T; Suda, K; Tsujikawa, A; Yoshimura, N | 1 |
| Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Goldwasser, F; Joly, C; Thomas-Schoemann, A; Tlemsani, C; Vidal, M | 1 |
| Chellappan, DK; Chellian, J; Foo, JH; Gupta, G; Hang, LY; Ling, J; Nathan, S; Ng, ZY; Sim, YJ; Singh, Y; Theng, CW; Wong, M; Yang, GJ | 1 |
| Coen, M; Cramer, B; Serratrice, J | 1 |
| Choi, H; Gupta, S; Kang, HC; Lu, L; Matrana, MR; Tannir, NM; Wei, W | 1 |
| Ariad, S; Douvdevani, A; Dresler, H; Keizman, D; Mermershtain, W; Neulander, EZ; Riff, R; Rouvinov, K; Shani-Shrem, N | 1 |
| Deguchi, S; Endo, M; Hayashi, N; Katagiri, H; Mitsuya, K; Murata, H; Nakasu, Y; Takahashi, M; Wasa, J | 1 |
| Figlin, RA; Leibovich, BC; Negrier, S; Stewart, GD | 1 |
| Agarwal, N; Ghate, SR; Li, N; Meiselbach, MK; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML | 2 |
| Akiyama, M; Chen, KR; Hioki, T; Makita, S; Takama, H; Watanabe, D | 1 |
| Abe, S; Akiyama, T; Goto, T; Hirai, T; Ikegami, M; Kawano, H; Kobayashi, H; Ohki, T; Oka, H; Okuma, T; Sato, K; Sawada, R; Shinoda, Y; Tanaka, S | 1 |
| Abdelwahed, R; Arakawa, H; Ellawatty, WEA; Fujita, KI; Ishida, H; Kato, Y; Masuo, Y; Nakamichi, N; Sasaki, Y; Yamazaki, E | 1 |
| Akashi, K; Arita, S; Ariyama, H; Baba, E; Jiroumaru, R; Kusaba, H; Nakano, T; Nio, K; Oda, Y; Tsuchihashi, K; Yasumatsu, R; Yoshihiro, T | 1 |
| Bupathi, M; Chen, JL; Hays, JL | 1 |
| Andrianteranagna, M; Anthony, E; Aynaud, MM; Baulande, S; Bohec, M; Bourdeaut, F; Cairo, S; Chauvin, C; Del Nery, E; Delattre, O; Han, ZY; Leruste, A; Lescure, A; Maillot, L; Masliah-Planchon, J; Richer, W; Roman-Roman, S; Surdez, D; Tauziede-Espariat, A; Zaidi, S | 1 |
| Benjamin, RS; Dembla, V; Fu, S; Groisberg, R; Herzog, CE; Hess, K; Hong, DS; Janku, F; Karp, DD; Meric-Bernstam, F; Patel, S; Piha-Paul, SA; Ravi, V; Roszik, J; Somaiah, N; Subbiah, V; Wheler, J; Zinner, R | 1 |
| Cefalu, M; Guo, A; Ho, TH; Janssen, P; Justice, C; Kempton, A; Makara, M; Smith, SA | 1 |
| Kim, HJ; Kim, Y; Lee, J; Lee, SJ; Park, SH | 1 |
| Kondo, T; Ochiya, T; Shiozawa, K; Shuting, J; Yoshioka, Y | 1 |
| Bruno, R; Chatelut, E; Ratain, MJ | 1 |
| Doshi, JA; Jahnke, J; Li, P; Pettit, AR; Wong, YN | 1 |
| Sleijfer, S; Vos, M | 1 |
| Benjamin, RS; Benson, J; Camacho, P; Cuglievan, B; Daw, N; Hayes-Jordan, A; Huh, W; Lamhamedi-Cherradi, SE; Leung, CH; Ludwig, JA; Menegaz, BA; Patel, S; Subbiah, V; Warneke, CL | 1 |
| Chen, SJ; Chen, YK; Cheng, FT; Chou, YY; Lapke, N; Ou-Yang, F; Tung, KC | 1 |
| Beuselinck, B; Caruana, L; Couchy, G; de Reyniès, A; Job, S; Joniau, S; Laguerre, B; Lerut, E; Oyen, R; Rioux-Leclercq, N; Van Den Eynde, K; Van Poppel, H; Verbiest, A; Wozniak, A; Zucman-Rossi, J | 1 |
| Aghajanian, C; Alvarez Secord, A; Carney, ME; Coleman, RL; Gray, HJ; Hanjani, P; Hu, W; Kehoe, SM; Landrum, LM; Lankes, HA; Pearl, ML; Richardson, DL; Sill, MW; Sood, AK; Van Le, L; Zhou, XC | 1 |
| 'Aho, T; Armitage, JN; Eisen, T; Fife, K; Klatte, T; Matakidou, A; Riddick, AC; Sachdeva, M; Stewart, GD; Welsh, SJ | 1 |
| Beijnen, JH; Huitema, ADR; Nan, L; Rosing, H; Schellens, JHM; Steeghs, N; Thijssen, B; Venekamp, N; Verheijen, RB | 1 |
| Hoffman-Censits, J; Mehrotra, P; Wilde, L | 1 |
| Barrett, C; Bologna, A; Buck, M; Calvert, P; Debruyne, P; du Bois, A; Friedlander, M; Herzog, TJ; Hilpert, F; Kim, JW; King, MT; Lee, CK; Lesoin, A; Malander, S; Meier, W; Monk, BJ; Petru, E; Poveda, A; Rau, J; Scambia, G; Shimada, M | 1 |
| Hasebe, N; Kabara, M; Maruyama, K; Matsuki, M; Nakagawa, N; Ogawa, Y; Shindo, M; Suzuki, A | 1 |
| Buchler, T; Chloupkova, R; Dusek, L; Fiala, O; Finek, J; Kiss, I; Kopeckova, K; Kopecký, J; Lakomy, R; Melichar, B; Petrakova, K; Poprach, A; Slaby, O; Studentova, H; Zemanova, M | 1 |
| Basterretxea-Badiola, L; Climent, MA; Muñoz-Langa, J; Santander-Lobera, C | 1 |
| Cooper, A; De Souza, P; Harris, BHL; Manders, P; Neciunaite, R; Walsh, JL | 1 |
| Díaz Gómez, E; García Díaz, B; Hidalgo Correas, FJ; Puebla Villaescusa, A; Ramírez Cruz, S; Salcedo Mingoarranz, ÁL | 1 |
| Bastholt, L; Bengtsen, C; Jensen, BL; Jensen, NV; Madsen, K; Tinning, AR | 1 |
| Yu-Li Su, H | 1 |
| Ball, MW; Srinivasan, R | 1 |
| Burk, O; Jeske, J; Keminer, O; Kronenberger, T; Kuzikov, M; Schwab, M; Thasler, WE; Windshügel, B; Wrenger, C | 1 |
| Bosse, T; Bovée, JVMG; Gelderblom, H; Verschoor, AJ; Warmerdam, FARM | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, BS; Kim, HG; Lee, KH; Lee, SH; Min, YJ; Park, K; Sun, JM; Yi, SY; Yun, HJ | 1 |
| Agresta, L; Dasgupta, R; Kim, H; Nagarajan, R; Plemmons, A; Pressey, JG; Sorger, JI; Szabo, S; Turpin, BK | 1 |
| Afsar, B; Armagan, B; Bilgetekin, I; Cetin, B; Demirci, U; Gulbahar, O; Gumusay, O; Ozet, A; Uner, A; Yılmaz, GE | 1 |
| Gunderson, CC; Matulonis, U; Moore, KN | 1 |
| Asthagiri, AR; Chen, CJ; Ilyas, A; Mehta, GU; Oldfield, EH; Schiff, D; Taylor, DG | 1 |
| Ativitavas, T; Kongsuphon, N; Konmun, J; Ngamphaiboon, N; Soukavanitch, M; Teeraaumpornpunt, N | 1 |
| Kushnir, I; Merimsky, O; Soyfer, V | 1 |
| Koc, ON; Parambil, JG; Woodard, TD | 1 |
| Hendriks, MP; van Kalleveen, MW; Walraven, M | 1 |
| Fulda, S | 1 |
| Chen, H; Jia, J; Li, X; Liu, D; Liu, L; Ma, J; Qiao, Y; Wang, W; Wang, Y; Wu, P; Xi, H; Yang, J; Zeng, Y; Zhang, L; Zhao, Y | 1 |
| Chougnet, C; Goldwirt, L; Huynh, HH; Le Maignan, C; Madelaine, I; Mourah, S; Plé, A; Pressiat, C; Sauvageon, H | 1 |
| Aston, J; Chism, DD; Du, L; Koyama, T; McAlister, RK; Pollack, M | 1 |
| Sugihara, H; Taylor, LS | 1 |
| Desar, IME; Fleuren, EDG; van der Graaf, WTA | 1 |
| Buclin, T; Cagnon, L; Cardoso, E; Csajka, C; Decosterd, L; Diezi, M; Ellefsen-Lavoie, K; Homicsko, K; Mercier, T; Michielin, O; Wagner, AD; Widmer, N | 1 |
| Allal, B; Arellano, C; Chatelut, E; Lafont, T; Le Louedec, F; Paludetto, MN; Puisset, F | 1 |
| Bakouny, Z; Eid, R; Haddad, FG; Kattan, J; Kourie, HR | 1 |
| Bun, S; Ebata, T; Fujiwara, Y; Miyake, M; Narita, Y; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yoshida, A | 1 |
| Bando, Y; Fujisawa, M; Furukawa, J; Guru, KA; Harada, K; Hinata, N; Hussein, AA; Nakano, Y; Shigemura, K; Terakawa, T | 1 |
| Foo, WC; George, DJ; Labriola, M; Zhang, T | 1 |
| Alavi, SN; Florou, V; Tinoco, G; Trent, JC; Wilky, BA | 1 |
| Arbour, KC; Riely, GJ | 1 |
| Burris, HA; Daniel, DB; Finney, L; Gian, VG; Greco, FA; Hainsworth, JD; Heymach, JV; Lipman, AJ; Shih, KC; Spigel, DR; Waterhouse, DM | 1 |
| Almonacid, DE; Bascur, JP; González-Nilo, FD; Juritz, EI | 1 |
| Asai, T; Horie, S; Ichiyanagi, O; Kabasawa, T; Kato, T; Nishida, H; Sakurai, T; Tsuchiya, N; Yagi, M | 1 |
| Ahmad, QI; Ghate, S; Jiao, X; Park, J; Vogelzang, NJ; Wilson, T | 1 |
| Dietrich, M; Grünwald, V; Pond, GR | 1 |
| Beijnen, JH; Groenland, SL; Herbrink, M; Huitema, ADR; Nuijen, B; Schellens, JHM; Steeghs, N | 1 |
| Hanashi, A; Ishikawa, A; Kakutani, S; Kinoshita, Y; Miyamoto, S; Sato, Y | 1 |
| Botticelli, A; Calabrò, F; Caponnetto, S; Gelibter, A; Marchetti, P; Napoletano, C; Nuti, M; Rahimi, H; Rossi, E; Rughetti, A; Ruscito, I; Schinzari, G; Zizzari, IG | 1 |
| Alentorn, A; Apra, C; Kalamarides, M; Mokhtari, K; Sanson, M | 1 |
| Baich, TM; Derbala, MH; Guo, AS; Ho, TH; Justice, CN; Kempton, AN; Smith, SA | 1 |
| Bhatia, S; Blom, A; Nghiem, P; Olencki, T; Parvathaneni, U; Tarabadkar, ES; Thomas, H | 1 |
| Cihan, YB | 1 |
| Albersen, M; Bastin, J; Bechter, O; Beuselinck, B; Clement, P; Decallonne, B; Dumez, H; Lerut, E; Oyen, R; Punie, K; Schöffski, P; Vanderschueren, D; Verbiest, A; Werbrouck, E; Wildiers, H; Woei-A-Jin, FJ; Wolter, P | 1 |
| Iida, S; Joh, T; Kanamori, T; Kataoka, H; Kinoshita, S; Komatsu, H; Kondo, M; Kuroda, J; Mori, Y; Takemoto, M | 1 |
| Kerbel, RS; Man, S; Reguera-Nuñez, E; Xu, P | 1 |
| Chou, CJ; Huang, Y; Jia, Y; Li, X; Liang, X; Xu, W; Zang, J; Zhang, Y | 1 |
| Ahmad, Q; Azad, A; Carrasco-Alfonso, MJ; Chang, YH; Chung, J; Davis, ID; Guo, J; Han, J; Jin, J; Lee, JL; Lim, HY; Motzer, R; Nanua, B; Oya, M; Rha, SY; Takahashi, S; Tatsugami, K; Uemura, H; Wu, HC | 1 |
| Anurova, O; Asano, N; Ben-Ami, E; Benjamin, RS; Blay, JY; Boye, K; Brahmi, M; Broto, JM; Brunello, A; Casali, PG; Collini, P; Dei Tos, AP; Desar, IME; Fedenko, A; Flucke, U; Frezza, AM; Gelderblom, H; Grignani, G; Gronchi, A; Hall, KS; Hornick, JL; Jones, RL; Kawai, A; Lo Vullo, S; Lobmaier, I; Lucibello, F; Mariani, L; Mir, O; Palmerini, E; Philippe, T; Picci, P; Ranchere, D; Ratan, R; Renne, SL; Rutkowski, P; Sbaraglia, M; Stacchiotti, S; Teterycz, P; Thway, K; Vincenzi, B; Wagner, AJ; Wagrodzki, M; Wang, WL; Yoshida, A | 1 |
| Arslan, BM; Bajrami, A; Cabalar, M; Demir, E; Yayla, V | 1 |
| Gonzalez, FJ; Li, F; Liang, WQ; Wang, YK; Xiao, XR; Xiao, Y; Yang, XN; Zhao, Q | 1 |
| Chang, YS; Chou, WC; Huang, KG; Huang, PW; Hung, CY; Liau, CT; Liu, CT; Lu, CH; Shen, WC; Su, YL | 1 |
| Lozano Cejudo, C; Martín-Lagos Maldonado, A; Sáenz Lozano, A | 1 |
| El-Masry, M; Fruehauf, JP; Jakowatz, JG; Osann, K; Parmakhtiar, B; Yamamoto, M | 1 |
| Basso, U; Bearz, A; Berruti, A; Bracarda, S; Buti, S; Cartenì, G; Caserta, C; Cognetti, F; Cortesi, E; De Giorgi, U; Fornarini, G; Galli, L; Giannarelli, D; Lo Re, G; Pignata, S; Porta, C; Procopio, G; Rastelli, F; Sabbatini, R; Sternberg, CN; Turci, D | 1 |
| Bajpai, P; Gupta, VG; Rangaraju, RR; Saha, R | 1 |
| Adachi, A; Komine, M; Maekawa, T; Murata, S; Ohtsuki, M | 1 |
| Benedetti Panici, P; Tomao, F; Tomao, S | 1 |
| Coleman, RL; Richardson, DL; Sill, MW | 1 |
| Sherman, EJ; Tchekmedyian, V | 1 |
| Ciccarese, C; Iacovelli, R; Mosillo, C; Tortora, G | 1 |
| Amann, K; Büttner, A; Büttner-Herold, M; Daniel, C; Klewer, M; Pfister, F | 1 |
| Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kanaya, F; Kawaguchi, K; Kiyuna, T; Li, Y; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Russell, TA; Singh, AS; Singh, SR; Tome, Y | 1 |
| Biasco, E; Caserta, C; De Giorgi, U; Detti, B; Fornarini, G; Galli, L; Iacovelli, R; Masini, C; Morelli, F; Mosca, A; Palesandro, E; Paolieri, F; Santini, D; Sbrana, A | 1 |
| Arellano, C; Bernardes-Génisson, V; Bijani, C; Paludetto, MN; Puisset, F; Robert, A | 1 |
| Aboelhassan, R; Barsoum, M; Basaran, M; Erman, M; Esma, K; Hanene, D; Kamel, B; Karaca, B; Memon, MA; Pilipovic, V; Sevinc, A; Slader, C | 1 |
| Beckham, TH; Brinkman, T; Fagin, JA; Groen, AH; Lee, NY; McBride, S; Riaz, N; Romesser, PB; Sabol, C; Sabra, M; Shaha, AR; Sherman, EJ; Spielsinger, D; Tsai, CJ; Tuttle, RM; Wong, RJ | 1 |
| Campagna, A; Rodriguez-Pla, A; Wang, H | 1 |
| Pavlović, M; Šeparović, R; Silovski, T; Tečić Vuger, A | 1 |
| Berry, P; Chakinala, MM; Donaldson, J; Faughnan, ME; Gossage, JR; Hughes, CCW; Kasthuri, R; McWilliams, JP; Oh, SP; Parambil, JG; Paul, G; Sprecher, DL; Vozoris, N | 1 |
| Arroyo, A; Choueiri, TK; Dean, M; Escudier, B; Geertsen, PF; George, D; Grande, E; Gross-Goupil, M; Gurney, H; Kollmannsberger, C; Markby, DW; Motzer, RJ; Pal, S; Park, SH; Pikiel, J; Powles, T; Rha, SY; Suarez, C | 1 |
| Bastos, DA; Bonadio, RRCC; Dzik, C; Isaacsson Velho, P; Marta, GN; Muniz, DQB; Nardo, M; Souza, MCLA | 1 |
| Abate, ME; Boye, K; Cesari, M; Donati, D; Hompland, I; Longhi, A; Paioli, A; Palmerini, E; Setola, E; Spinnato, P | 1 |
| Bellmunt, J; Bossé, D; Choueiri, TK; Harshman, LC; Jacobus, S; Lalani, AA; Lundgren, K; Moreno, I; Polacek, L; Rosenberg, JE; Takeda, DY; Van Allen, EM; Wagle, N; Wankowicz, SA | 1 |
| Gan, ZJ; Hu, XN; Ran, DZ; Shang, SQ; Wang, HJ; Yuan, JY; Zhang, D | 1 |
| Chen, WJ; Wu, CC; Wu, IC; Yu, FJ | 1 |
| Ahrar, K; Fuller, GN; Gombos, DS; Jonasch, E; Liu, D; Matin, SF; McCutcheon, IE; Perrier, ND; Pilie, PG; Robichaux, CC; Villarreal, MF; Waguespack, SG; Weldon, JA; Woodson, AH | 1 |
| Giles, RH; Gläsker, S | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, M; Kim, TM; Kim, YJ; Moon, KC; Paeng, JC | 1 |
| Basappa, N; Bjarnason, GAG; Dragomir, A; Heng, D; Jewett, M; Kapoor, A; Kollmannsberger, C; Lévesque, E; Nazha, S; Reaume, MN; Soulières, D; Tanguay, S; Wood, L | 1 |
| Basso, U; Berardi, R; Bersanelli, M; Burattini, L; Buti, S; Conti, A; De Giorgi, U; Iuliani, M; Lolli, C; Maruzzo, M; Mazzucchelli, R; Montironi, R; Mosca, A; Piva, F; Santini, D; Santoni, M; Terrone, C | 1 |
| Albiges, L; Barthélémy, P; Bouleftour, W; Chevreau, C; Culine, S; Espenel, S; Fizazi, K; Gravis, G; Guillot, A; Houede, N; Joly, C; Mahammedi, H; Meriaux, E; Negrier, S; Oriol, M; Pouessel, D; Roubaud, G; Tartas, S; Tinquaut, F; Vassal, C | 1 |
| Ahmed, T; Balagani, A; Grosu, HB; Muhammad, HA; Ost, DE; Sabath, B; Vakil, E; Vial, MR | 1 |
| Chawla, S; Chmielowski, B; Dry, SM; Eckardt, MA; Eilber, FC; Higuchi, T; Hoffman, RM; Igarashi, K; Kanaya, F; Kawaguchi, K; Kiyuna, T; Li, Y; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Oshiro, H; Razmjooei, S; Russell, TA; Singh, AS; Singh, SR; Sugisawa, N; Tome, Y; Wangsiricharoen, S; Zhang, Z; Zhao, M | 1 |
| Bertozzi, CR; Brewer, WJ; Cambier, CJ; Cronan, MR; Foglia, MD; Marass, M; Poss, KD; Rossi, A; Stainier, DYR; Tobin, DM; Walton, EM | 1 |
| Basturk, O; Corrias, G; Giancipoli, RG; Keohan, ML; Klimstra, D; Mannelli, L; Monti, S; Sawan, P; Schillaci, O | 1 |
| Ahn, JB; Choi, YD; Chung, HC; Han, JW; Heo, SJ; Hur, H; Kim, HS; Kim, JH; Kim, KS; Kim, S; Kim, SH; Kim, SK; Lee, YH; Noh, SH; Park, HS; Rha, SY; Shin, KH; Suh, JS | 1 |
| Bauer, J; Grimm, D; Grosse, J; Infanger, M; Kopp, S; Krüger, M; Milling, RV; Wehland, M | 1 |
| Amin, A; Bauer, TM; Berghorn, E; Carducci, M; Ernstoff, MS; Hammers, HJ; Heng, DYC; Knox, J; Kollmannsberger, C; Lewis, LD; McDermott, DF; Plimack, ER; Rini, BI; Spratlin, J; Voss, MH; Yang, L | 1 |
| Liu, L; Mehta, CR; Theuer, C | 1 |
| Bins, S; Bouazzaoui, SE; Gelderblom, H; Hamberg, P; Huitema, ADR; Koolen, SLW; Laven, P; Mathijssen, RHJ; Sleijfer, S; Steeghs, N; van Erp, N; van Herpen, C; van Schaik, RHN; Yu, H | 1 |
| Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Gavalas, N; Gkerzelis, I; Karavasilis, V; Kostouros, E; Koutras, A; Koutsoukos, K; Samantas, E; Tzannis, K; Zagouri, F | 1 |
| Alva, AS; Daignault-Newton, S; Dedinsky, R; Felton, JA; Gersch, C; Karsies, D; Kraft, S; Rae, JM; Redman, BG; Reimers, MA; Riddle, L; Shango, MM; Wen, B | 1 |
| Corrie, P; Danson, S; Goff, M; Love, SB; Marshall, E; Mauch, C; Middleton, MR; Mohammed, SB; Plummer, E; Schadendorf, D; Scudder, C; Urbonas, V; Wheater, M; Zimmer, L | 1 |
| Fujisawa, M; Hinata, N; Jimbo, N; Shigemura, K; Shiraishi, Y; Terakawa, T | 1 |
| Kondo, T; Ochiya, T; Qiao, Z; Shiozawa, K; Shuting, J; Yoshioka, Y | 1 |
| Chien, CR; Geynisman, DM; Kim, B; Shih, YT; Xu, Y | 1 |
| Anido, U; Chirivella, I; Etxaniz, O; Fernández-Parra, E; Gallardo, E; Guix, M; Hernández, C; Lambea, J; Méndez-Vidal, MJ; Molina, Á; Montesa, Á; Pinto, Á; Ros, S | 1 |
| Ravaud, A | 1 |
| Groenland, SL; Huitema, ADR; Katz, D; Steeghs, N | 1 |
| Bedke, J; Beeker, A; Bögemann, M; Bokemeyer, C; Bolenz, C; De Santis, M; Frank, M; Grimm, MO; Gschwend, JE; Indorf, M; Lehmann, J; Leiber, C; Müller, L; Retz, M; Teber, D; van Alphen, R; Wirth, M; Zimmermann, U | 1 |
| Akers, LJ; Albritton, KH; Basha, R; Elete, KR; Ray, A | 1 |
| Ebi, H; Ikeda, H; Kotani, H; Ohtsubo, K; Takeuchi, S; Tanimoto, A; Yamada, T; Yamashita, K; Yano, S | 1 |
| Bae, WK; Byun, SS; Chung, HS; Chung, J; Hong, SH; Hwang, EC; Hwang, JE; Jeong, CW; Jung, SI; Kim, MS; Kwak, C; Kwon, DD; Park, JY; Seo, SI; Song, C | 1 |
| Agarwal, N; Batten, J; Boucher, K; Dechet, C; Gill, D; Hawks, JL; Jones, J; Liu, T; Lowrance, W; Martin, C; Maughan, BL; Nachaegari, G; Nussenzveig, R; Pal, SK; Salgia, M; Stephenson, R | 1 |
| Bernabeu, D; Biscuola, M; Blay, JY; Casali, PG; Collini, P; Cruz, J; de Alava, E; Dei Tos, AP; Diaz-Martin, J; Dopazo, J; Dumont, S; Garcia Del Muro, X; Grignani, G; Gutierrez, A; Hindi, N; Italiano, A; LeCesne, A; Lopez-Pousa, A; Martin-Broto, J; Martinez-Trufero, J; Moura, DS; Palmerini, E; Peña-Chilet, M; Ranchere-Vince, D; Redondo, A; Sebio, A; Stacchiotti, S; Taron, M | 1 |
| Riedel, RF | 1 |
| Jensen, E; Maganti, K; Raiker, NK; Wodzinski, B | 1 |
| Borchiellini, D | 1 |
| Hira, D; Ikeda, Y; Kageyama, S; Kawauchi, A; Morita, SY; Murai, R; Noda, S; Terada, T; Tomita, K; Tsuru, T; Yoshida, T | 1 |
| Jeon, SY; Lee, NR; Yim, CY | 1 |
| Albiges, L; Auclin, E; Auvray, M; Barthelemy, P; Bono, P; De Velasco, G; Escudier, B; Gravis, G; Gross-Goupil, M; Kellokumpu-Lehtinen, P; Mouillet, G; Mourey, L; Powles, T; Priou, F; Rolland, F; Vano, YA | 1 |
| Hayashi, K; Igarashi, K; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N | 1 |
| Bando, M; Endo, S; Hagiwara, K; Kurosaki, A; Mato, N; Niki, T; Onuki, T; Sakamoto, N; Takigami, A; Tetsuka, K; Yamasawa, H | 1 |
| Itonaga, I; Iwasaki, T; Kawano, M; Tanaka, K; Tsumura, H | 1 |
| Trent, JC; Van Tine, BA | 1 |
| Çiçin, İ; Demircan, NC; Erdoğan, B; Gökyer, A; Hacıoğlu, MB; Köstek, O; Tunçbilek, N; Uzunoğlu, S; Yılmaz, E | 1 |
| Kaneko, G; Kondo, H; Makabe, H; Nishimoto, K; Okabe, T; Oyama, M; Shirotake, S; Todo, M; Yasumizu, Y | 1 |
| Anota, A; Berthod, D; Bonnetain, F; Es-Saad, I; Fritzsch, J; Meurisse, A; Mouillet, G; Mouyabi, K; Paget-Bailly, S; Pozet, A; Thiery-Vuillemin, A; Vernerey, D | 1 |
| Barra, F; De Cian, F; Di Domenico, S; Ferraioli, D; Ferrero, S; Tantari, M; Vellone, VG | 1 |
| Blay, JY; Gelderblom, H; Gronchi, A; Le Cesne, A; Leahy, M; Lia, M; Litière, S; Mathijssen, RHJ; Mir, O; Sleijfer, S; Touati, N; Van der Graaf, WT; Van Erp, NP; Young, R | 1 |
| Ak, G; Bozkaya, ÜF; Hamarat Şanlıer, Ş; Tanıyan, G; Ünal, A; Yıldırım, Y; Yıldız Türkyılmaz, G; Yılmaz, H | 1 |
| Fujisawa, M; Furukawa, J; Harada, K; Hinata, N; Inoue, T; Nakamura, I; Nakano, Y; Ogawa, T; Okamura, Y; Terakawa, T | 1 |
| Gourd, E | 1 |
| Hasunuma, N; Manabe, M; Osada, SI; Toyoshima, A; Yamada, K; Yamada, M | 1 |
| Fujita, KI; Ishida, H; Iwase, M; Kato, Y; Kiuchi, Y; Masuo, Y; Nishimura, Y; Seba, N | 1 |
| Kirkwood, JM; Massa, RC | 1 |
| He, J; Li, Z; Ren, X; Tu, C; Zhang, C | 1 |
| Hindi, N; Martin-Broto, J; Moura, DS | 1 |
| DE Geus-Oei, LF; Desar, IME; Grootjans, W; Koenen, AM; Oyen, WJ; Steeghs, N; VAN DER Graaf, WT; VAN Erp, NP; Verheijen, RB; Vlenterie, M | 1 |
| Attenberger, U; Derigs, HG; Dimitrakopoulou-Strauss, A; Gaiser, T; Hohenberger, P; Jakob, J; Karampinis, I; Kasper, B; Nowak, K; Pilz, L; Ronellenfitsch, U; Sachpekidis, C; Schwarzbach, M | 1 |
| Ahmad, Q; Bamias, A; Bono, P; Dezzani, L; Hawkins, R; Hirschberg, Y; Jonasch, E; Kalofonos, H; Pisal, CB; Procopio, G; Sanchez, AR; Schmidinger, M; Srihari, N; Vázquez, S | 1 |
| Hsiao, HH; Lin, MH | 1 |
| Chen, S; Gong, P; Huang, C; Lowerison, MR; Lucien, F; Song, P; Wang, D | 1 |
| Berdel, WE; Bormann, E; Brümmendorf, TH; Crysandt, M; Gerss, J; Hartmann, W; Kessler, T; Kirsch, A; Koschmieder, S; Lenz, G; Mikesch, JH; Müller-Tidow, C; Pohlen, M; Schliemann, C; Stelljes, M; Vehring, K; von Stillfried, S; Wardelmann, E | 1 |
| Hata, H; Imafuku, K; Kitamura, S; Maeda, T; Masuzawa, M; Shimizu, H; Yanagi, T | 1 |
| Fukuda, H; Iizuka, J; Ishida, H; Ishihara, H; Kobayashi, H; Kondo, T; Okumi, M; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Milhem, M; Stein, J; Vaena, D | 1 |
| Skubitz, KM | 1 |
| Christian, S; Danciu, OC; Dudek, AZ; Fischer, JH; Liu, LC; Russell, MJ; Shah, HA; Venepalli, NK; Zacny, JP | 1 |
| Anzawa, K; Ishizaki, Y; Mochizuki, T; Watanabe, J | 1 |
| Abbas, H; Alam, T; Faust, G; Nair, A; Paskins, J; Uccello, M | 1 |
| Hohenberger, P; Ronellenfitsch, U | 1 |
| Ferreira, AO; Fidalgo, C; Gouveia, C; Palmela, C | 1 |
| Chatzidimitriou, E; Christofidou, E; Dimitrakopoulou, A; Kostaki, M; Plaka, M; Polydorou, D; Stathopoulou, A; Stratigos, A; Zaras, A | 1 |
| Donskov, F; Fristrup, N | 1 |
| Cao, Z; Deng, H; Hong, Z; Huang, Y; Wei, Y; Yuan, X; Zhang, W | 1 |
| Burger, DM; Colbers, A; Gelderblom, H; Hamberg, P; Jansman, FGA; Lubberman, FJE; Luelmo, S; Moes, DJAR; Mulder, SF; van der Graaf, WTA; van Erp, NP; van Herpen, CML; Vervenne, WL | 1 |
| Dry, SM; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Kiyuna, T; Li, Y; Miwa, S; Miyake, K; Miyake, M; Nelson, SD; Russell, TA; Singh, SR; Tsuchiya, H; Yamamoto, N | 1 |
| Carter, JJ; Cooper, SL; March, J; Woolard, J | 1 |
| Ahmed, S; Azad, NS; Ball, DW; Bishop, JA; Gocke, CD; Ha, Y; Karunsena, E; Kurzrock, R; Nelkin, BD; O'Connor, A; Parkinson, RM; Rudek, MA; Sharma, R; Sherman, SI; Subbiah, V; Zahurak, ML; Zinner, R | 1 |
| Ahmad, Q; Bamias, A; Bono, P; Dezzani, L; Estevez, SV; Hawkins, R; Hirschberg, Y; Jonasch, E; Kalofonos, H; Pisal, CB; Procopio, G; Rodriguez, CS; Sánchez, AR; Schmidinger, M; Srihari, N | 1 |
| Barangi, M; Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Homma, Y; Katsuya, Y; Li, Y; Matsuyama, R; Miyake, K; Murakami, T; Nelson, SD; Oshiro, H; Park, JH; Razmjooei, S; Singh, SR; Sugisawa, N; Zhang, Z | 1 |
| Chow, A; Lifton, J; Moshfeghi, AA | 1 |
| Antoniou, G; Bertulli, R; Blay, JY; Brahmi, M; Casali, PG; Collini, P; Dei Tos, AP; Dufresne, A; Fucà, G; Fumagalli, E; Gronchi, A; Grosso, F; Hindi, N; Jones, RL; Le Cesne, A; Mir, O; Provenzano, S; Sanfilippo, R; Sbaraglia, M; Stacchiotti, S | 1 |
| Von Mehren, M | 1 |
| Albersen, M; Albigès, L; Beuselinck, B; Caruso, S; Couchy, G; Elaidi, RT; Fridman, WH; Job, S; Laenen, A; Lerut, E; Oudard, S; Renders, I; Rioux-Leclercq, N; Sautès-Fridman, C; Schöffski, P; Vano, Y; Verbiest, A; Verkarre, V; Wozniak, A; Zucman-Rossi, J | 1 |
| Bauernhofer, T; Gerritsmann, H; Kratochvill, F; Kretz, M; Loidl, W; Marszalek, M; Mitterberger, M; Mraz, B; Niedersüß-Beke, D; Pfleger, G; Pichler, R; Schmidinger, M; Stöger, H; Tinchon, C; Tulchiner, G; Vogl, U; Wiesinger, CG | 1 |
| Chen, JL; Hoffman, SE; Legasto, CS; McLaughlin, EM; Pisano, SG; Porter, K | 1 |
| Chandramohan, A; Corn, PG; Devine, CE; Gonzalez, GMN; Karam, JA; Lim, ZD; Msaouel, P; Pruitt, L; Ross, JA; Tannir, NM; Wang, J; Wang, X; Wood, CG; Zurita, AJ | 1 |
| Araki, N | 1 |
| Baker, LH | 1 |
| Bernabeu, D; Blay, JY; Brenca, M; Brich, S; Casali, PG; Castelli, C; Collini, P; Cruz, J; Dagrada, GP; de Alava, E; Dumont, S; Ferrari, S; Frezza, AM; Grignani, G; Gutierrez, A; Hindi, N; Italiano, A; Karanian, M; LeCesne, A; Lopez-Pousa, A; Maestro, R; Martin-Broto, J; Morosi, C; Palmerini, E; Penel, N; Racanelli, D; Redondo, A; Stacchiotti, S; Vallacchi, V; Vaz Salgado, MA | 1 |
| Badolo, L; Jede, C; Koziolek, M; Kubas, H; Lecomte, M; Wagner, C; Weber, C; Weigandt, M; Weitschies, W | 1 |
| Altavilla, A; Attademo, L; De Giorgi, U; De Lisi, D; Pignata, S; Procopio, G; Santini, D; Verzoni, E | 1 |
| Domike, R; Gurumurthi, K; Kluetz, P; Pazdur, R; Raju, GK; Singh, H; Weinstock, C; Woodcock, J | 1 |
| Bagrodia, A; Bowman, I; Brugarolas, J; Choy, H; Christie, A; Courtney, K; Desai, N; Garant, A; Hammers, H; Hannan, R; Margulis, V; Mohamad, O; Schoenhals, J; Singla, N; Timmerman, R; Wang, C; Zhang, Y | 1 |
| Aglietta, M; Ahmad, Q; Bauer, S; Blay, JY; Cesne, AL; Demetri, GD; Dezzani, L; Gelderblom, H; Han, G; Hohenberger, P; Judson, I; Schöffski, P | 1 |
| Costa, RSD; Couto, DHN; Meirelles, IO | 1 |
| Balgetir, F; Er, MB; Gonen, M; Yildirim, N | 1 |
| Arranz, JA; Bellmunt, J; Calvo, A; Del Alba, AG; Del Muro, XG; Esteban, E; Etxaniz, O; Gallardo, E; Guix, M; Larriba, JLG; Maroto, P; Redrado, M; Sepúlveda, JM | 1 |
| Anand, M; Armstrong, AJ; Barak, I; George, DJ; Halabi, S; Harrison, MR; Healy, P; Klein, M; Martinez, E; Nixon, AB; Szmulewitz, R; Wilder, R; Winters, C | 1 |
| Blay, JY | 1 |
| Araujo, DM; Chow, W; Frankel, P; Hartner, L; Milhem, M; Okuno, S; Ruel, C; Staddon, A; Undevia, S | 1 |
| Esser, M; Gast, GC; Horger, M; Kloth, C; Kraus, MS; Reinert, CP; Thaiss, WM | 1 |
| Bologna, A; Calvert, PM; Carrasco-Alfonso, MJ; Colombo, N; Del Campo, JM; du Bois, A; Floquet, A; Friedlander, M; Fujiwara, K; Hanker, LC; Harter, P; Herzog, TJ; Kim, JW; Lee, JY; Meunier, J; Mirza, MR; Monk, BJ; Pignata, S; Rau, J; Tsibulak, I; Vergote, I | 1 |
| Arellano, C; Bernardes-Génisson, V; Chatelut, E; Paludetto, MN; Puisset, F; Robert, A; Stigliani, JL | 1 |
| Adam, J; Assi, T; Baldi, GG; Barisella, M; Ben-Ami, E; Benjamin, RS; Blay, JY; Casali, PG; Czarnecka, AM; Desar, I; Duffaud, F; Dufresne, A; Fedenko, A; Ferraro, R; Frezza, AM; Gelderblom, H; Gounder, M; Gronchi, A; Hornick, JL; Jones, RL; Kawai, A; Le Cesne, A; Lo Vullo, S; Maki, RG; Mariani, L; Meurgey, A; Mir, O; Noguchi, E; Pantaleo, MA; Ravi, V; Sbaraglia, M; Schuetze, S; Siontis, B; Stacchiotti, S; Teterycz, P; Thornton, K; Vincenzi, B; Wagner, AJ; Yonemori, K | 1 |
| Aspinall, SL; Becker, D; Cunningham, FE; Geraci, MC; Good, CB; Heron, BB; Lee, S; Prasad, V; Zhao, X | 1 |
| Eryılmaz, MK; Karaağaç, M | 1 |
| Belgioia, L; Bertulli, R; Buscaglia, M; Catalano, F; Comandini, D; Grassi, M; Rebuzzi, SE; Satragno, C | 1 |
| Arakawa, Y; Hara, T; Hosokawa, T; Oguma, E; Yamada, Y | 1 |
| Ito, K; Koike, H; Nishida, Y; Sakai, T | 1 |
| Italiano, A | 1 |
| Brown, JN; Hammond, JM; Lee, S; Sneed, GT | 1 |
| Anderson, E; Bell, AC; Fan, D; Ganly, I; Groen, AH; Kang, JJ; Lee, NY; Leeman, JE; Lok, BH; Ma, J; McBride, S; Olsen, KS; Riaz, N; Shaha, AR; Sherman, EJ; Tsai, CJ | 1 |
| Bjarnason, GA; Choueiri, TK; Dezzani, L; Grünwald, V; Han, J; Hutson, TE; Kollmannsberger, C; Motzer, RJ; Porta, C; Sternberg, CN; Tannir, NM | 1 |
| Chamberlain, S; Mole, DR; Protheroe, A; Purshouse, K; Soares, M; Tuthill, M | 1 |
| Campos-Gomez, S; Chacon, M; Del Castillo, C; Dezzani, L; Jenkins, M; Lema Medina, M; Lerzo, G; Lopera, D; Martin, A; Queiroz Muniz, D; Ratto, B; Salman, P; Signorovitch, J; Yang, H; Zhao, J | 1 |
| Bøttger, P; Donskov, F; Fink, TL; Hamilton-Dutoit, S; Henriksen, JN; Hermansen, CK; Ladefoged, SA; Nissen, PH | 1 |
| Altavilla, D; Cannavò, SP; Riso, G; Vaccaro, M | 1 |
| Elms, ML; Huang, PH; Jones, RL; Judson, I; Tan, AC; Wilding, CP | 1 |
| Guru, PK; Patel, PR; Pereira, ROL; Sanghavi, DK | 1 |
| Browne, LP; Cost, CR; Galambos, C; Knight-Perry, J; Koo, J | 1 |
| de Geeter, P; Decker, T; Quiering, C; Resch, A; Schmitz, S; Schostak, M | 1 |
| Cao, X; Gao, W; Jin, L; Poole, A; Ratto, B; Ravichandran, S; Swallow, E; Tang, D; Vogelzang, NJ | 1 |
| Alcoser, SY; Borgel, S; Bottaro, DP; Chen, AP; Chen, L; Chuaqui, R; Doroshow, JH; Ferry-Galow, KV; Hollingshead, MG; Kinders, RJ; Konaté, MM; Kummar, S; Lawrence, SM; Makhlouf, HR; Miller, SB; Navas, T; Parchment, RE; Rubinstein, L; Srivastava, AK; Subramanian, J; Vilimas, T; Voth, AR; Wilsker, DF | 1 |
| Aktepe, O; Bas, O; Erman, M; Guven, D; Kertmen, N; Kılıc, L; Ozbek, A | 1 |
| Aboagye, EO; Arshad, M; Barwick, TD; Challapalli, A; Chambers, E; Chen, M; Cole, T; Dubash, S; Gabra, H; Inglese, M; Lozano-Kuehne, JP; Montes, A; Sharma, R; Tharakan, G; Valls, PO | 1 |
| Haniuda, H; Horita, S; Kagawa, Y; Katagiri, M; Nakamura, H; Nakazato, T; Watanabe, M | 1 |
| Desar, IME; Steeghs, N; van der Graaf, WTA; van Erp, NP; Westerdijk, K | 1 |
| Akgül Babacan, N; Akın Telli, T; Alan, Ö; Alsan Çetin, İ; Arıkan, R; Başoğlu Tüylü, T; Çiçek, FC; Dane, F; Demircan, NC; Ercelep, Ö; Ergelen, R; Kaya, S; Öztürk, MA; Tinay, İ; Yumuk, PF | 1 |
| Orbach, D; Penel, N; Ryckewaert, T | 1 |
| Choi, H; Gupta, S; Kang, HC; Matrana, MR; Sun, J; Tannir, NM | 1 |
| Bay, JO; Bertucci, F; Bompas, E; Bozec, L; Chenuc, G; Chevreau, C; Cupissol, D; Delaye, J; Delcambre, C; Duffaud, F; Eymard, JC; Guillemet, C; Isambert, N; Italiano, A; Pautier, P; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Rios, M; Saada, E | 1 |
| Agostinetto, E; D'Amico, T; De Sanctis, R; Lorenzi, E; Santoro, A; Simonelli, M | 1 |
| Adjei, AA; Allen-Ziegler, K; Esplin, B; Mandrekar, SJ; Marchello, B; Molina, JR; Parikh, K; Tan, AD | 1 |
| Bertucci, F; Blay, JY; Bompas, E; Brodowicz, T; Chaigneau, L; Chevreau, C; Decoupigny, E; Delcambre, C; Italiano, A; Laroche, L; Le Cesne, A; Le Deley, MC; Mir, O; Penel, N; Ray-Coquard, I; Saada-Bouzid, E; Salas, S; Taieb, S; Vanseymortier, M; Wallet, J | 1 |
| Giuffrida, D; Puglisi, C; Puliafito, I; Russo, A; Sciacca, D | 1 |
| Banerjee, S; Clamp, AR; Dive, C; Hall, M; Hasan, J; Jayson, GC; Lyon, AR; Morgan, RD; Orbegoso, C; Rustin, GJS; Taylor, S; Tugwood, J; Zhou, C | 1 |
| Azam, C; Bardies, C; Canonge, JM; Chevreau, C; Claraz, P; Cottura, E; Guibaud, S; Le Goff, M; Mourey, L; Pelagatti, V; Pollet, O; Pouessel, D; Puisset, F; Vinson, C | 1 |
| Albuquerque, EV; Bastos, DA; Bonadio, RC; Cavalcante, A; Coelho, RF; Cordeiro, MD; Nahas, WC; Pontes, J; Sarkis, AS; Sierra, PS | 1 |
| Aravantinos, G; Demiri, S; Fountzilas, G; Koliou, GA; Lampropoulou, DI; Pectasides, D; Pentheroudakis, G; Psyrri, A; Razis, E; Samantas, E; Sgouros, J; Zagouri, F | 1 |
| Beijnen, JH; de Vries, N; Groenland, SL; Huitema, ADR; Koolen, SLW; Mathijssen, RHJ; Rosing, H; Steeghs, N; Thijssen, B; van Eerden, RAG; Verheijen, RB | 1 |
| Botikova, A; Dats, I; Dutka, I; Gazdikova, K; Kruzliak, P; Kubatka, P; Mytsyk, Y; Pasichnyk, S; Skrzypczyk, M; Urdzik, P; Uteuliyev, Y; Vorobets, D | 1 |
| Crucitta, S; Danesi, R; Del Re, M; Fogli, S; Gianfilippo, G; Porta, C; Rini, BI; Schmidinger, M | 1 |
| Bhatla, N; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Ray, MD; Sharma, A | 1 |
| Chen, L; Cheng, B; Cui, X; Gan, S; Hong, T; Li, J; Wang, C; Wang, Y; Zhang, J; Zuo, L | 1 |
| Edeline, J; Frenel, JS; Gilabert, M; Raoul, JL; Senellart, H | 1 |
| Araz, M; Artaç, M; Eryılmaz, MK; Kaplan, MA; Karaağaç, M; Sezgin, Y | 1 |
| Bernabeu, D; Blay, JY; Casali, PG; Collini, P; Cruz, J; de Alava, E; Diaz-Martin, J; Dopazo, J; Fernandez-Serra, A; Gonzalez-Aguilera, C; Grignani, G; Gutierrez, A; Hindi, N; Karanian, M; Le Cesne, A; Lopez-Guerrero, JA; Lopez-Pousa, A; Luna, P; Marcilla, D; Martin-Broto, J; Moura, DS; Peña-Chilet, M; Penel, N; Redondo, A; Stacchiotti, S | 1 |
| Benson, C; Lee, ATJ | 1 |
| Broaddus, R; Fu, S; Hess, K; Hong, D; Janku, F; Karp, D; Kopetz, S; Liu, L; Naing, A; Overman, M; Piha-Paul, S; Shi, N; Subbiah, V; Tsimberidou, AM; Wang, Y; Yao, J | 1 |
| Endo, M; Harabayashi, T; Hiraga, H; Nagamori, S; Sugawara, M; Takekuma, Y; Tanaka, H | 1 |
| Bhutani, G; Emamekhoo, H; Kyriakopoulos, CE; Matkowskyj, KA; Zarling, L; Ziemlewicz, T | 1 |
| Bannykh, S; Fan, X; Hu, J; Nelson, T; Rudnick, J; Vail, E | 1 |
| Guo, J; He, Z; Huang, Y; Jin, J; Qin, S; Ren, X; Sheng, X; Wang, B; Wang, J; Ye, D; Zhang, X; Zhou, A; Zhou, F | 1 |
| Cengiz, FP; Kelahmetoglu, O | 1 |
| Bajpai, J; Deodhar, K; Ghosh, J; Gulia, S; Gupta, S; Maheshwari, A; Rath, S; Shylasree, TS; Thakur, M | 1 |
| Barroilhet, LM; Brown, J; Darus, C; Duska, LR; Jelovac, D; McGuire, WP; Moore, KN; Petroni, GR; Secord, AA; Varhegyi, N | 1 |
| Hayashi, M; Makino, T; Mizawa, M; Mori, N; Shimizu, T | 1 |
| Alifieris, CE; Avgoustou, C; Delis, SG; Griniatsos, J; Nikolaou, M; Panagiotidis, MI; Souferi-Chronopoulou, E; Trafalis, DT | 1 |
| Božina, N; Kuruc Poje, D; Šimičević, L; Žabić, I | 1 |
| Fujiwara, S; Nakamura, K; Nakano, E; Nishigori, C; Ogura, K; Washio, K | 1 |
| Adachi, H; Ito, A; Kawasaki, Y; Kikuchi, M; Mano, N; Takasaki, S | 1 |
| Aydın, D; Beşiroğlu, M; Bilici, M; Dane, F; Doğu, GG; Hacıoğlu, B; Kaplan, NB; Karaca, M; Koca, S; Oruç, Z; Özçelik, M | 1 |
| Fujiwara, K; Ishida, H; Kanamitsu, K; Shimada, A; Tsukahara, H; Washio, K | 1 |
| Albersen, M; Baldewijns, M; Beuselinck, B; Bourgain, C; Debruyne, PR; Haaker, L; Laenen, A; Laguerre, B; Lerut, E; Oudard, S; Renders, I; Rioux-Leclercq, N; Roussel, E; Tryssesoone, L; Van den Bulck, H; Verbiest, A; Wynendaele, W | 1 |
| Albersen, M; Baldewijns, M; Bechter, O; Beuselinck, B; Poncelet, R; Roussel, E; Spriet, I; Tack, J; Van De Sijpe, G; Van Nieuwenhuyse, T | 1 |
| Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K | 1 |
| Matsumine, A; Nakamura, T; Satonaka, H; Sudo, A; Tsujii, M | 1 |
| Akaike, K; Hayashi, T; Ikegami, M; Kaneko, K; Kato, S; Kim, Y; Kohsaka, S; Kojima, S; Kurihara, T; Mano, H; Mizuno, S; Okubo, T; Saito, T; Sano, K; Sasa, K; Suehara, Y; Ueno, T; Yamaguchi, S | 1 |
| Biró, K; Budai, B; Géczi, L; Gyergyay, F; Kiss, E; Küronya, Z; Ladányi, A; Martin, T; Nagyiványi, K; Szőnyi, MD | 1 |
| Ando, M; Goto, T; Hiraga, H; Kawai, A; Kobayashi, E; Kunisada, T; Matsumoto, Y; Naka, N; Nakayama, R; Nishida, Y; Okuma, T; Ozaki, T; Tsuchiya, H; Ueda, T; Urakawa, H | 1 |
| Bastos, DA; Bonadio, RRC; de Azevedo Souza, MCL; Dzik, C; Faraj, SF; Isaacsson Velho, P; Muniz, DQB; Nader Marta, G; Nardo, M | 1 |
| Levin, AS | 1 |
| Ahn, JH; Hong, JY; Kim, HS; Kim, JE; Kim, JH; Kim, TW; Lee, JS; Oh, CR | 1 |
| Azzouz, F; Braychenko, E; Elaidi, R; Epaillard, N; Moreira, M; Oudard, S; Simonaggio, A; Sun, CM; Thibault, C; Vano, YA | 1 |
| Feng, C; Li, Y; Shen, Y; Wen, H; Zhu, Z | 1 |
| Chao, A; Huang, HJ; Lai, CH; Lee, LY; Lee, YS; Lin, CY; Peng, MT; Tsai, CL; Ueng, SH; Wang, HS; Wu, RC; Yang, LY | 1 |
| Ae, K; Ando, M; Ando, Y; Goto, T; Hamada, S; Hiraga, H; Kawai, A; Kobayashi, E; Kuwatsuka, Y; Matsumoto, Y; Naka, N; Nakayama, R; Nishida, Y; Ozaki, T; Takahashi, S; Tsuchiya, H; Ueda, T; Urakawa, H | 1 |
| Harada, Y; Kakimoto, S; Shimizu, T | 1 |
| Iwaki, Y; Kamo, R; Nakai, K; Ozawa, T; Tsuruta, D; Watanabe, M | 1 |
| Maeda, T; Nakano, E; Namikawa, K; Oashi, K; Shibata, T; Takahashi, A; Teramoto, Y; Tsutsumida, A; Yamazaki, N; Yokota, K | 1 |
| Eisen, T; Fife, K; Gordon, J; Hawkins, R; Hurst, M; Matakidou, A; Naicker, N; Nolasco, S; Wang, M | 1 |
| Hasegawa, H; Kawashima, M; Kobayashi, H; Saito, N; Shin, M; Shinya, Y; Takahashi, W | 1 |
| Hattori, Y; Ito, M; Iwata, H; Maeda, O; Mitsuishi, T; Murakami, F; Nagasaka, T; Ogino, H; Uematsu, T | 1 |
| Agulnik, M; Attia, S; Eulo, V; Haarberg, S; Hirbe, AC; Kershner, T; Luo, J; Milhem, M; Monga, V; Moon, CI; Myles, S; Okuno, S; Parkes, A; Robinson, S; Seetharam, M; Toeniskoetter, J; Van Tine, BA | 1 |
| de Geeter, P; Goebell, PJ; Grünwald, V; Herrmann, E; Hogrefe, C; Marschner, N; Merling, M; Panic, A; Potthoff, K; Staehler, M; Vannier, C | 1 |
| Barzaghi, P; Perego, G; Petrelli, F; Vavassori, I | 1 |
| Chun, FKH; Deuker, M; Karakiewicz, PI | 1 |
| Antonescu, CR; Bandlamudi, C; Chi, P; D'Angelo, SP; Dickson, M; Donoghue, M; Gounder, M; Kelly, C; Keohan, ML; Movva, S; Nacev, B; Qin, LX; Rosenbaum, E; Seier, K; Simeone, N; Slotkin, EK; Tap, WD | 1 |
| Bari, A; Caputo, F; Cerma, K; Dominici, M; Fanelli, M; Gelsomino, F; Pozzi, S | 1 |
| Bauer, S; Chemnitz, JM; Crysandt, M; Egerer, G; Grünwald, V; Ivanyi, P; Karch, A; Kasper, B; Kopp, HG; Kunitz, A; Lindner, LH; Liu, X; Richter, S; Schöffski, P; Schuler, M; Steffen, B; Stein, A; Zimmermann, S | 1 |
| Buckle, A; McLean, L; Siva, S; Tran, B; Zhong, YY | 1 |
| Claps, M; Di Maio, M; Grassi, P; Guadalupi, V; Martinetti, A; Mennitto, A; Procopio, G; Raimondi, A; Sepe, P; Sottotetti, E; Stellato, M; Verzoni, E; Zattarin, E | 1 |
| Albersen, M; Baldewijns, M; Beuselinck, B; Caruso, S; Couchy, G; García-Donas, J; Graña-Castro, O; Laenen, A; Rodriguez-Antona, C; Roussel, E; Schöffski, P; Van Hoef, V; Verbiest, A; Wozniak, A; Zucman-Rossi, J | 1 |
| Benhadji, KA; Le Cesne, A; Massard, C; Mir, O; Soria, JC; Watson, S | 1 |
| Adamski, H; Battistella, M; Bertucci, F; Da Meda, L; Dalac, S; Delyon, J; Ghrieb, Z; Guillot, B; Jouary, T; Lebbe, C; Leccia, MT; Meyer, N; Mortier, L; Mourah, S; Pedeutour, F; Porcher, R; Vicaut, E | 1 |
| Dong, YA; Fang, W; Jiang, W; Liu, L; Tong, Z; Wang, Y; Yan, C; Yao, M; Zhang, F; Zhang, H; Zhao, P; Zheng, Y | 1 |
| Basso, U; Bergo, E; Bimbatti, D; Brunello, A; Lamberti, E; Maruzzo, M; Pierantoni, F; Tierno, G; Zagonel, V | 1 |
| Abe, K; Fujita, M; Hashimoto, Y; Hayashi, M; Kobayashi, Y; Ohira, H; Takahashi, A | 1 |
| Itoh, H; Iwasaki, T; Kawano, M; Matsumoto, A; Shiraiwa, K; Suzuki, Y; Tanaka, K; Tanaka, R; Tatsuta, R; Tsumura, H | 2 |
| Azumi, M; Fukudo, M; Shibata, H; Tamaki, G; Tandai, S | 1 |
| Houchi, H; Kawakita, K; Kosaka, S; Kuroda, Y; Okazaki, T; Suzuki, K; Takahashi, K; Tanaka, H; Tatsumichi, T | 1 |
| Cui, Y; Lv, Q; Ma, L; Shen, G | 1 |
| Bex, A; Hofmann, F; Hwang, EC; Lam, TB; Ljungberg, B; Marconi, LS; Yuan, Y | 1 |
| Capri, S; Condorelli, C; Kalra, M; Khare, A; Modi, N; Porta, C; Premoli, E; Ratto, B | 1 |
| Asanuma, K; Hagi, T; Nakamura, T; Sudo, A | 1 |
| Guillén Climent, S; Monteagudo Castro, C; Pons Benavent, M; Silva Díaz, E | 1 |
| Kobayashi, T; Kodama, Y; Koma, YI; Masuda, A; Nakano, R; Sakai, A; Shigeoka, M; Shiomi, H; Tanaka, S; Tanaka, T | 1 |
| Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E | 1 |
| Beckermann, KE; Bortone, DS; Davis, NB; Ferguson, JE; Haake, SM; Karam, JA; Kim, WY; Maygarden, SJ; Milowsky, MI; Moore, DT; Parker, JS; Powles, T; Rathmell, WK; Vincent, BG; Wallen, EM; Whisenant, JG; Wood, CG | 1 |
| Basso, U; Bersanelli, M; Boccardo, F; Caffo, O; Cartenì, G; De Giorgi, U; Fornarini, G; Galli, L; Mosca, A; Naglieri, E; Porta, C; Procopio, G | 1 |
| Akagunduz, B; Çoban, A; Kara, AV; Lacın, S; Mammadov, R; Ozcıcek, F; Ozer, M; Özkaraca, M; Suleyman, B; Suleyman, H | 1 |
| Hayashi, T; Ijiri, Y; Imano, H; Kato, R | 1 |
| Gerber, F; Jungo, P; Navarini, AA; Vasconcelos-Berg, R | 1 |
| Fukasawa, N; Nomura, S; Teshima, Y | 1 |
| Dicaudo, DJ; Karlin, N; Mangold, AR; Nafissi, NN; Pittelkow, MR | 1 |
| Abdelhamid, AH; Agarwal, S; Bobbili, PJ; Chugh, R; Demetri, GD; Duh, MS; Gounder, MM; Huynh, L; Lax, AK; Merriam, P; Patel, SR; Rajarethinam, A; Ratan, R; Thornton, M; Totev, TI; Van Tine, BA; Villalobos, VM; Whalen, J; Yang, J | 1 |
| Bria, E; Cintoni, M; Gasbarrini, A; Mele, MC; Pompili, M; Ponziani, FR; Pozzo, C; Raoul, P; Rinninella, E; Strippoli, A; Tortora, G | 1 |
| Alameh, IA; Assi, HI; Charafeddine, M; Farhat, F; Halim, NA; Karak, FE; Khoury, J; Nakib, CE; Sayed, RE; Zerdan, MB | 1 |
| Crysandt, M; Cygon, F; Egerer, G; Eigendorff, E; Heißner, K; Kasper, B; Kessler, T; Kopp, HG; Kunitz, A; Lindner, LH; Mayer-Steinacker, R; Meinert, F; Niederwieser, D; Petersen, I; Reichardt, P; Rüssel, J; Schmoll, HJ; Steighardt, J; Stein, A | 1 |
| Aimone, P; Choueiri, TK; Chowdhury, S; Doehn, C; Donskov, F; Gross-Goupil, M; Haas, N; Izquierdo, M; Kopyltsov, E; Lee, JL; Lim, HY; McDermott, R; Melichar, B; Michael, A; Motzer, RJ; Reaume, MN; Rini, B; Russo, P; Stenzl, A; Sternberg, CN; Varlamov, S; Wood, L; Zemanova, M; Zhang, H | 1 |
| Bondarenko, A; Borisov, P; Tishova, Y; Tsimafeyeu, I; Zakurdaeva, K; Zukov, R | 1 |
| Keam, B; Kim, DW; Kim, M; Kim, SH; Kim, TM; Kim, YJ; Kwak, Y; Moon, KC; Park, C | 1 |
| Dahlem, R; Fisch, M; Fühner, C; Hillemacher, T; Janisch, F; Kienapfel, C; Klotzbücher, T; Marks, P; Meyer, CP; Mori, K; Mostafei, H; Rink, M; Shariat, SF; Yu, H | 1 |
| Armstrong, AJ; Brown, LC; Campbell, MT; Corn, P; Economides, M; Gao, J; Garmezy, B; George, DJ; Gupta, RT; Harrison, MR; Jonasch, E; Kao, C; Kinsey, EN; Laccetti, AL; Msaouel, P; Shah, A; Tannir, N; Venkatesan, A; Xiao, L; Zhang, T; Zurita-Saavedra, A | 1 |
| Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X | 1 |
| Afable, M; Aljumaily, R; Bendell, J; Drakaki, A; Ferry, D; Hung, A; Kim, JS; Naing, A; Papadopoulos, KP; Tannir, NM; Wong, DJ | 1 |
| Balardy, L; Cabarrou, B; Chatelut, E; Digue, L; Filleron, T; Gomez-Roca, CA; Le Louedec, F; Mourey, L; Olivier, P; Paludetto, MN; Ravaud, A; Valentin, T | 1 |
| Bishop, AJ; Ratan, R; Roland, CL | 1 |
| Bakhshi, S; Biswas, B; Kataria, B; Pushpam, D; Sharma, A | 1 |
| Kargar, M; Sadeghi, S | 1 |
| Anandappa, G; Boink, Y; Bond, SJ; Brune, C; Cheriyan, J; Gajendragadkar, P; Hubsch, A; Jodrell, DI; Mäki-Petäjä, KM; McEniery, CM; McGeoch, A; Meyer, PAR; Mir, F; Ramenatte, N; Santos Franco, S; Schönlieb, CB; Wilkinson, IB; Yang, LL | 1 |
| Baek, W; Han, JW; Jeon, MK; Kim, HS; Kim, JH; Kim, SH; Kim, SK; Lee, YH; Woo, HY | 1 |
| Fujita, M; Kamada, R; Nakanishi, K; Nishikawa, T; Oka, T; Shioyama, W; Yagi, T; Yasui, T | 1 |
| Kabir, MZ; Kandandapani, S; Mohamad, SB; Ridzwan, NFW; Tayyab, S | 1 |
| Maruo, K; Tabata, H; Takagi, Y; Takahashi, A; Takayanagi, A | 1 |
| Higuchi, T; Hoffman, RM; Kanaya, F; Miyake, K; Nishida, K; Oshiro, H; Sugisawa, N; Tome, Y | 1 |
| Brezinová, B; Chovanec, M; Dubovan, P; Gomolčáková, J; Jurišová, S; Mardiak, J; Mego, M; Rejlekova, K | 1 |
| Allaf, M; Ged, Y; Pierorazio, P; Singla, N | 1 |
| Araz, M; Artaç, M; Er, MM; Eryılmaz, MK; Karaağaç, M; Karabacak, M; Uğraklı, M | 1 |
| Aimone, P; Arkenau, T; Chowdhury, S; Hawkins, R; Infante, JR; McDermott, DF; Naeije, I; Perini, R; Reising, A; Voskoboynik, M; Voss, MH | 1 |
| Drabick, JJ; Mackley, HB; Spengler, M; Wheelden, M | 1 |
| Abbinanti, S; Agulnik, M; Attia, S; Cehic, R; Charlson, J; Helenowski, I; Hirbe, AC; Milhem, M; Mohindra, N; Monga, V; Okuno, S; Oppelt, P; Robinson, S; Schulte, B; Van Tine, BA | 1 |
| Jang, BC; Yadav, AK | 1 |
| Chauhan, R; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Mathur, S; Sharma, A; Singh, M; Sreenivas, V | 1 |
| Argyle, D; Bradley, M; Dong, H; Gao, Q; Geng, J; Neumann, K; Porter, H; Potter, M; Ren, H; Zhang, Y | 1 |
| Hiramatsu, H; Hiraoka, S; Kato, I; Kosaka, T; Mizowaki, T; Sakamoto, A; Takita, J; Umeda, K; Uto, M | 1 |
| Emami Riedmaier, A; Kesisoglou, F; Parrott, N; Pepin, XJH; Wagner, C | 1 |
| Stretton, O | 1 |
| Chisti, MM; Solano, C; Thapa, S | 1 |
| Bottaro, DP; Cecchi, F; Chen, AP; Do, KT; Doroshow, JH; Jeong, W; Johnson, BC; Kummar, S; Lee, YH; Navas, T; Parchment, RE; Park, SR; Rubinstein, L; Srivastava, AK; Voth, AR; Wright, JJ | 1 |
| Bedognetti, D; Castelli, C; Chaussabel, D; Cova, A; de Braud, F; De Cecco, L; Dugo, M; Huber, V; Lalli, L; Procopio, G; Ratta, R; Rinchai, D; Rivoltini, L; Rodolfo, M; Roelands, J; Squarcina, P; Vallacchi, V; Verzoni, E | 1 |
| Borikun, TV; Pikul, MV; Rossylna, OV; Semko, SL; Stakhovsky, EO; Vitruk, Yu V; Voylenko, OA; Yalovenko, TM; Zadvornyi, TV | 1 |
| Blasco Cordellat, A; Camps Herrero, C; Meri-Abad, M | 1 |
| Endo, M; Kanno, N; Nakahashi, K; Numahata, K; Shiikawa, M; Shiono, S | 1 |
| Aiba, H; Hayashi, K; Kawaguchi, Y; Kimura, H; Miwa, S; Murakami, H; Nakanishi, R; Okamoto, H; Saito, S; Sakai, T; Tatematsu, T; Yamada, S | 1 |
| Bauer, S; Blach Rossen, P; Eriksson, M; Foukakis, T; Goplen, D; Hagberg, H; Hagberg, O; Hansson, L; Hohenberger, P; Joensuu, H; Krarup-Hansen, A; Pulkkanen, K; Reichardt, P; Sundby Hall, K | 1 |
| Al-Samkari, H; Gossage, JR; McCrae, KR; Menon, KVN; Parambil, JG; Pederson, DP; Sprecher, DL; Timmerman, KL; Woodard, TD | 1 |
| Bendová, B; Büchler, T; Fiala, O; Filipovský, J; Fínek, J; Hora, M; Ostašov, P; Rozsypalová, A; Šorejs, O; Šustr, J; Trávníček, I | 1 |
| Aktas, BY; Kilickap, S; Koksal, D; Koylu, B; Tekin, F | 1 |
| Jiang, W; Li, L; Liao, Y; Liu, Y; Luan, Y; Sun, D; Wang, Y; Xue, X; Zhang, J; Zhang, Y; Zhao, X | 1 |
| Adomi, S; Banno, E; De Velasco, MA; Fujimoto, S; Fujita, K; Hashimoto, M; Inoguchi, S; Kikuchi, T; Minami, T; Mori, Y; Nakayama, T; Nishimoto, M; Nose, K; Nozawa, M; Saito, Y; Shimizu, N; Uemura, H; Yoshimura, K | 1 |
| Bardet, S; Benisvy, D; Borson Chazot, F; Chougnet, CN; Dalban, C; de la Fouchardière, C; Digue, L; Do Cao, C; Gautier, J; Godbert, Y; Illouz, F; Lamartina, L; Leboulleux, S; Niccoli, P; Pérol, D; Schwartz, P; Wassermann, J; Zalzali, M; Zerdoud, S | 1 |
| Biswas, B; Chen, L; Chikatapu, C; Chung, HJ; Danchaivijitr, P; Erman, M; Hashem, T; Ingles, S; Kanesvaran, R; Karabulut, B; Lim, CS; Slimane, K; Wong, YF | 1 |
| Alwaqfi, RR; Bossler, AD; Guseva, NN; Ma, D; Ouyang, M; Samuelson, MI | 1 |
| Bovee, JVMG; Fiocco, M; Gelderblom, H; Haas, RL; Hayes, AJ; Koenen, AM; Krol, S; Miah, AB; Schrage, Y; Steeghs, N; Thway, K; van Coevorden, F; van Houdt, W; van Meekeren, M; Zaidi, S | 1 |
| Sütcüoğlu, O; Unsal, O; Yazıcı, O | 1 |
| Caldari, E; De Paolis, M; Fiore, M; Giannini, C; Pirini, MG; Sambri, A; Spinnato, P; Zucchini, R | 1 |
| Al-Batran, SE; Bartels, P; Breithaupt, K; Gläser, D; Hinke, A; Högner, A; Homann, N; Lorenz, M; Malfertheiner, P; Siveke, JT; Stein, A; Tamm, I; Thuss-Patience, P; Vogel, A | 1 |
| Bendel, A; McDonald, W; Nelson, AT; Patel, S; Schultz, KAP; Skrypek, M; Tabori, U | 1 |
| Brouwer, KLR; Ho, H; Honkakoski, P; Niskanen, J; Saran, C; Sundqvist, L | 1 |
| Chin, S; Choi, JW; Kim, SG; Kim, YS; Yoo, JJ | 1 |
| Assis, C; de Souza Bezerra, R; Lacerda Cintra, AJ; Li, C; Martins do Vale, WK; Max Gomes Martins, R; Meira Menezes, T; Neves, JL; Seabra, GM; Silva Dos Santos, RC | 1 |
| Krens, SD; Mulder, SF; van Erp, NP | 1 |
| Ajebo, EM; Belcher, MD; Gossage, JR; Moon, JY | 1 |
| Ata, S; Cil, T; Duman, BB; Haksoyler, V; Koseci, T; Nayir, E; Olgun, P | 1 |
| Hoshi, M; Iwai, T; Nakamura, H; Oebisu, N; Takada, N | 1 |
| Amani, AM; Dehaen, W; Ramezanpour, S; Shiri, P | 1 |
| Adams, B; Attia, S; Brohl, AS; Burgess, MA; Chawla, S; Cheang, MCU; Cranmer, LD; Ganjoo, KN; Italiano, A; Jones, RL; Liu, L; Maki, RG; Ravi, V; Robertson, L; Theuer, C; Thornton, K | 1 |
| Álvarez-Fernández, C; Ángel Climent, M; Castellano, DE; Durán, I; García Carbonero, I; García-Del-Muro, X; García-Donas, J; Gil-Martin, M; González Del Alba, A; Hernández, AG; Mellado, B; Perez-Gracia, JL; Virizuela, JA | 1 |
| Ahrens, M; Andresen, C; Apostolidis, L; Aybey, B; Bauer, S; Beck, K; Bitzer, M; Boerries, M; Brandts, CH; Brors, B; Egerer, G; Folprecht, G; Fröhling, S; Glimm, H; Hamacher, R; Heilig, CE; Heining, C; Hohenberger, P; Horak, P; Hübschmann, D; Illert, AL; Jost, PJ; Keilholz, U; Kindler, T; Klauschen, F; Köhler, BC; Kreutzfeldt, S; Laßmann, A; Lipka, DB; Mechtersheimer, G; Mock, A; Möhrmann, L; Mughal, SS; Pirmann, S; Renner, M; Richter, D; Richter, S; Schlenk, RF; Schröck, E; Schulze-Osthoff, K; Siveke, JT; Stenzinger, A; Teleanu, V; von Bubnoff, N; Weichert, W; Westphalen, CB; Winter, U | 1 |
| Farrugia, D; Fife, K; Hodgkins, AM; MacDonald-Smith, C; Pirrie, S; Porfiri, E; Stubbs, C; Vasudev, N; Zarkar, A | 1 |
| Chen, C; Li, CG; Li, Y; Liu, HL; Wang, CL; Zhang, ZF | 1 |
| Futamura, M; Hayashi, H; Makiyama, A; Matsuhashi, N; Miyazaki, T; Murase, K; Okumura, N; Saigo, C; Takahashi, T; Takeuchi, T; Tanaka, Y; Yasufuku, I; Yoshida, K | 1 |
| Compton, S; Luan, Y; Tang, W; Wang, Q; Wu, D; Yuan, Q | 1 |
| Agulnik, M; Kraft, AS; Litwin, S; Movva, S; Ravi, V; Schuetze, SM; Somaiah, N; Tetzlaff, ED; Thiebaud, JA; von Mehren, M | 1 |
| Amaro, F; Bastos, ML; Carvalho, M; Guedes de Pinho, P; Pinto, J; Pisoeiro, C; Valente, MJ | 1 |
| Alfsen, GC; Farkas, L; Geisler, J; Kristensen, VN; Müller, S; Naji, F; Nilsen, FS; Oldenburg, J; Puco, K; Tahiri, A | 1 |
| Gulmez, A | 1 |
| Baek, W; Cho, HJ; Choi, YL; Hong, JY; Kim, HS; Kim, SH; Kim, SK; Kwon, M; Lee, J; Lee, Y; Lee, YH; Yun, KH | 1 |
| Connell, W; MacIsaac, M; Wu, K | 1 |
| Bauer, S; Chemnitz, JM; Crysandt, M; Egerer, G; Grünwald, V; Hamacher, R; Hentschel, L; Ivanyi, P; Kasper, B; Kopp, HG; Kunitz, A; Lindner, L; Liu, X; Richter, S; Schöffski, P; Schuler, MK; Steffen, B; Stein, A | 1 |
| Estenaga Pérez de Albéniz, A; García-Martínez, FJ | 1 |
| Alam, S; Ghosh-Ray, S; Gogbashian, A; Lakhani, A; Nathan, P; Padhani, A; Sharma, A | 1 |
| Aoyama, T; Azuma, K; Furutani, R; Hama, T; Hashimoto, K; Hiraide, M; Ito, K; Kobayashi, K; Nakano, K; Okawa, T; Sato, H; Sugiyama, E; Suzuki, K; Tajima, M; Takahashi, S; Tomomatsu, J; Yuasa, T | 1 |
| Chen, J; Fang, H; Pan, G; Wang, H; Wang, X; Zhang, Y | 1 |
| Banna, GL; Brighi, N; Brunelli, M; Buti, S; Caffo, O; Cattrini, C; Corianò, M; De Giorgi, U; Fornarini, G; Giannarelli, D; Giudice, GC; Kinspergher, S; Malgeri, A; Mennitto, A; Puglisi, S; Rametta, A; Rebuzzi, SE; Roviello, G; Santoni, M; Scartabellati, G; Signori, A; Stellato, M; Tommasi, C; Verzoni, E | 1 |
| Carducci, MA | 1 |
| Acar, R; Akgul, F; Artac, M; Aydin, SG; Bahceci, A; Besiroglu, M; Bilici, A; Cinkir, HY; Dal, P; Demir, H; Demiray, AG; Derin, S; Eraslan, E; Erdem, D; Ergun, Y; Erol, C; Goksu, SS; Guc, ZG; Gumusay, O; Gunaydin, UM; Kaplan, MA; Karaagac, M; Karaca, M; Koca, S; Koral, L; Menekse, S; Ocak, B; Ozkul, O; Ozveren, A; Ozyukseler, DT; Paydas, S; Sahin, S; Sakalar, T; Sakin, A; Seker, MM; Sunar, V; Turhal, S; Unal, OU; Yekeduz, E | 1 |
| Gwak, SY; Hong, GR; Kim, YJ; Shim, CY | 1 |
| Bray, D; Garzon-Muvdi, T; Ioachimescu, A; Maldonado, J; Mayol, M; Medina, EJ; Morales, B; Neill, S; Porto, E; Pradilla, G; Read, W; Revuelta Barbero, JM; Rodas, A; Zohdy, YM | 1 |
| Hashida, T; Hirabatake, M; Ikesue, H; Kawakita, M; Morimoto, M; Muroi, N; Yamasaki, T; Yoshino, S | 1 |
| Du, H; He, S; Sun, Y; Wang, L; Yu, X | 1 |
164 review(s) available for indazoles and pazopanib
| Article | Year |
|---|---|
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides | 2007 |
Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides | 2008 |
Novel drugs for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2008 |
Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
Topics: Animals; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Drugs, Investigational; Humans; Indazoles; Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2008 |
Targeted therapies in metastatic renal cancer in 2009.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors | 2009 |
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Pazopanib: an antiangiogenic drug in perspective.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Indazoles; Neoplasms; Pyrimidines; Sulfonamides | 2009 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Pazopanib: therapeutic developments.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indazoles; Kidney Neoplasms; Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Vascular Endothelial Growth Factors | 2009 |
Pazopanib for the treatment of renal cell carcinoma and other malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Indazoles; Kidney Neoplasms; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides | 2009 |
Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
Topics: Administration, Oral; Animals; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides | 2010 |
Pazopanib: Clinical development of a potent anti-angiogenic drug.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indazoles; Neoplasms; Pyrimidines; Sulfonamides | 2011 |
Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2010 |
[Antiangionic drugs in soft tissue sarcoma].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Doxorubicin; Humans; Indazoles; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
Topics: Angiogenesis Inhibitors; Animals; Disease-Free Survival; Humans; Indazoles; Neoplasms; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Pazopanib: in advanced renal cell carcinoma.
Topics: Anticarcinogenic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides | 2010 |
Pazopanib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2010 |
The therapy of kidney cancer with biomolecular drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indazoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases | 2010 |
[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Europe; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
Topics: Hand-Foot Syndrome; Humans; Incidence; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Skin; Sulfonamides | 2012 |
Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Treatment Outcome | 2011 |
[Novelties in the treatment for advanced renal-cell cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Pazopanib for the treatment of renal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sulfonamides | 2011 |
[Treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2011 |
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Fatigue; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Sunitinib | 2011 |
[Systemic treatment of renal cell carcinoma - recent update].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Evidence-Based Medicine; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Palliative Care; Phenylurea Compounds; Practice Guidelines as Topic; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2011 |
[Dermatologic side effects induced by new angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Topics: Administration, Oral; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Humans; Indazoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides; Treatment Outcome | 2011 |
Pazopanib for the treatment of breast cancer.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Indazoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides | 2012 |
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing | 2012 |
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Pazopanib for the treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides; Treatment Outcome | 2012 |
Targeted therapeutic strategies for the management of renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Tuberous Sclerosis; United States | 2012 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Current treatment considerations in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Nephrectomy; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2012 |
Pazopanib in the treatment of soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides | 2012 |
Concise drug review: pazopanib and axitinib.
Topics: Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Meta-Analysis as Topic; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; United States; United States Food and Drug Administration | 2012 |
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Evaluation; Drug Monitoring; Humans; Indazoles; Kidney Neoplasms; Neoplasm Proteins; Pharmacovigilance; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Sulfonamides; Up-Regulation; Vascular Endothelial Growth Factor A | 2012 |
[Soft-tissue sarcoma: recent developments].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Gemcitabine; Humans; Hyperthermia, Induced; Indazoles; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sirolimus; Soft Tissue Neoplasms; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Drug Substitution; Drugs, Investigational; Endpoint Determination; Humans; Indazoles; Molecular Targeted Therapy; Neoplasm Metastasis; Outcome and Process Assessment, Health Care; Prognosis; Pyrimidines; Sarcoma; Sirolimus; Sulfonamides; Survival Rate; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Hypertension; Incidence; Indazoles; Neoplasms; Prospective Studies; Publication Bias; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Risk; Sulfonamides | 2013 |
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
[Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indazoles; Mice; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome | 2013 |
Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Decision Making; Drug Approval; Drug Costs; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Technology Assessment, Biomedical; United Kingdom | 2013 |
Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Humans; Indazoles; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sulfonamides | 2013 |
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.
Topics: Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Gilbert Disease; Glucuronosyltransferase; Humans; Indazoles; Lapatinib; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients.
Topics: Angiogenesis Inhibitors; Humans; Indazoles; Liver; Neoplasms; Pyrimidines; Retrospective Studies; Risk Factors; Sulfonamides | 2013 |
Pazopanib in sarcomas: expanding the PALETTE.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides | 2013 |
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Palliative Care; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases | 2013 |
Side-effects associated with targeted therapies in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib | 2013 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Indazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Failure | 2013 |
Systemic treatment options for untreated patients with metastatic clear cell renal cancer.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib | 2013 |
Molecular markers to predict response to therapy.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Gene Dosage; Humans; Immunotherapy; Indazoles; Indoles; Kidney Neoplasms; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein | 2013 |
Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
Topics: Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides | 2013 |
Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indazoles; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Signal Transduction; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Induction Chemotherapy; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting | 2014 |
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Risk; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Emerging therapeutic targets for synovial sarcoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sarcoma, Synovial; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.
Topics: Antineoplastic Agents; Dioxoles; Doxorubicin; Evidence-Based Medicine; Humans; Ifosfamide; Indazoles; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
Pazopanib: a review of its use in the management of advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Sulfonamides | 2014 |
[Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sarcoma; Sulfonamides | 2014 |
Merkel cell carcinoma: current status of targeted and future potential for immunotherapies.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Biomarkers; Carcinoma, Merkel Cell; CD56 Antigen; Electrochemotherapy; Hepatitis A Virus Cellular Receptor 2; Humans; Imatinib Mesylate; Immunotherapy; Immunotherapy, Adoptive; Indazoles; Inhibitor of Apoptosis Proteins; Interferons; Interleukin-12; Interleukin-2; Ipilimumab; Lymphatic Metastasis; Membrane Proteins; Merkel cell polyomavirus; Oligonucleotides, Antisense; Piperazines; Polyomavirus Infections; Prognosis; Programmed Cell Death 1 Receptor; Pyrimidines; Receptors, Somatomedin; Skin Neoplasms; Somatostatin; Sulfonamides; Survivin; Thionucleotides; TOR Serine-Threonine Kinases | 2014 |
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib; Survival Analysis | 2014 |
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase 4; Humans; Indazoles; Indoles; Ipilimumab; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2014 |
Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Differentiation; Chemoradiotherapy; Clinical Trials as Topic; Drugs, Investigational; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radioisotopes; Sirolimus; Somatostatin; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Kidney cancer in 2014: Key advances promise progress for kidney cancer patients.
Topics: Angiogenesis Inhibitors; Carcinogenesis; Carcinoma, Renal Cell; Disease Progression; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Nephrons; Organ Sparing Treatments; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Pazopanib for the treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2015 |
Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Liver; Male; Middle Aged; Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Young Adult | 2015 |
Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Female; Hemangioendothelioma, Epithelioid; Humans; Immunohistochemistry; Indazoles; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Signal Transduction; Sulfonamides; Sunitinib; Time Factors; Treatment Outcome | 2015 |
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Drug Design; Humans; Indazoles; Molecular Targeted Therapy; Pyrimidines; Sarcoma; Sulfonamides | 2015 |
Pazopanib in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Disease-Free Survival; Female; Humans; Indazoles; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pyrimidines; Salvage Therapy; Sulfonamides; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review.
Topics: Adult; Angiogenesis Inhibitors; Brain Neoplasms; Cervical Vertebrae; Female; Follow-Up Studies; Hemangioblastoma; Humans; Indazoles; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Pyrimidines; Sulfonamides; von Hippel-Lindau Disease | 2015 |
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2015 |
Clinical management of metastatic kidney cancer: the role of new molecular drugs.
Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2016 |
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report.
Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Half-Life; Humans; Indazoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Pyrimidines; Renal Dialysis; Sulfonamides; Treatment Outcome | 2016 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review.
Topics: Adult; Antineoplastic Agents; Dioxoles; Furans; Humans; Indazoles; Ketones; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2016 |
Systemic therapy in metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Nivolumab; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome | 2016 |
Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Topics: Aged; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Interactions; Drug Monitoring; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrimidines; Sarcoma; Sulfonamides | 2016 |
Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.
Topics: Axitinib; Carcinoma, Renal Cell; Everolimus; Fatal Outcome; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Middle Aged; Nephrotic Syndrome; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sulfonamides | 2017 |
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |
Neoadjuvant Therapy in Differentiated Thyroid Cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Humans; Indazoles; Japan; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Slovenia; Sorafenib; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2016 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Targeted Therapy for Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.
Topics: Angiogenesis Inhibitors; Animals; Dose-Response Relationship, Drug; Humans; Indazoles; Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2017 |
Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis.
Topics: Alopecia; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Hair Color; Humans; Indazoles; Kidney Neoplasms; Male; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides | 2017 |
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Chemotherapy, Adjuvant; Deoxycytidine; Diagnostic Errors; Dioxoles; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Hysterectomy; Indazoles; Laparoscopy; Leiomyoma; Leiomyosarcoma; Morcellation; Neoplasm Staging; Pyrimidines; Sulfonamides; Taxoids; Tetrahydroisoquinolines; Trabectedin; Uterine Myomectomy; Uterine Neoplasms | 2017 |
[Recurrence of Well Differentiated Intrascrotal Liposarcoma in Retroperitoneum Five Years after Resection : A Case Report].
Topics: Aged; Angiogenesis Inhibitors; Chemotherapy, Adjuvant; Humans; Indazoles; Liposarcoma; Male; Orchiectomy; Pyrimidines; Recurrence; Retroperitoneal Neoplasms; Sulfonamides; Testicular Neoplasms; Time Factors; Tomography, X-Ray Computed | 2017 |
Renal cell carcinoma.
Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Diseases; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2017 |
Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.
Topics: Angiogenesis Inhibitors; Bevacizumab; Clinical Trials as Topic; Female; Humans; Indazoles; Molecular Targeted Therapy; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Survival Analysis; Treatment Outcome | 2017 |
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Furans; Humans; Indazoles; Japan; Ketones; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin | 2017 |
Pazopanib: a Review in Advanced Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indazoles; Male; Pyrimidines; Sulfonamides | 2017 |
PharmGKB summary: pazopanib pathway, pharmacokinetics.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Gene Regulatory Networks; Humans; Indazoles; Neoplasms; Pharmacogenomic Variants; Pyrimidines; Sulfonamides; Treatment Outcome | 2017 |
Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.
Topics: Angiogenesis Inhibitors; Female; Humans; Indazoles; Leiomyosarcoma; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Uterine Neoplasms | 2017 |
[Eye Drops Instead of Intravitreal Injections? The Dream of Treating Macular Diseases by Topically Administered Drugs].
Topics: Algorithms; Cholestanols; Double-Blind Method; Indazoles; Indoles; Intravitreal Injections; Ophthalmic Solutions; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2017 |
The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.
Topics: Angiogenesis Inhibitors; Humans; Indazoles; Neoplasms; Neovascularization, Pathologic; Pyrimidines; Sulfonamides | 2017 |
Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
Topics: Brain; Fatal Outcome; Female; Humans; Indazoles; Magnetic Resonance Imaging; Middle Aged; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Sulfonamides | 2018 |
EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Therapy; Forecasting; Humans; Indazoles; Neoplasm Metastasis; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin | 2018 |
Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis | 2018 |
Kidney cancer in 2017: Challenging and refining treatment paradigms.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents, Immunological; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; CTLA-4 Antigen; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Nephrectomy; Nivolumab; Programmed Cell Death 1 Receptor; Pyridines; Pyrimidines; Sulfonamides | 2018 |
Management of the toxicities of common targeted therapeutics for gynecologic cancers.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Autoimmune Diseases; Bevacizumab; Diarrhea; Epistaxis; Fatigue; Female; Genital Neoplasms, Female; Headache; Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Perforation; Molecular Targeted Therapy; Nausea; Neutropenia; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Proteinuria; Pyrimidines; Risk Assessment; Sulfonamides; Vomiting; Water-Electrolyte Imbalance | 2018 |
Repurposing anticancer drugs for targeting necroptosis.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Drug Repositioning; Humans; Imidazoles; Indazoles; Necrosis; Oximes; Pyridazines; Pyrimidines; Reperfusion Injury; Sorafenib; Sulfonamides; Systemic Inflammatory Response Syndrome; Vemurafenib | 2018 |
Systemic Treatment for Adults with Synovial Sarcoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Indazoles; Pyrimidines; Sarcoma, Synovial; Sulfonamides; Trabectedin | 2018 |
The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis.
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Indazoles; Indoles; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib | 2018 |
A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib.
Topics: Humans; Indazoles; Precision Medicine; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2018 |
Drug review: Pazopanib.
Topics: Animals; Clinical Trials as Topic; Humans; Indazoles; Neoplasms; Pyrimidines; Sulfonamides | 2018 |
The Impact of Pazopanib on the Cardiovascular System.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cardiovascular Diseases; Cardiovascular System; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Risk Assessment; Risk Factors; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome | 2018 |
Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature.
Topics: Anilides; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Middle Aged; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Topics: Anilides; Carcinoma, Neuroendocrine; Cardiotoxicity; Humans; Hypertension; Indazoles; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sulfonamides; Thyroid Neoplasms | 2018 |
Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review.
Topics: Carcinoma, Renal Cell; Cost of Illness; Cost-Benefit Analysis; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Time Factors | 2019 |
Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Quality of Life; Sulfonamides; Treatment Outcome | 2018 |
Adjuvant therapy after nephrectomy for renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Progression-Free Survival; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib | 2018 |
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Nivolumab; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Sunitinib | 2018 |
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin | 2019 |
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Doxorubicin; Female; Humans; Indazoles; Male; Neoplasm Metastasis; Neoplasm Staging; Odds Ratio; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Treatment Outcome | 2019 |
Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Combined Modality Therapy; Doxorubicin; Female; Humans; Indazoles; Leiomyosarcoma; Prognosis; Pyrimidines; Sulfonamides; Uterine Neoplasms | 2019 |
Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature.
Topics: Adult; Aged; Carcinoma, Renal Cell; Chordoma; Female; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Skull Base Neoplasms; Sulfonamides | 2020 |
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Health Care Costs; Humans; Indazoles; Kidney Neoplasms; Liver; Middle Aged; Neutropenia; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome | 2019 |
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2019 |
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Decision Making; Drug Approval; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Risk Assessment; Sulfonamides; United States; United States Food and Drug Administration | 2020 |
Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review.
Topics: Aged; Antineoplastic Agents, Immunological; Axons; Carcinoma, Renal Cell; Drug Substitution; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Motor Neurons; Nivolumab; Paraparesis; Polyneuropathies; Pyrimidines; Skin Neoplasms; Sulfonamides | 2019 |
Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.
Topics: Doxorubicin; Dyspnea; Female; Heart Failure; Humans; Indazoles; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Stroke Volume; Sulfonamides; Ventricular Function, Left | 2020 |
Periosteal Reaction Possibly Induced by Pazopanib: A Case Report and Literature Review.
Topics: Adenomatous Polyposis Coli; Adolescent; Angiogenesis Inhibitors; Humans; Ilium; Indazoles; Male; Periosteum; Prognosis; Pyrimidines; Scapula; Sulfonamides | 2020 |
The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Fatigue; Humans; Hypertension; Indazoles; Kidney Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2019 |
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
Topics: Drug Resistance, Neoplasm; Humans; Indazoles; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma; Sulfonamides | 2019 |
Pediatric Metastatic Cardiac Angiosarcoma Successfully Treated With Multimodal Therapy: Case Report and Review of Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Child; Combined Modality Therapy; Heart Neoplasms; Hemangiosarcoma; Humans; Indazoles; Male; Neoplasms, Second Primary; Prognosis; Pyrimidines; Sulfonamides; Surgical Procedures, Operative | 2021 |
Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
Topics: Antineoplastic Agents; Drug Monitoring; Humans; Imatinib Mesylate; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib | 2020 |
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Topics: Angiogenesis Inhibitors; Anilides; Axitinib; Carcinoma, Renal Cell; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib | 2020 |
[Proton pump inhibitors and cancers: A hazardous association?]
Topics: Antineoplastic Agents; Bacterial Infections; Capecitabine; Contraindications, Drug; Drug Interactions; Dysbiosis; Erlotinib Hydrochloride; Fractures, Bone; Gastrointestinal Absorption; Gastrointestinal Neoplasms; Gefitinib; Humans; Indazoles; Kidney; Neoplasms; Prognosis; Protein-Tyrosine Kinases; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2020 |
Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure.
Topics: Anilides; Axitinib; Carcinoma, Renal Cell; Drug Therapy, Combination; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases | 2020 |
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature.
Topics: Angiogenesis Inhibitors; Fibroma; Fibrosarcoma; Humans; Indazoles; Male; Middle Aged; Polycythemia; Protein Kinase Inhibitors; Pyrimidines; Soft Tissue Neoplasms; Sulfonamides | 2021 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Axitinib; Bevacizumab; Bias; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2020 |
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.
Topics: Gefitinib; Humans; Imatinib Mesylate; Indazoles; Muscle, Skeletal; Neoplasms; Phenylurea Compounds; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2021 |
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult | 2021 |
Desmoid Fibromatosis: Management in an Era of Increasing Options.
Topics: Antineoplastic Agents; Fibromatosis, Aggressive; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Watchful Waiting | 2021 |
The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives.
Topics: Anthracyclines; Antineoplastic Agents; Chemotherapy, Adjuvant; Epigenomics; Gene Expression Regulation, Neoplastic; Genomics; Humans; Ifosfamide; Indazoles; Molecular Targeted Therapy; Pyrimidines; Radiotherapy, Adjuvant; Sarcoma, Synovial; Soft Tissue Neoplasms; Sulfonamides; Surgical Procedures, Operative; Trabectedin | 2021 |
A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy.
Topics: Humans; Indazoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Tyrosine | 2022 |
Gastric carcinosarcoma with FGFR2 amplification under long-term control with pazopanib: a case report and literature review.
Topics: Aged; Carcinosarcoma; Gastrectomy; Humans; Indazoles; Male; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Sulfonamides | 2022 |
Gastrointestinal: Diarrhea in a patient treated with pazopanib: A rare case of a common adverse effect.
Topics: Angiogenesis Inhibitors; Diarrhea; Gastrointestinal Tract; Humans; Indazoles; Kidney Neoplasms; Pyrimidines | 2023 |
The Efficacy and Safety of Pazopanib Plus Chemotherapy in Treating Recurrent or Persistent Ovarian Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Ovarian Neoplasms; Pyrimidines; Sulfonamides | 2023 |
Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
Topics: Humans; Indazoles; Male; Middle Aged; Pituitary Neoplasms; POU Domain Factors; Prolactinoma | 2023 |
232 trial(s) available for indazoles and pazopanib
| Article | Year |
|---|---|
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).
Topics: Adult; Aged; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Safety; Salvage Therapy; Sulfonamides; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 620
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2009 |
Phase I trial of pazopanib in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Anorexia; Cohort Studies; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Hypertension; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Pyrimidines; Sulfonamides; Vomiting | 2009 |
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Sulfonamides; Treatment Outcome | 2010 |
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Carcinoma, Renal Cell; Double-Blind Method; Female; Humans; Indazoles; International Agencies; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Indazoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrimidines; Sulfonamides; Treatment Outcome | 2010 |
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Topics: Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Cytokines; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrimidines; Sulfonamides | 2010 |
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Fatigue; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypertension; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Sulfonamides; Treatment Outcome | 2010 |
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; CA-125 Antigen; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides; Survival Rate | 2010 |
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indazoles; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Retreatment; Sulfonamides; Uterine Cervical Neoplasms | 2010 |
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Breast Neoplasms; Disease Progression; ErbB Receptors; Female; Humans; Indazoles; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Pyrimidines; Sulfonamides | 2010 |
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Cell Differentiation; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Iodine Radioisotopes; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Radiography; Radiopharmaceuticals; Sulfonamides; Thyroid Neoplasms; Time Factors; Treatment Failure; United States; Young Adult | 2010 |
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Genotype; Humans; Indazoles; Isoenzymes; Male; Middle Aged; Molecular Probes; Neoplasms; New Hampshire; Phenotype; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Singapore; Substrate Specificity; Sulfonamides; Treatment Outcome | 2010 |
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Cohort Studies; Cross-Over Studies; Dietary Fats; Fatigue; Female; Food-Drug Interactions; Humans; Hypertension; Indazoles; Male; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides | 2010 |
Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma.
Topics: Aged; Alanine Transaminase; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Genes, MHC Class I; Genes, MHC Class II; Genetic Markers; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Indazoles; Kidney Neoplasms; Male; Membrane Proteins; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrimidines; Sulfonamides | 2011 |
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
[Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or loc
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Double-Blind Method; Germany; Humans; Indazoles; Kidney Neoplasms; Nephrectomy; Placebo Effect; Prevalence; Pyrimidines; Risk Assessment; Risk Factors; Sulfonamides; Survival Analysis; Survival Rate | 2011 |
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Health Status; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Quality of Life; Sulfonamides | 2012 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anorexia; Asian People; Carcinoma; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrimidines; Sulfonamides; Treatment Outcome; Vomiting | 2011 |
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Demography; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Pyrimidines; Sulfonamides; Suspensions; Tablets; Time Factors; Treatment Outcome | 2012 |
Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Liver Neoplasms; Male; Middle Aged; Pyrimidines; Sulfonamides | 2011 |
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.
Topics: Antineoplastic Agents; Chicago; Diarrhea; Early Termination of Clinical Trials; Fatigue; Humans; Indazoles; Male; Orchiectomy; Patient Compliance; Prostatic Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome; United States; United States Department of Defense; Universities | 2012 |
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Pyrimidines; Sulfonamides | 2011 |
Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Early Termination of Clinical Trials; Feasibility Studies; Female; Genital Neoplasms, Female; Humans; Indazoles; Middle Aged; Paclitaxel; Pyrimidines; Sulfonamides | 2012 |
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2012 |
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome; Young Adult | 2012 |
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides; Treatment Outcome | 2012 |
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2012 |
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.
Topics: Aged; Animals; Disease Progression; Disease-Free Survival; Endpoint Determination; Female; Humans; Indazoles; Male; Mice; Mice, Nude; Middle Aged; Pyrimidines; Sulfonamides; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cytokines; Disease-Free Survival; Female; Humans; Indazoles; Interleukin-12 Subunit p40; Male; Membrane Proteins; Middle Aged; Placenta Growth Factor; Polycomb-Group Proteins; Pregnancy Proteins; Pyrimidines; Repressor Proteins; Sarcoma; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2012 |
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Italy; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrimidines; Risk Assessment; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome; Tumor Burden; Urologic Neoplasms; Urothelium | 2012 |
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides; Young Adult | 2013 |
Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Everolimus; Female; Humans; Immunosuppressive Agents; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Pyrimidines; Quality of Life; Sirolimus; Sulfonamides; Surveys and Questionnaires; Survivors; Treatment Outcome | 2013 |
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; Indazoles; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Demography; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Pyrimidines; Quinazolines; Sulfonamides; Treatment Outcome | 2013 |
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Demography; Dose-Response Relationship, Drug; Female; Glutamates; Guanine; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pemetrexed; Pyrimidines; Sulfonamides | 2013 |
Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization.
Topics: Adult; Aged; Angiogenesis Inhibitors; Corneal Neovascularization; Female; Follow-Up Studies; Humans; Indazoles; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Female; Humans; Indazoles; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome | 2013 |
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Humans; Indazoles; Lapatinib; Middle Aged; Neoplasm Staging; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome | 2013 |
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cross-Over Studies; Diarrhea; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome | 2013 |
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Anti-Bacterial Agents; Aza Compounds; Blood Pressure; Confidence Intervals; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Heart Rate; Humans; Indazoles; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Neoplasms; Pyrimidines; Quinolines; Sulfonamides; Young Adult | 2013 |
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides | 2013 |
Bayesian methods for pharmacokinetic/pharmacodynamic modeling of pazopanib-induced increases in blood pressure and transaminases.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Angiogenesis Inhibitors; Aspartate Aminotransferases; Bayes Theorem; Blood Pressure; Humans; Indazoles; Logistic Models; Middle Aged; Models, Biological; Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Young Adult | 2013 |
Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Early Termination of Clinical Trials; Humans; Indazoles; Male; Neutropenia; Organoplatinum Compounds; Palliative Care; Prospective Studies; Pyrimidines; Salvage Therapy; Sulfonamides; Thrombocytopenia; Urologic Neoplasms; Vinblastine | 2013 |
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Indazoles; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carbon Radioisotopes; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sulfonamides | 2013 |
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Withholding Treatment | 2013 |
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Esomeprazole; Female; Humans; Indazoles; Ketoconazole; Male; Middle Aged; Neoplasms; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2013 |
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Humans; Indazoles; Liver Diseases; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome | 2013 |
Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases | 2013 |
Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Combined Modality Therapy; Double-Blind Method; Female; Humans; Indazoles; Kidney; Kidney Neoplasms; Kinetics; Logistic Models; Male; Middle Aged; Models, Biological; Pharmacogenetics; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tumor Burden | 2013 |
Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sulfonamides; Sunitinib; Survival Rate; Treatment Failure | 2014 |
Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Indazoles; Male; Neoplasms; Pyrimidines; Sarcoma; Sulfonamides; Young Adult | 2013 |
Pazopanib and soft-tissue sarcomas. Too toxic.
Topics: Angiogenesis Inhibitors; Double-Blind Method; Heart Failure; Humans; Indazoles; Liver; Pneumothorax; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides | 2013 |
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA, Neoplasm; Follow-Up Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Indazoles; Kidney Neoplasms; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Pyrimidines; Signal Transduction; Sulfonamides; Survival Rate; Von Hippel-Lindau Tumor Suppressor Protein | 2013 |
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Transitional Cell; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neovascularization, Pathologic; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Failure; Urologic Neoplasms; Urothelium | 2013 |
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib | 2013 |
Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Intestinal Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Stomach Neoplasms; Sulfonamides; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Complement Factor H; Female; Genotype; Humans; Indazoles; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Single-Blind Method; Sulfonamides; Treatment Outcome; Visual Acuity; Wet Macular Degeneration; Young Adult | 2013 |
Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Choroidal Neovascularization; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indazoles; Macular Degeneration; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Pyrimidines; Sulfonamides; Treatment Outcome; Visual Acuity | 2014 |
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cytokines; Enzyme-Linked Immunosorbent Assay; Humans; Indazoles; Interleukin-8; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Urologic Neoplasms | 2014 |
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Failure; Tumor Burden; Young Adult | 2014 |
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Endothelial Cells; Female; Humans; Ifosfamide; Indazoles; Male; Middle Aged; Neoplasms; Placenta Growth Factor; Pregnancy Proteins; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2014 |
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Pyrimidines; Sulfonamides; Survival Rate | 2013 |
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Lapatinib; Male; Middle Aged; Neoplasms; Pyrimidines; Quinazolines; Sulfonamides | 2014 |
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Placebos; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sarcoma; Sulfonamides; Treatment Outcome | 2014 |
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytokines; Disease-Free Survival; E-Selectin; Epothilones; Fatigue; Female; Humans; Indazoles; Male; Middle Aged; Neoplasms; Neutropenia; Pyrimidines; Retreatment; Sulfonamides; Survival Rate; Thrombocytopenia | 2016 |
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.
Topics: Aged; Angiogenesis Inhibitors; Carcinosarcoma; Disease-Free Survival; Female; Humans; Indazoles; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Recurrence, Local; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome; Uterine Neoplasms | 2014 |
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Medullary; Disease Progression; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2014 |
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Lymphatic Metastasis; Male; Middle Aged; Mutation; Precision Medicine; Pyrimidines; Radionuclide Imaging; Sequence Analysis, DNA; Sulfonamides; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms | 2014 |
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Over Studies; Double-Blind Method; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Patient Preference; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib; Surveys and Questionnaires | 2014 |
Pharmacokinetics of pazopanib administered in combination with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug Interactions; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2014 |
[First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of pat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Survival Rate; Young Adult | 2014 |
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Follow-Up Studies; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2014 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
Clinical evaluation of pazopanib eye drops in healthy subjects and in subjects with neovascular age-related macular degeneration.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biological Availability; Double-Blind Method; Female; Healthy Volunteers; Humans; Indazoles; Male; Middle Aged; Ophthalmic Solutions; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retina; Sulfonamides; Tissue Distribution; Visual Acuity; Wet Macular Degeneration; Young Adult | 2014 |
A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Indazoles; Kallikreins; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Sulfonamides; Tosyl Compounds; Treatment Outcome | 2015 |
A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Sulfonamides; Treatment Outcome | 2014 |
Incorporation of pazopanib in maintenance therapy of ovarian cancer.
Topics: Angiogenesis Inhibitors; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2014 |
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anorexia; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hair Color; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Pyrimidines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2014 |
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Sulfonamides; Topoisomerase I Inhibitors; Treatment Outcome | 2015 |
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; Male; MAP Kinase Signaling System; Mice, SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Cross-Over Studies; Drug Administration Schedule; Drug Monitoring; Feasibility Studies; Female; Humans; Indazoles; Male; Middle Aged; Precision Medicine; Pyrimidines; Sulfonamides; Young Adult | 2015 |
Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Biomarkers; Double-Blind Method; Female; Fluorescein Angiography; Humans; Indazoles; Intravitreal Injections; Male; Neoplasm Proteins; Ophthalmic Solutions; Pharmacogenetics; Pyrimidines; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tomography, Optical Coherence; Visual Acuity; Wet Macular Degeneration | 2015 |
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
Topics: Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Endpoint Determination; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides | 2015 |
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sulfonamides; Sunitinib | 2015 |
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides | 2015 |
Proteinuria with first-line therapy of metastatic renal cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrimidines; Retrospective Studies; Sulfonamides | 2016 |
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Interactions; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides; Taxoids | 2015 |
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Female; Gene Expression; Humans; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Lymphocyte Count; Macrophages; Male; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Indazoles; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Sulfonamides | 2015 |
Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Indazoles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Pyrimidines; Sulfonamides | 2015 |
Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Calcium-Binding Proteins; Carcinoma, Renal Cell; China; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A | 2015 |
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasms; Neovascularization, Pathologic; Proportional Hazards Models; Protein Stability; Proteolysis; Pyrimidines; Sulfonamides; Texas; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53; Vorinostat; Young Adult | 2015 |
A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Indazoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Organ Size; Prospective Studies; Pyrimidines; Retrospective Studies; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Italy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrimidines; Sulfonamides; Treatment Outcome | 2015 |
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indazoles; Male; Middle Aged; Mutation; Neoplasm Staging; Neoplasms; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2015 |
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Topics: Adult; Aged; Angiogenesis Inhibitors; Chemoradiotherapy, Adjuvant; Extremities; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Young Adult | 2015 |
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.
Topics: Aged; Carcinoid Tumor; Cohort Studies; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome | 2015 |
Dried blood spot analysis for therapeutic drug monitoring of pazopanib.
Topics: Adult; Aged; Dried Blood Spot Testing; Drug Monitoring; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sulfonamides; Young Adult | 2015 |
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for res
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2015 |
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Neuroendocrine Tumors; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrimidines; Sulfonamides; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2015 |
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2015 |
Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib.
Topics: Adolescent; Albumins; Alkaline Phosphatase; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Humans; Indazoles; Kidney Neoplasms; Nomograms; Prognosis; Pyrimidines; Sulfonamides | 2015 |
A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gene Amplification; Humans; Indazoles; Lapatinib; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides | 2015 |
Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Pancreatic Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome; Young Adult | 2015 |
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoadjuvant Therapy; Pyrimidines; Sarcoma; Sulfonamides; Taxoids; Treatment Outcome | 2015 |
Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indazoles; Indoles; Kidney Neoplasms; Lymph Nodes; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Risk Assessment; Sulfonamides; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2016 |
Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.
Topics: Antineoplastic Agents; Binding Sites; Blood Proteins; Case-Control Studies; Chromatography, High Pressure Liquid; Humans; In Vitro Techniques; Indazoles; Neoplasms; Protein Binding; Pyrimidines; Serum Albumin; Sulfonamides; Tandem Mass Spectrometry | 2016 |
Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study.
Topics: Adult; Aged; Aged, 80 and over; Asia, Eastern; Asian People; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor Receptor-1; Young Adult | 2018 |
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
Topics: Adult; Aged; Carcinoma, Renal Cell; Databases, Factual; Disease-Free Survival; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Pyrimidines; Retrospective Studies; Risk Factors; Spain; Sulfonamides | 2016 |
Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Pressure; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).
Topics: Angiogenesis Inhibitors; Chemotherapy, Adjuvant; Disease-Free Survival; Endothelial Progenitor Cells; Germany; Humans; Indazoles; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Risk; Sarcoma; Sulfonamides | 2016 |
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genome-Wide Association Study; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides; White People; Young Adult | 2016 |
Pharmacokinetic interaction between pazopanib and cisplatin regimen.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome | 2016 |
Benefits of pazopanib over sunitinib for renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Patient Safety; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Sensitivity and Specificity; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diagnosis, Differential; Femoral Neoplasms; Fracture Fixation, Intramedullary; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Middle Aged; Oximes; Pyrimidines; Radiodermatitis; Radiotherapy, Adjuvant; Sulfonamides | 2016 |
Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Disease Progression; Female; Humans; Indazoles; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Sulfonamides; Young Adult | 2016 |
Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib; Young Adult | 2016 |
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Follow-Up Studies; Humans; Indazoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Pyrimidines; Stomach Neoplasms; Sulfonamides; Young Adult | 2016 |
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Leiomyosarcoma; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Survival Rate; Uterine Neoplasms; Young Adult | 2016 |
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrimidines; Sulfonamides; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2016 |
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calpain; Carcinoma, Renal Cell; Everolimus; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Nephrectomy; NF-kappa B; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Drug Administration Schedule; Female; Humans; Indazoles; Infusions, Intravenous; Male; Melanoma; Paclitaxel; Pyrimidines; Skin Neoplasms; Sulfonamides; Treatment Outcome; Up-Regulation | 2016 |
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.
Topics: Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proteinuria; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A | 2016 |
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Proportional Hazards Models; Pyrimidines; Sulfonamides; Treatment Outcome | 2016 |
A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
Topics: Age Factors; Aged; Antibiotics, Antineoplastic; Belgium; Clinical Protocols; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Geriatric Assessment; Germany; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Research Design; Risk Factors; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Time Factors; Treatment Outcome | 2016 |
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Contrast Media; Disease Progression; Female; Humans; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2017 |
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Follow-Up Studies; Hemangioendothelioma, Epithelioid; Hemangiosarcoma; Humans; Indazoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate; Tunica Intima | 2017 |
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Quality of Life; Sulfonamides | 2017 |
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Tertiary Care Centers; Treatment Outcome; Young Adult | 2017 |
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Topics: Acetylation; Adult; Aged; Alanine Transaminase; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Benzofurans; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Drug Resistance; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fatigue; Female; Gene Expression; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pyrimidines; Sulfonamides; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2017 |
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2017 |
Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.
Topics: Adult; Angiogenesis Inhibitors; Disease Progression; Humans; Indazoles; Male; Neoplasms, Germ Cell and Embryonal; Pyrimidines; Sulfonamides; Testicular Neoplasms; Treatment Outcome | 2017 |
Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pyrimidines; Sulfonamides; Survival Rate; Urologic Neoplasms | 2017 |
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carboplatin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Treatment Outcome | 2017 |
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Indazoles; Leukopenia; Liver Function Tests; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Pyrimidines; Sulfonamides | 2017 |
Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sulfonamides | 2018 |
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
Topics: Adult; Aged; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Proliferation; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Indazoles; Indoles; London; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasms, Second Primary; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2017 |
A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Indazoles; Iodine Radioisotopes; Male; Middle Aged; Pyrimidines; Sulfonamides; Thyroid Neoplasms | 2017 |
Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease-Free Survival; Electrocardiography; Endocrine Gland Neoplasms; Female; Humans; Indazoles; Male; Middle Aged; Paraganglioma; Pheochromocytoma; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Failure | 2017 |
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Monitoring; Female; Humans; Indazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrimidines; Sulfonamides; Treatment Outcome | 2017 |
Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Follow-Up Studies; Humans; Indazoles; Liposarcoma; Male; Middle Aged; Neoplasm Grading; Prospective Studies; Pyrimidines; Sulfonamides; Survival Rate; Young Adult | 2017 |
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Nephrectomy; Placebos; Pyrimidines; Sulfonamides; Young Adult | 2017 |
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrimidines; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Sulfonamides | 2017 |
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Placebos; Progression-Free Survival; Proto-Oncogene Mas; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance th
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Reported Outcome Measures; Progression-Free Survival; Pyrimidines; Quality of Life; Sulfonamides; Time-to-Treatment | 2018 |
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Platinum; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
Pazopanib therapy for desmoid tumors in adolescent and young adult patients.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Child; Child, Preschool; Female; Fibromatosis, Aggressive; Follow-Up Studies; Humans; Indazoles; Male; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Young Adult | 2018 |
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Progression-Free Survival; Proteomics; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2018 |
Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Regression Analysis; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Sunitinib; Treatment Outcome; Tumor Burden | 2018 |
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Sunitinib; White People; Young Adult | 2018 |
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Pyrimidines; Sulfonamides | 2018 |
Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia.
Topics: Adult; Female; Hemorrhage; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic | 2019 |
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anilides; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyridines; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome | 2018 |
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; DNA Copy Number Variations; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Kidney Neoplasms; Male; Microtubule-Associated Proteins; Mutation; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Sequence Analysis, DNA; Sulfonamides; Survival Analysis; Treatment Outcome; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein | 2018 |
Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.
Topics: Adult; Angiogenesis Inhibitors; Female; Humans; Indazoles; Male; Prospective Studies; Pyrimidines; Sulfonamides; Texas; Time Factors; Treatment Outcome; von Hippel-Lindau Disease | 2018 |
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
Topics: Adult; Angiogenesis Inhibitors; Female; Humans; Indazoles; Male; Neoplasm Metastasis; Pyrimidines; Sarcoma, Alveolar Soft Part; Sulfonamides | 2019 |
Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Canada; Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Kidney Neoplasms; Male; Markov Chains; Middle Aged; Pyrimidines; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Treatment Outcome | 2018 |
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyrimidines; Sulfonamides; Sunitinib | 2018 |
An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Epidemiologic Research Design; Follow-Up Studies; Hemangiosarcoma; Humans; Indazoles; Patient Selection; Prognosis; Pyrimidines; Sulfonamides; Survival Rate | 2019 |
Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients.
Topics: Angiogenesis Inhibitors; Cytochrome P-450 CYP3A; Female; Heterozygote; Humans; Indazoles; Male; Middle Aged; Models, Biological; Neoplasms; Polymorphism, Single Nucleotide; Pyrimidines; Sulfonamides | 2019 |
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2019 |
Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Combined Modality Therapy; Diet, Fat-Restricted; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Sulfonamides | 2019 |
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Indazoles; Male; Melanoma; Middle Aged; Mutation; Paclitaxel; Prognosis; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Sulfonamides; Survival Rate | 2019 |
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Patient Safety; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Survival Rate; Young Adult | 2019 |
Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial.
Topics: Humans; Indazoles; Male; Prostatectomy; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor A | 2018 |
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Humans; Indazoles; Male; Middle Aged; Multivariate Analysis; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Soft Tissue Neoplasms; Solitary Fibrous Tumors; Sulfonamides; Survival Analysis | 2019 |
Usefulness of Implementing Comprehensive Pharmaceutical Care for Metastatic Renal Cell Carcinoma Outpatients Treated with Pazopanib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Incidence; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Metastasis; Outpatients; Patient Compliance; Pyrimidines; Self Report; Sulfonamides; Treatment Outcome | 2019 |
Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Sulfonamides; Sunitinib; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2019 |
Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Gastric Acid; Humans; Indazoles; Male; Middle Aged; Neoplasm Grading; Prognosis; Pyrimidines; Sarcoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
GAS agents limit pazopanib activity in soft-tissue sarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Indazoles; Male; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Sarcoma; Sulfonamides | 2019 |
Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04).
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Follow-Up Studies; Germany; Humans; Indazoles; Male; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Prognosis; Pyrimidines; Risk Factors; Sarcoma; Sulfonamides | 2019 |
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Marrow; Female; Gastrointestinal Diseases; Humans; Indazoles; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Microvessels; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Salvage Therapy; Sulfonamides; Treatment Outcome; Tumor Microenvironment | 2019 |
Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors.
Topics: Adult; Age Factors; Aged; Azepines; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Patient Safety; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Assessment; Sex Factors; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Dose-Response Relationship, Drug; Fasting; Female; Food-Drug Interactions; Half-Life; Humans; Indazoles; Male; Metabolic Clearance Rate; Middle Aged; Patient Preference; Patient Safety; Patient Satisfaction; Pyrimidines; Sulfonamides; Young Adult | 2019 |
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrimidinones; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2019 |
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Risk Assessment; Single-Blind Method; Sirolimus; Sulfonamides | 2020 |
Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chondrosarcoma; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Staging; Neoplasms, Connective and Soft Tissue; Pyrimidines; Retrospective Studies; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome | 2019 |
Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era.
Topics: Biomarkers; Carcinoma, Renal Cell; Female; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2021 |
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome | 2019 |
Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chondrosarcoma; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Prospective Studies; Pyrimidines; Sulfonamides | 2020 |
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Pyrimidines; Quality of Life; Sulfonamides; Treatment Outcome; Young Adult | 2019 |
Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions
Topics: Aldehydes; Angiogenesis Inhibitors; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Indazoles; Microsomes, Liver; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins; Serum Albumin, Human; Sulfonamides; Sunitinib | 2020 |
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indazoles; Kidney Neoplasms; Logistic Models; Male; Pyrimidines; Random Allocation; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2019 |
A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ).
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrimidines; Sulfonamides; Sunitinib; Treatment Failure; Treatment Outcome | 2020 |
[
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Ovarian Neoplasms; Paclitaxel; Peptides; Polyethylene Glycols; Positron-Emission Tomography; Pyrimidines; Sulfonamides | 2020 |
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Leiomyosarcoma; Male; Middle Aged; Pyrimidines; Sulfonamides | 2020 |
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
Topics: Aged; Aged, 80 and over; Humans; Indazoles; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pyrimidines; Sulfonamides | 2020 |
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Cross-Over Studies; Diarrhea; Disease Progression; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome | 2020 |
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cardiotoxicity; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Ovarian Neoplasms; Progression-Free Survival; Pyrimidines; Stilbenes; Sulfonamides; Survival Rate | 2020 |
First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2020 |
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Prospective Studies; Pyrimidines; Sulfonamides | 2020 |
Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diffusion Magnetic Resonance Imaging; Female; Healthy Volunteers; Humans; Indazoles; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Retrospective Studies; ROC Curve; Sulfonamides; Treatment Outcome | 2020 |
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.
Topics: Aged; Female; Follow-Up Studies; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Solitary Fibrous Tumors; Sulfonamides; Survival Rate | 2020 |
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Topics: Adult; Aged; Angiogenesis Inhibitors; Boron Compounds; Glycine; Humans; Indazoles; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasms; Progression-Free Survival; Pyrimidines; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53; Vorinostat; Young Adult | 2020 |
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; China; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Sulfonamides; Sunitinib; Young Adult | 2020 |
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Indazoles; Middle Aged; Peritoneal Neoplasms; Pyrimidines; Sulfonamides | 2020 |
Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Indazoles; Irinotecan; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Pyrimidines; Sulfonamides | 2020 |
Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2020 |
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Neoplasm Metastasis; Nivolumab; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib | 2020 |
Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Indazoles; Male; Middle Aged; Neoplasm Grading; Neurofibrosarcoma; Neutropenia; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Sulfonamides; Young Adult | 2021 |
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
Topics: Aged; Female; Humans; Indazoles; Male; Neoplasm Metastasis; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2020 |
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Hypothyroidism; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2021 |
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.
Topics: Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Chemotherapy-Induced Febrile Neutropenia; Doxorubicin; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neutropenia; Patient Reported Outcome Measures; Progression-Free Survival; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides | 2020 |
A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans.
Topics: Adult; Aged; Biomarkers, Tumor; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Skin; Skin Neoplasms; Sulfonamides; Tumor Burden | 2021 |
Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Case-Control Studies; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate; Transcriptome | 2020 |
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Indazoles; Middle Aged; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2021 |
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
Topics: Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Neoplasm Recurrence, Local; Nephrectomy; Pyrimidines; Sulfonamides | 2021 |
Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Follow-Up Studies; Humans; Hypogonadism; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Quality of Life; Sulfonamides; Sunitinib; Testosterone | 2021 |
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indazoles; Interleukin-10; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Polyethylene Glycols; Pyrimidines; Sulfonamides; Survival Analysis; Treatment Outcome; Young Adult | 2021 |
VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Indazoles; Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome | 2021 |
Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cardiac Output; Endothelium, Vascular; Female; Hemodynamics; Humans; Hypertension; Indazoles; Male; Middle Aged; Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Vascular Resistance; Vascular Stiffness | 2021 |
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome | 2021 |
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Osteosarcoma; Prospective Studies; Pyrimidines; Sarcoma; Sulfonamides; Topotecan; Treatment Outcome; Young Adult | 2021 |
Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Progression-Free Survival; Pyrimidines; Quality of Life; Sulfonamides | 2021 |
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatocyte Growth Factor; Humans; Indazoles; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrimidines; Pyrrolidinones; Quinolines; Sulfonamides; Vascular Endothelial Growth Factor A | 2021 |
Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST).
Topics: Gastrointestinal Stromal Tumors; Humans; Indazoles; Indoles; Pyrimidines; Pyrroles; Sulfonamides | 2021 |
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Iodine Radioisotopes; Male; Middle Aged; Pyrimidines; Sulfonamides; Thyroid Neoplasms; Treatment Failure | 2021 |
Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Asia; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Middle East; Progression-Free Survival; Prospective Studies; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome; Young Adult | 2021 |
A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma.
Topics: Humans; Indazoles; Neoadjuvant Therapy; Prospective Studies; Pyrimidines; Sarcoma; Sulfonamides | 2021 |
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junction; Female; Fluorouracil; Humans; Indazoles; Male; Middle Aged; Oxaliplatin; Pyrimidines; Stomach Neoplasms; Sulfonamides | 2022 |
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Hemangiosarcoma; Humans; Indazoles; Male; Pyrimidines; Sulfonamides | 2022 |
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group.
Topics: B7-H1 Antigen; Biomarkers; Carcinoma, Renal Cell; Humans; Indazoles; Interferon-alpha; Kidney Neoplasms; Prognosis; Pyrimidines; Sulfonamides; Treatment Outcome; Tumor Necrosis Factor-alpha | 2022 |
A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial.
Topics: Adolescent; Adult; Aged; Carcinoma, Renal Cell; Humans; Immune Checkpoint Inhibitors; Indazoles; Kidney Neoplasms; Prospective Studies; Pyrimidines; Sulfonamides | 2022 |
OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma.
Topics: Hemangiosarcoma; Humans; Indazoles; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome; Vascular Endothelial Growth Factor A | 2022 |
A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome.
Topics: Activities of Daily Living; Aged; Doxorubicin; Humans; Indazoles; Sarcoma; Soft Tissue Neoplasms | 2023 |
636 other study(ies) available for indazoles and pazopanib
| Article | Year |
|---|---|
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunoprecipitation; Indazoles; Mice; Microarray Analysis; Multiple Myeloma; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Sulfonamides | 2006 |
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell-Free System; Cornea; Dose-Response Relationship, Drug; Female; Fibroblast Growth Factor 2; Humans; Indazoles; Inhibitory Concentration 50; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sulfones; Vascular Endothelial Growth Factor A | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Biomedical Research; CA-125 Antigen; Clinical Trials as Topic; Dasatinib; Female; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Neoplasms; Ovarian Neoplasms; Pyrimidines; Snake Venoms; Sulfonamides; Thiazoles; Treatment Outcome | 2007 |
Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist.
Topics: Adrenergic beta-Antagonists; Coronary Angiography; Electrocardiography; Humans; Indazoles; Male; Metoprolol; Middle Aged; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Takotsubo Cardiomyopathy | 2009 |
New drugs for ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bevacizumab; BRCA2 Protein; Carboplatin; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A | 2008 |
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.
Topics: Animals; Cells, Cultured; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Indazoles; Isoenzymes; Mice; Models, Molecular; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Xenograft Model Antitumor Assays | 2008 |
Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Biological Availability; Choroid; Choroidal Neovascularization; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Indazoles; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Pyrimidines; Retina; Sulfonamides; Tissue Distribution | 2009 |
Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
Topics: Chemistry, Pharmaceutical; Chromatography, Liquid; Drug Contamination; Indazoles; Mass Spectrometry; Mutagens; Pyrimidines; Spectrophotometry, Ultraviolet; Sulfonamides | 2009 |
Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.
Topics: Aged; Base Sequence; Biomarkers; Carcinoma, Merkel Cell; DNA Mutational Analysis; Fatal Outcome; Female; Humans; Indazoles; Keratins; Mutation; Neoplasm Metastasis; Phosphopyruvate Hydratase; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Scalp; Skin Neoplasms; Sulfonamides | 2009 |
Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Indazoles; Lapatinib; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2009 |
Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor.
Topics: Adult; Aged; Granulosa Cell Tumor; Humans; Indazoles; Male; Neovascularization, Pathologic; Pyrimidines; Salvage Therapy; Sulfonamides; Testicular Neoplasms; Tomography, X-Ray Computed | 2009 |
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Hematologic Diseases; Hematopoietic Stem Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Myelopoiesis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Substrate Specificity; Sulfonamides; Sunitinib | 2009 |
Pazopanib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2010 |
StatBite: FDA oncology drug product approvals in 2009.
Topics: Administration, Oral; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetuximab; Depsipeptides; Drug Approval; Everolimus; Ferrosoferric Oxide; Glutamates; Guanine; Humans; Indazoles; Injections; Panitumumab; Pemetrexed; Pyrimidines; Sirolimus; Sulfonamides; United States; United States Food and Drug Administration | 2010 |
New weapons against kidney cancer. Two recent drug options appear to extend survival for kidney cancer patients who can't tolerate existing medications.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2010 |
Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping.
Topics: Drug Contamination; Indazoles; Pyrimidines; Sulfonamides; Technology, Pharmaceutical | 2010 |
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Therapy; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; Kaplan-Meier Estimate; Mice; Models, Biological; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Prognostic factors in patients treated with VEGF-targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factors | 2010 |
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Bilirubin; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Genotype; Gilbert Disease; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kidney Neoplasms; Liver; Male; Middle Aged; Nephrectomy; Polymorphism, Genetic; Pyrimidines; Sulfonamides | 2010 |
Everolimus and pazopanib: two new drugs for renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Interactions; Everolimus; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sirolimus; Sulfonamides | 2010 |
Pazopanib in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2010 |
Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib.
Topics: Aged; Antibiotics, Antineoplastic; Blood Glucose; Diabetes Mellitus, Type 2; Epirubicin; Humans; Hypoglycemic Agents; Indazoles; Male; Prostatic Neoplasms; Pyrimidines; Sulfonamides | 2010 |
Effect of pazopanib on tumor microenvironment and liposome delivery.
Topics: Angiogenesis Inhibitors; Animals; Cell Hypoxia; Doxorubicin; Drug Delivery Systems; Extracellular Fluid; Humans; Indazoles; Liposomes; Mice; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Pressure; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sulfonamides; Tissue Distribution; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Bar the windows but open the door to randomization.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Sulfonamides; Treatment Outcome | 2010 |
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
Topics: Adenoma, Oxyphilic; Adult; Black or African American; Female; Hair; Humans; Hypopigmentation; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Skin; Sulfonamides; Thyroid Neoplasms | 2010 |
Pazopanib trial data cannot support first-line use.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2010 |
Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.
Topics: B-Lymphocytes; Base Sequence; Blotting, Western; Catalytic Domain; Cell Line, Tumor; DNA Primers; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Pyrimidines; Receptor-Like Protein Tyrosine Phosphatases, Class 3; Receptors, Vascular Endothelial Growth Factor; src-Family Kinases; Substrate Specificity; Sulfonamides; ZAP-70 Protein-Tyrosine Kinase | 2010 |
The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phosphorylation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape.
Topics: Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome | 2010 |
Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Echocardiography; Heart; Immunohistochemistry; In Situ Nick-End Labeling; Indazoles; Indoles; Male; Microscopy, Electron, Transmission; Mitochondria; Myocardium; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Rats; Sorafenib; Sulfonamides; Sunitinib; Troponin I | 2010 |
Is advanced renal cell carcinoma becoming a chronic disease?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Protein Serine-Threonine Kinases; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
Kinase inhibitors for refractory thyroid cancers.
Topics: Antineoplastic Agents; Cell Differentiation; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Humans; Indazoles; Multicenter Studies as Topic; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Thyroid Neoplasms; Time Factors; Treatment Outcome | 2010 |
A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Cycle; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Humans; Indazoles; Intracellular Space; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2010 |
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2010 |
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Pyrimidines; Receptor, ErbB-2; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Image Enhancement; Indazoles; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrimidines; Sulfonamides; Tumor Burden; Ultrasonography; Xenograft Model Antitumor Assays | 2011 |
NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2011 |
Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.
Topics: Antineoplastic Agents; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Indazoles; Pyrimidines; Sulfonamides; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2011 |
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Cross-Over Studies; Disease-Free Survival; DNA Mutational Analysis; Genetic Markers; Genotype; Germ-Line Mutation; Humans; Indazoles; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Proteins; Neovascularization, Physiologic; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrimidines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sulfonamides | 2011 |
Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Cell Movement; Choroid; Down-Regulation; Endothelial Cells; Humans; Indazoles; Intracellular Space; Macular Degeneration; Male; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Rats; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sulfonamides; Vascular Endothelial Growth Factor A | 2011 |
Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2011 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Topics: Administration, Metronomic; Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Endothelial Cells; Humans; Indazoles; Mice; Mice, Inbred NOD; Mice, SCID; Microvessels; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neuroblastoma; Osteosarcoma; Pyrimidines; Random Allocation; Rhabdomyosarcoma; Stem Cells; Sulfonamides; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2011 |
Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication.
Topics: Anastomosis, Surgical; Angiogenesis Inhibitors; Anti-Bacterial Agents; Carcinoma; Colectomy; Female; Humans; Hysterectomy; Indazoles; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Peritoneal Neoplasms; Pyrimidines; Salpingectomy; Sulfonamides; Surgical Wound Dehiscence; Treatment Outcome | 2011 |
Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Differentiation; Female; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2011 |
Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Indazoles; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2011 |
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection | 2012 |
Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage.
Topics: Administration, Ophthalmic; Animals; Blood Glucose; Blood Proteins; Blood-Retinal Barrier; Body Weight; Capillary Permeability; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Indazoles; Leukocytes; Leukostasis; Macular Edema; Male; Molecular Targeted Therapy; Ophthalmic Solutions; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Inbred BN; Sulfonamides; Time Factors; Vitreous Body | 2011 |
Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indazoles; Kidney Neoplasms; Nursing Methodology Research; Oncology Nursing; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides | 2011 |
Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasm Transplantation; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Sulfonamides; Sunitinib | 2011 |
[Pharmacological sheet: pazopanib (Votrient), oral administration].
Topics: Antineoplastic Agents; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2011 |
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; MAP Kinase Signaling System; Melanoma; Mice; Neovascularization, Pathologic; Proto-Oncogene Proteins B-raf; Pyrimidines; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
Topics: Antineoplastic Agents; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Sulfonamides | 2011 |
Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Child; Child, Preschool; Female; Humans; Indazoles; Mice; Mice, SCID; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Rhabdomyosarcoma; Sarcoma, Ewing; Sulfonamides; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2012 |
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2012 |
Second-line treatment for renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Retreatment; Sulfonamides; Sunitinib | 2012 |
A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway.
Topics: Animals; Cell Line, Tumor; G1 Phase; Humans; Indazoles; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sarcoma, Synovial; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report.
Topics: Cerebellar Neoplasms; Hemangioblastoma; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sulfonamides; Treatment Outcome; von Hippel-Lindau Disease | 2012 |
Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2012 |
Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Humans; Immunohistochemistry; Indazoles; Light; Middle Aged; Neuropilin-1; Neuropilin-2; Neuropilins; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Retinal Pigment Epithelium; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Rapid analysis of whole blood by paper spray mass spectrometry for point-of-care therapeutic drug monitoring.
Topics: Humans; Indazoles; Mass Spectrometry; Paper; Pharmaceutical Preparations; Point-of-Care Systems; Pyrimidines; Sulfonamides | 2012 |
Pazopanib and the treatment palette for soft-tissue sarcoma.
Topics: Antineoplastic Agents; Female; Humans; Indazoles; Male; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2012 |
Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Cell Line; Dogs; Erlotinib Hydrochloride; Indazoles; Male; Mice; Morpholines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sulfonamides | 2012 |
Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases.
Topics: Animals; Antineoplastic Agents; Carbonic Anhydrases; Drug Delivery Systems; Enzyme Activation; Enzyme Inhibitors; Humans; Indazoles; Models, Molecular; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfonamides | 2012 |
Decade of molecular targeted therapy: abdominal manifestations of drug toxicities--what radiologists should know.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Chemical and Drug Induced Liver Injury; Cholecystitis; Early Diagnosis; Edema; Fatty Liver; Female; Health Knowledge, Attitudes, Practice; Humans; Indazoles; Infections; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms; Pancreatitis; Protein-Tyrosine Kinases; Pyrimidines; Radiography, Abdominal; Sulfonamides; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS).
Topics: Animals; Brain Chemistry; Chromatography, Liquid; Drug Stability; Indazoles; Least-Squares Analysis; Mice; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Tandem Mass Spectrometry | 2012 |
Targeted therapies: pazopanib for soft-tissue sarcoma: a PALETTE of data emerges.
Topics: Clinical Trials, Phase III as Topic; Humans; Indazoles; Molecular Targeted Therapy; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Survival Rate | 2012 |
Biomarkers in personalised treatment of renal-cell carcinoma.
Topics: Angiogenic Proteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cytokines; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2012 |
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Topics: Angiogenic Proteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cluster Analysis; Cytokines; Disease-Free Survival; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Linear Models; Logistic Models; Multicenter Studies as Topic; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome; Tumor Burden | 2012 |
Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
Topics: Aged; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor A | 2012 |
Antiangiogenic treatment in metastatic urothelial cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Male; Pyrimidines; Sulfonamides; Urologic Neoplasms; Urothelium | 2012 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
Topics: Aged; Chromatography, Liquid; Drug Monitoring; Drug Stability; Female; Humans; Indazoles; Least-Squares Analysis; Limit of Detection; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Tandem Mass Spectrometry | 2012 |
Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.
Topics: Alanine Transaminase; Anticholesteremic Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Interactions; Humans; Hypercholesterolemia; Incidence; Indazoles; Neoplasm Proteins; Neoplasms; Polymorphism, Single Nucleotide; Pyrimidines; Reference Values; Simvastatin; Sulfonamides | 2012 |
Pazopanib: in advanced soft tissue sarcoma.
Topics: Adult; Angiogenesis Inhibitors; Humans; Indazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Treatment Outcome | 2012 |
Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Movement; Cell Proliferation; Coculture Techniques; Immunoenzyme Techniques; Indazoles; Lung Neoplasms; Mice; Mice, Inbred C3H; Osteosarcoma; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sulfonamides | 2012 |
Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
Topics: Adrenal Cortex Hormones; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Delayed Diagnosis; Diagnostic Errors; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Heart Neoplasms; Hemangiosarcoma; Humans; Ifosfamide; Indazoles; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Myocardium; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Pericarditis; Pericardium; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrimidines; Remission Induction; Sulfonamides; Vincristine | 2012 |
Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit.
Topics: Administration, Oral; Administration, Topical; Angiogenesis Inhibitors; Animals; Blood-Retinal Barrier; Capillary Permeability; Female; Fluorophotometry; Indazoles; Intravitreal Injections; Kidney; Lung; Mannitol; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Fluorescence; Pyrimidines; Rabbits; Retinal Neovascularization; Species Specificity; Sulfonamides; Vascular Endothelial Growth Factor A | 2013 |
Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Humans; Immunosuppressive Agents; Indazoles; Kidney Neoplasms; Male; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor A | 2013 |
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; United States | 2013 |
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Separation; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Indazoles; Mice; Mice, Nude; Mitosis; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Protein Serine-Threonine Kinases; Pyrimidines; RNA, Small Interfering; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Tubulin Modulators | 2013 |
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2013 |
Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Nephrectomy; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome | 2013 |
Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Cohort Studies; Databases, Pharmaceutical; Drug Interactions; Female; Humans; Imatinib Mesylate; Indazoles; Male; Middle Aged; Piperazines; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; United States; Young Adult | 2013 |
Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease.
Topics: Administration, Oral; Administration, Topical; Angiogenesis Inhibitors; Animals; Autoradiography; Choroidal Neovascularization; Drug Delivery Systems; Female; Fluorescein Angiography; Half-Life; Indazoles; Melanins; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Pyrimidines; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor; Sulfonamides; Sulfones; Uvea; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Urological medical oncology: land of opportunity.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomedical Research; Clinical Trials, Phase III as Topic; Humans; Indazoles; Medical Oncology; Pyrimidines; Scotland; Sulfonamides; Urologic Neoplasms; Urology | 2013 |
A case of metastatic adamantinoma responding to treatment with pazopanib.
Topics: Adamantinoma; Adult; Antineoplastic Agents; Female; Humans; Indazoles; Lung Neoplasms; Pyrimidines; Sulfonamides | 2013 |
[Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
Topics: Angiogenesis Inhibitors; Astrocytes; Axitinib; Cell Survival; Cornea; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Corneal; Humans; Imidazoles; Indazoles; Lens, Crystalline; Microscopy, Phase-Contrast; Niacinamide; Optic Disk; Organ Culture Techniques; Oxidative Stress; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Pigment Epithelium; Sorafenib; Sulfonamides; Trabecular Meshwork; Wet Macular Degeneration | 2013 |
Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Breast Neoplasms; Drug Evaluation, Preclinical; Female; Humans; Indazoles; Mice; Neoplasm Micrometastasis; Neoplasm Proteins; Neoplasm Transplantation; Neuroglia; Phosphorylation; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sulfonamides; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
[Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2013 |
Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Synergism; Female; Gene Expression; Humans; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Pyrimidines; Pyrroles; Sirolimus; Stearoyl-CoA Desaturase; Sulfonamides; Sunitinib; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid | 2013 |
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
Topics: Animals; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Dimerization; Humans; Indazoles; Interleukin-3; Ligands; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Protein Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides | 2013 |
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides | 2013 |
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Necrosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reactive Oxygen Species; Sulfonamides; Sunitinib; Urinary Bladder Neoplasms | 2013 |
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Solitary Fibrous Tumors; Sulfonamides; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Bevacizumab; Duodenal Diseases; Humans; Indazoles; Indoles; Intestinal Diseases; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography; Radiosurgery; Radiotherapy Dosage; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Stomach Ulcer; Sulfonamides; Sunitinib; Ulcer | 2013 |
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib | 2013 |
Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blotting, Western; Disease Models, Animal; Fluorescent Antibody Technique; Humans; Indazoles; Male; Mice; Mice, Nude; Neoplasms, Germ Cell and Embryonal; Pyrimidines; Real-Time Polymerase Chain Reaction; Sulfonamides; Testicular Neoplasms; Xenograft Model Antitumor Assays | 2013 |
[Frequent gout attacks during therapy - what can be done?].
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Colchicine; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides | 2013 |
Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Decision Making, Organizational; Health Care Costs; Humans; Incidence; Indazoles; Kidney Neoplasms; Markov Chains; Neoplasm Staging; Prevalence; Pyrimidines; Spain; Sulfonamides | 2013 |
Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Female; Genital Neoplasms, Female; Humans; Indazoles; Middle Aged; Pyrimidines; Sulfonamides; Topotecan | 2013 |
Self-assembled phenylalanine-α,β-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor.
Topics: Animals; Delayed-Action Preparations; Indazoles; Intravitreal Injections; Nanotubes; Phenylalanine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rats; Retina; Sulfonamides; Vitreous Body | 2013 |
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.
Topics: Bilirubin; Biomarkers, Pharmacological; Genetic Association Studies; Genotype; Gilbert Disease; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Indoles; Liver; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib | 2013 |
[First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Humans; Hungary; Hypertension; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; Treatment Outcome | 2013 |
Design, synthesis and biological evaluation of pazopanib derivatives as antitumor agents.
Topics: Animals; Antineoplastic Agents; Aorta; Cell Survival; Cells, Cultured; Drug Design; Enzyme Activation; Indazoles; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Targeted therapies: treating advanced kidney cancer-miles to go before we sleep.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2013 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
Angiosarcoma of the scalp successfully treated with pazopanib.
Topics: Angiogenesis Inhibitors; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Scalp; Skin Neoplasms; Sulfonamides | 2014 |
Radiation recall dermatitis induced by pazopanib.
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Radiodermatitis; Radiotherapy, Conformal; Sulfonamides; Treatment Outcome | 2013 |
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobin A; Humans; Indazoles; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2014 |
Complete pathologic response in soft tissue sarcoma lung metastases with pazopanib.
Topics: Angiogenesis Inhibitors; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Pyrimidines; Sarcoma; Sulfonamides; Tomography, X-Ray Computed | 2014 |
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Eligibility Determination; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Pazopanib outscores sunitinib on tolerability.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib | 2014 |
Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Dose-Response Relationship, Drug; Indazoles; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Structure-Activity Relationship; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides | 2014 |
Dramatic response to pazopanib in a patient with metastatic malignant granular cell tumor.
Topics: Aged; Female; Granular Cell Tumor; Humans; Indazoles; Lung Neoplasms; Lymphatic Metastasis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome | 2014 |
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Genome, Human; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Transcriptome | 2014 |
Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Cell Line, Tumor; Drug Synergism; Female; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Indazoles; Membrane Proteins; Mice, Nude; Microtubule-Associated Proteins; Pyrimidines; Receptors, Death Domain; Sarcoma; Signal Transduction; Sulfonamides; Valproic Acid | 2014 |
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Treatment Outcome | 2014 |
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitory Concentration 50; Irinotecan; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome | 2014 |
Treatment of metastatic melanoma with pazopanib: A report of five patient cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Indazoles; Male; Melanoma; Middle Aged; Pyrimidines; Sulfonamides | 2015 |
Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.
Topics: Animals; Carcinoma; Carcinoma, Papillary; Cell Culture Techniques; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Humans; Indazoles; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.
Topics: Adult; Angiogenesis Inhibitors; Humans; Incidence; Indazoles; Male; Middle Aged; Pneumothorax; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2014 |
Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib.
Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Myasthenia Gravis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Uveal Neoplasms | 2014 |
How to interpret patient preferences in selecting the best drug: are the current measurements up to the job?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Patient Preference; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2014 |
[Metastasized renal cell carcinoma - research subjects needed!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Metastasis; Niacinamide; Patient Selection; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides | 2014 |
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2014 |
New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.
Topics: Amino Acid Sequence; Axitinib; Binding, Competitive; Cell Line, Tumor; Chromatography, Liquid; Female; Humans; Imidazoles; Indazoles; K562 Cells; Models, Chemical; Molecular Docking Simulation; Molecular Sequence Data; Molecular Structure; Placenta; Pregnancy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sequence Homology, Amino Acid; Small Molecule Libraries; Sulfonamides; Tandem Mass Spectrometry | 2014 |
[Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indazoles; Indoles; Liver Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sulfonamides; Sunitinib | 2014 |
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Comorbidity; Databases, Factual; Drug Prescriptions; Drug Utilization Review; Female; Humans; Indazoles; Insurance Claim Reporting; Kidney Neoplasms; Male; Medication Adherence; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome; United States | 2014 |
Drugs to exclude from your list.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Humans; Indazoles; Panitumumab; Patient Selection; Pyrimidines; Risk Assessment; Risk Factors; Sulfonamides | 2014 |
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Eosinophils; Female; Hemoglobins; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2014 |
In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2014 |
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Cone-Beam Computed Tomography; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Subacute cutaneous lupus erythematosus induced by the new multikinase inhibitor pazopanib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Humans; Indazoles; Kidney Neoplasms; Lupus Erythematosus, Cutaneous; Male; Pyrimidines; Sulfonamides | 2014 |
Pazopanib combined with radiation: in vivo model of interaction.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Pyrimidines; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS.
Topics: Adult; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromosome Breakpoints; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Mice; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-met; Pyrimidines; Sarcoma, Clear Cell; Signal Transduction; Soft Tissue Neoplasms; Sulfonamides; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dioxoles; Disease Progression; Drug Costs; Humans; Indazoles; Probability; Pyrimidines; Quality-Adjusted Life Years; Sarcoma; Spain; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2015 |
Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum.
Topics: Fatal Outcome; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Retroperitoneal Neoplasms; Sarcoma, Ewing; Sulfonamides | 2014 |
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice.
Topics: Angiogenesis Inhibitors; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Indazoles; Limit of Detection; Liquid-Liquid Extraction; Neoplasms; Pyrimidines; Spectrophotometry, Ultraviolet; Sulfonamides | 2015 |
Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Esophageal Neoplasms; Gastric Fundus; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Stomach Neoplasms; Sulfonamides | 2015 |
[Effective treatment of metastatic rhabdomyosarcoma with pazopanib].
Topics: Angiogenesis Inhibitors; Biopsy, Needle; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Peritoneal Neoplasms; Pyrimidines; Rhabdomyosarcoma; Sulfonamides | 2014 |
Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Humerus; Indazoles; Lung Neoplasms; Male; Neoplasms, Radiation-Induced; Osteosarcoma; Pyrimidines; Skull Neoplasms; Sulfonamides; Young Adult | 2014 |
Bespoke treatment: drivers beware!
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fatal Outcome; Female; Humans; Indazoles; Liver Neoplasms; Microtubule-Associated Proteins; Middle Aged; Molecular Targeted Therapy; Mutation; Oncogenes; Pancreatic Neoplasms; Paraneoplastic Syndromes; Pyrimidines; Radiography; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides | 2014 |
In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Medulloblastoma; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Ovarian cancer and antiangiogenic therapy: caveat emptor.
Topics: Angiogenesis Inhibitors; Female; Humans; Indazoles; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2014 |
What next? Choosing second-line therapy in progressive renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Radiography; Spinal Neoplasms; Sulfonamides | 2014 |
Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.
Topics: Animals; Cell Line, Tumor; Disease-Free Survival; Humans; Immunohistochemistry; Indazoles; Mice; NIH 3T3 Cells; Protein Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Sulfonamides | 2014 |
Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Topics: Aldehyde Dehydrogenase 1 Family; Angiogenesis Inhibitors; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Indazoles; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Mice, Inbred NOD; Neoadjuvant Therapy; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Dehydrogenase; Sarcoma; Sorafenib; Sulfonamides; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2014 |
Response of refractory Ewing sarcoma to pazopanib.
Topics: Angiogenesis Inhibitors; Bone Neoplasms; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Pyrimidines; Salvage Therapy; Sarcoma, Ewing; Sulfonamides; Young Adult | 2015 |
Reversible hair depigmentation in a Japanese female treated with pazopanib.
Topics: Adult; Bone Neoplasms; Female; Hair Diseases; Hip Joint; Humans; Indazoles; Pigmentation Disorders; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma; Sulfonamides | 2014 |
Pazopanib-induced leg ulcer in a patient with malignant fibrous histiocytoma.
Topics: Aged, 80 and over; Female; Histiocytoma, Malignant Fibrous; Humans; Indazoles; Leg Ulcer; Protein-Tyrosine Kinases; Pyrimidines; Soft Tissue Neoplasms; Sulfonamides | 2014 |
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Pressure; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Neoplasm Staging; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Rate; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.
Topics: Adolescent; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Genome-Wide Association Study; Humans; Indazoles; Kidney Neoplasms; Male; Polymorphism, Single Nucleotide; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2015 |
Inhibition of c-Kit by tyrosine kinase inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles | 2015 |
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Withholding Treatment | 2015 |
First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Community Networks; Electronic Health Records; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; United States; Young Adult | 2015 |
Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?
Topics: Axitinib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Nucleoside Transport Proteins; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
Bronchopleural fistula arising after commencement of pazopanib for progressive sarcoma.
Topics: Angiogenesis Inhibitors; Bronchial Fistula; Female; Humans; Indazoles; Lung Neoplasms; Middle Aged; Pleural Diseases; Pyrimidines; Sarcoma; Sulfonamides | 2017 |
Health care costs among renal cancer patients using pazopanib and sunitinib.
Topics: Carcinoma, Renal Cell; Female; Health Care Costs; Health Services; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; United States | 2015 |
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Models, Economic; Pyrimidines; Pyrroles; Quality of Life; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Analysis; United States | 2015 |
Maintenance pazopanib in ovarian cancer.
Topics: Female; Humans; Indazoles; Ovarian Neoplasms; Pyrimidines; Sulfonamides | 2014 |
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
Topics: Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Tandem Mass Spectrometry | 2015 |
Kidney cancer, version 3.2015.
Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2015 |
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Indoles; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib; Survival Analysis; Young Adult | 2015 |
Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Pyrimidines; Republic of Korea; Sulfonamides; Treatment Outcome | 2016 |
Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Treatment Outcome | 2015 |
Pazopanib: retinal detachment.
Topics: Angiogenesis Inhibitors; Humans; Indazoles; Patient Safety; Protein Kinase Inhibitors; Pyrimidines; Retinal Detachment; Risk Assessment; Risk Factors; Sulfonamides | 2015 |
Promising management of pazopanib-induced liver toxicity.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisolone; Pyrimidines; Salvage Therapy; Sarcoma, Synovial; Sulfonamides | 2015 |
Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.
Topics: Amino Acids; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Humans; Indazoles; Ketoconazole; Molecular Docking Simulation; Ovarian Neoplasms; Oxidation-Reduction; Pyrimidines; Sulfonamides | 2016 |
Piloting international production of rapid relative effectiveness assessments of pharmaceuticals.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Comparative Effectiveness Research; Europe; Humans; Indazoles; International Cooperation; Kidney Neoplasms; Pilot Projects; Program Evaluation; Prohibitins; Pyrimidines; Sulfonamides; Surveys and Questionnaires; Technology Assessment, Biomedical | 2014 |
Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Hemangiosarcoma; Humans; Indazoles; Male; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms; Sulfonamides; Treatment Outcome | 2015 |
Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Transitional Cell; Female; Gene Amplification; Humans; Indazoles; Lung Neoplasms; Mutation; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides; Urinary Bladder Neoplasms | 2015 |
[Spontaneous enterocutaneous and rectovaginal fistula: potential complications during therapy with anti-angiogenic drugs in renal cancer].
Topics: Angiogenesis Inhibitors; Female; Humans; Indazoles; Intestinal Fistula; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Rectovaginal Fistula; Sulfonamides | 2015 |
Imatinib inhibits inactivation of the ATM/ATR signaling pathway and recovery from adriamycin/doxorubicin-induced DNA damage checkpoint arrest.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Checkpoint Kinase 1; DNA Damage; DNA Repair; Doxorubicin; Enzyme Activation; HeLa Cells; Humans; Imatinib Mesylate; Indazoles; Protein Kinases; Pyrimidines; Repressor Proteins; Signal Transduction; Sulfonamides; Tripartite Motif-Containing Protein 28 | 2015 |
Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Scalp; Skin Neoplasms; Sulfonamides | 2015 |
Pyoderma gangrenosum of the penis possibly associated with pazopanib treatment.
Topics: Aged; Humans; Indazoles; Male; Penile Diseases; Pyoderma Gangrenosum; Pyrimidines; Sulfonamides | 2016 |
Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
Topics: Administration, Metronomic; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Synergism; Humans; Indazoles; Kidney Neoplasms; Maximum Tolerated Dose; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Survival Analysis; Topotecan; Xenograft Model Antitumor Assays | 2015 |
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.
Topics: Animals; Bacterial Infections; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Escherichia coli; Heat-Shock Proteins; Humans; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Polynucleotide 5'-Hydroxyl-Kinase; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Virus Diseases | 2015 |
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides | 2015 |
Nasal tumoral lesion: challenge. Cutaneous metastasis of renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Biopsy; Carcinoma, Renal Cell; Fatal Outcome; Humans; Immunohistochemistry; Indazoles; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Nose Neoplasms; Pyrimidines; Skin Neoplasms; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib | 2015 |
Pazopanib: pericardial effusion.
Topics: Angiogenesis Inhibitors; Humans; Indazoles; Pericardial Effusion; Pyrimidines; Sulfonamides | 2014 |
Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Heart Failure; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides | 2016 |
Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Proliferation; Disease Models, Animal; Endometriosis; Endometrium; Female; Indazoles; Indoles; Niacinamide; Ovarian Reserve; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Pazopanib and pancreatic toxicity: a case report.
Topics: Aged; Amylases; Female; Humans; Indazoles; Lipase; Pancreas; Pyrimidines; Sulfonamides | 2015 |
A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.
Topics: 3T3 Cells; Animals; Apoptosis; Cell Line, Tumor; Fas-Associated Death Domain Protein; HEK293 Cells; HT29 Cells; Humans; Imidazoles; Indazoles; Jurkat Cells; L Cells; MAP Kinase Kinase Kinases; Mice; Necrosis; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Pyridazines; Pyrimidines; Receptor-Interacting Protein Serine-Threonine Kinases; Sulfonamides; Tumor Necrosis Factor-alpha | 2015 |
Nursing considerations for patients with sarcoma on pazopanib therapy.
Topics: Angiogenesis Inhibitors; Clinical Competence; Humans; Indazoles; New York; Patient Education as Topic; Practice Patterns, Nurses'; Pyrimidines; Sarcoma; Sulfonamides; Surveys and Questionnaires | 2015 |
Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Medication Adherence; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; United States | 2015 |
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.
Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pulse Wave Analysis; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; Vascular Stiffness | 2016 |
Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome | 2016 |
[Pazopanib for three patients with recurrence of retroperitoneal liposarcoma : initial clinical experience].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Humans; Indazoles; Liposarcoma; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Recurrence; Retroperitoneal Neoplasms; Sulfonamides; Tomography, X-Ray Computed | 2015 |
Symptomatic cardiac metastasis responding to pazopanib in a patient with renal cell carcinoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Heart Neoplasms; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Pyrimidines; Sulfonamides; Watchful Waiting | 2015 |
[Systemic therapy of soft tissue sarcomas].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2015 |
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Everolimus; Female; Humans; Immunotherapy; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Cells; Neoplasm Metastasis; Programmed Cell Death 1 Receptor; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; T-Lymphocytes; Treatment Outcome | 2015 |
Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Endothelial Cells; Gene Expression Regulation, Leukemic; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sulfonamides; Tumor Burden; Vascular Endothelial Growth Factor A | 2015 |
Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein; Young Adult | 2015 |
Tumor-Targeting Salmonella typhimurium A1-R Arrests a Chemo-Resistant Patient Soft-Tissue Sarcoma in Nude Mice.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Disease Models, Animal; Gemcitabine; Indazoles; Mice; Mice, Nude; Pyrimidines; Salmonella Infections; Salmonella typhimurium; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis.
Topics: Animals; Apoptosis; Disease Progression; Dose-Response Relationship, Drug; Drug Delivery Systems; Hepatic Stellate Cells; Indazoles; Liver Cirrhosis; Male; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Sulfonamides | 2015 |
Primary Pleural Synovial Sarcoma Treated with Pazopanib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Doxorubicin; Dyspnea; Fatal Outcome; Female; Humans; Ifosfamide; Indazoles; Neoplasm Recurrence, Local; Pleural Effusion, Malignant; Pleural Neoplasms; Pyrimidines; Sarcoma, Synovial; Sulfonamides | 2015 |
Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Comparative Effectiveness Research; Cooperative Behavior; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Europe; Humans; Indazoles; Insurance, Health, Reimbursement; International Cooperation; Kidney Neoplasms; Models, Economic; Prohibitins; Pyrimidines; Sulfonamides; Treatment Outcome | 2015 |
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HeLa Cells; Hep G2 Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Jurkat Cells; MCF-7 Cells; Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcriptome | 2015 |
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trial
Topics: Adult; Aged; Blood Pressure; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Hypertension; Indazoles; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Sarcoma; Sulfonamides | 2015 |
Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indazoles; MAP Kinase Signaling System; Mice, Nude; Pyridones; Pyrimidines; Pyrimidinones; Sulfonamides; Thyroid Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Patients; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Rapid and fatal acute heart failure induced by pazopanib.
Topics: Antineoplastic Agents; Dyspnea; Fatal Outcome; Fatigue; Female; Heart Failure; Humans; Indazoles; Middle Aged; Pyrimidines; Sarcoma, Synovial; Sulfonamides; Thoracic Neoplasms | 2015 |
Characterization of forced degradation products of pazopanib hydrochloride by UHPLC-Q-TOF/MS and in silico toxicity prediction.
Topics: Animals; Chromatography, High Pressure Liquid; Computer Simulation; Drug Stability; Female; Indazoles; Limit of Detection; Male; Mice; Mutagens; Pyrimidines; Rats; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Sulfonamides | 2015 |
Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cohort Studies; Drug Costs; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Medicare; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United States; Young Adult | 2015 |
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Transitional Cell; DNA Copy Number Variations; DNA Mutational Analysis; Drug Resistance, Neoplasm; Humans; Indazoles; Mutation, Missense; Pyrimidines; Salvage Therapy; Sulfonamides; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Extracellular Fluid; HT29 Cells; Humans; Imatinib Mesylate; Indazoles; Infusions, Parenteral; Mice; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Peritoneal Absorption; Peritoneum; Pressure; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tumor Burden; Weight Loss; Xenograft Model Antitumor Assays | 2015 |
Preoperative Treatment With Pazopanib in a Case of Chemotherapy-Resistant Infantile Fibrosarcoma.
Topics: Angiogenesis Inhibitors; Axilla; Drug Resistance, Neoplasm; Fibrosarcoma; Humans; Indazoles; Infant; Male; Neoadjuvant Therapy; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2016 |
Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases.
Topics: Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Molecular Docking Simulation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Structure-Activity Relationship; Sulfonamides; Vascular Endothelial Growth Factor A | 2015 |
The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes.
Topics: Humans; Indazoles; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2015 |
Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis.
Topics: Carcinoma, Transitional Cell; Computer Simulation; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Kidney Pelvis; Middle Aged; Models, Molecular; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, ErbB-2; Receptor, Platelet-Derived Growth Factor beta; Sulfonamides; Urothelium | 2015 |
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom | 2016 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Female; Genetic Predisposition to Disease; Heterozygote; HLA-B Antigens; Humans; Indazoles; Liver Function Tests; Male; Middle Aged; Models, Molecular; Molecular Conformation; Neoplasms; Pyrimidines; Structure-Activity Relationship; Sulfonamides; Young Adult | 2016 |
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a sin
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome | 2016 |
Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Hyaluronan Receptors; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mice, Nude; Mice, Transgenic; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Peptides; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Rats; RNA, Messenger; Signal Transduction; Sulfonamides; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2016 |
Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Brain Edema; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Middle Aged; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Radiation Injuries; Sulfonamides | 2016 |
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Female; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indazoles; Kaplan-Meier Estimate; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Pyrimidines; Real-Time Polymerase Chain Reaction; Sulfonamides; Topotecan; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
Topics: Angiogenesis Inhibitors; Base Sequence; Disease-Free Survival; Female; Genetic Markers; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retinoblastoma Protein; Retrospective Studies; Sarcoma; Sequence Analysis, DNA; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.
Topics: Chromatography, Liquid; Dried Blood Spot Testing; Drug Stability; Humans; Indazoles; Pyrimidines; Sulfonamides; Tandem Mass Spectrometry | 2016 |
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comorbidity; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Fees, Pharmaceutical; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Topics: Adult; Aged; Biomarkers, Tumor; Cohort Studies; Exome; Female; Genome, Human; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Intestinal Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins B-raf; Pyrimidines; Stomach Neoplasms; Sulfonamides | 2016 |
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment | 2016 |
Effective Treatment of Pleural Epitheloid Hemangio-endothelioma with Pazopanib: A Case Report.
Topics: Adult; Disease-Free Survival; Hemangioendothelioma; Humans; Indazoles; Male; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome | 2016 |
Design, Synthesis, Spectral Analysis, In Vitro Anticancer Evaluation and Molecular Docking Studies of Some Fluorescent 4-Amino-2, 3-Dimethyl-1-Phenyl-3-Pyrazolin-5-One, Ampyrone Derivatives.
Topics: Ampyrone; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Humans; Indazoles; Magnetic Resonance Spectroscopy; Molecular Docking Simulation; Pyrazolones; Pyrimidines; Spectrometry, Fluorescence; Sulfonamides | 2017 |
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; United States | 2016 |
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC).
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Singapore; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Brain Metastasis Responsive to Pazopanib in Renal Cell Carcinoma: A Case Report and Review of the Literature.
Topics: Aged; Brain; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides | 2016 |
Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function.
Topics: Antineoplastic Agents; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Indazoles; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Sorafenib; Sulfonamides | 2016 |
Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Cross-Over Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Analysis | 2016 |
Bullous fixed drug eruption in a patient with metastatic renal cell carcinoma induced by iodinated contrast during pazopanib treatment.
Topics: Aged; Antineoplastic Agents; Blister; Carcinoma, Renal Cell; Contrast Media; Drug Eruptions; Hand Dermatoses; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Triiodobenzoic Acids | 2016 |
Triggering of Suicidal Erythrocyte Death by Pazopanib.
Topics: Calcium; Cell Size; Ceramides; Eryptosis; Erythrocytes; Humans; Indazoles; Oxidative Stress; Pyrimidines; Reactive Oxygen Species; Sulfonamides | 2016 |
The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Female; Fibrosarcoma; Humans; Hypertension; Indazoles; Japan; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Neurilemmoma; Pneumothorax; Product Surveillance, Postmarketing; Pyrimidines; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Sulfonamides; Survival Analysis; Thrombocytopenia | 2016 |
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.
Topics: A549 Cells; Animals; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Crizotinib; HEK293 Cells; HT29 Cells; Humans; Immunoassay; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Small Molecule Libraries; Stomach Neoplasms; Sulfonamides; Sulfones; Xenograft Model Antitumor Assays | 2016 |
[NEOADJUVANT TARGET THERAPY IN A RENAL-CELL CANCER].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
[Systemic therapy of metastatic renal cell carcinoma].
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2016 |
Patient Education Needs With Pazopanib Therapy for Soft Tissue Sarcoma.
Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Indazoles; Nurse's Role; Patient Education as Topic; Pyrimidines; Sarcoma; Sulfonamides | 2016 |
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
Topics: Adenosine Diphosphate; Animals; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Platelets; Cell Hypoxia; Cell Line, Tumor; Female; Focal Adhesion Kinase 1; Humans; Indazoles; Mice; Mice, Knockout; Neoplasm Proteins; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
[A Case of Chordoma of the Sacrum Treated with Pazopanib].
Topics: Aged; Angiogenesis Inhibitors; Biopsy; Chordoma; Humans; Indazoles; Male; Pyrimidines; Quality of Life; Sacrum; Spinal Neoplasms; Sulfonamides | 2016 |
Pazopanib for both GIST and soft-tissue sarcoma.
Topics: Humans; Indazoles; Pyrimidines; Sarcoma; Sulfonamides | 2016 |
Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib.
Topics: Breast Neoplasms; Female; Humans; Hyperthermia, Induced; Indazoles; Leiomyosarcoma; Middle Aged; Pyrimidines; Sulfonamides | 2018 |
Pharmacokinetic Analysis of a Hemodialyzed Patient Treated With Pazopanib.
Topics: Aged; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Renal Dialysis; Sulfonamides | 2016 |
Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Hemangiosarcoma; Humans; Indazoles; Male; Pyrimidines; Signal Transduction; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Genotype; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.
Topics: Angiogenesis Inhibitors; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; HEK293 Cells; Humans; Indazoles; Kinetics; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pyridinium Compounds; Pyrimidines; Renal Elimination; Sulfonamides; Transfection | 2016 |
Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
Topics: Aged; Carcinoma, Renal Cell; Drug Prescriptions; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; United States | 2016 |
Case of severe ulceration induced by pazopanib.
Topics: Adolescent; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Eruptions; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2017 |
Autopsy case of pulmonary artery sarcoma forming aneurysm without FDG uptake.
Topics: Adult; Aneurysm; Aneurysm, Ruptured; Fatal Outcome; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Indazoles; Leiomyosarcoma; Lung; Male; Neoplasm Invasiveness; Positron-Emission Tomography; Pulmonary Artery; Pyrimidines; Radiopharmaceuticals; Rupture, Spontaneous; Shock, Hemorrhagic; Sulfonamides; Vascular Neoplasms | 2016 |
Heterogeneous and Rare: Toward Histology-Specific Treatment of Soft-Tissue Sarcoma.
Topics: Antineoplastic Agents; Chromosomal Proteins, Non-Histone; Dioxoles; Disease-Free Survival; DNA-Binding Proteins; Furans; Humans; Indazoles; Ketones; Molecular Targeted Therapy; Mutation; Pyrimidines; Sarcoma; SMARCB1 Protein; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Transcription Factors | 2016 |
Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Autophagy; Binding Sites; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Female; Humans; Indazoles; Inhibitory Concentration 50; Mice; Mice, Nude; Microscopy, Fluorescence; Molecular Chaperones; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyrimidines; Receptor, ErbB-2; Receptor, ErbB-4; RNA, Small Interfering; Sildenafil Citrate; Sulfonamides; Xenograft Model Antitumor Assays | 2016 |
Balancing Prolonged Survival with QoL Using Low-dose Pazopanib Maintenance: A Comparison with the PALETTE Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Histiocytoma, Malignant Fibrous; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Quality of Life; Retrospective Studies; Sarcoma; Sulfonamides | 2016 |
Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Prescriptions; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Molecular Targeted Therapy; Netherlands; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
[A Case of Severe Hematological Toxicity in Response to Pazopanib].
Topics: Angiogenesis Inducing Agents; Female; Humans; Indazoles; Leiomyosarcoma; Middle Aged; Neutropenia; Pyrimidines; Recurrence; Retroperitoneal Neoplasms; Sulfonamides; Thrombocytopenia | 2016 |
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Exome Sequencing; Female; Fumarate Hydratase; GRB2 Adaptor Protein; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Cohort Studies; Computer Communication Networks; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Female; Health Care Costs; Humans; Indazoles; Indoles; Male; Middle Aged; Prescription Fees; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2016 |
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Republic of Korea; Retrospective Studies; Sulfonamides; Young Adult | 2016 |
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib | 2016 |
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chondrosarcoma; Disease Progression; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sarcoma; Sirolimus; Sulfonamides; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker?
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cholesterol; Ferritins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Indazoles; Indoles; Iron; Kidney Neoplasms; Lipids; Metabolome; Models, Theoretical; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Triglycerides | 2016 |
Intimal Sarcoma of the Pulmonary Artery Treated with Pazopanib.
Topics: Aged; Angiogenesis Inhibitors; Hand-Foot Syndrome; Humans; Indazoles; Male; Pulmonary Artery; Pyrimidines; Sulfonamides; Tunica Intima; Vascular Neoplasms | 2016 |
An unexpected skin ulcer and soft tissue necrosis after the nonconcurrent combination of proton beam therapy and pazopanib: A case of myxofibrosarcoma.
Topics: Angiogenesis Inhibitors; Debridement; Fatal Outcome; Fibrosarcoma; Head and Neck Neoplasms; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Myxoma; Necrosis; Proton Therapy; Pyrimidines; Skin Ulcer; Soft Tissue Infections; Sulfonamides; Tomography, X-Ray Computed | 2017 |
Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Indazoles; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2017 |
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Time Factors | 2017 |
[Treatment of bilateral spontaneous pneumothorax during pazopanib therapy for pulmonary soft tissue sarcoma metastases. What to do when there is so few evidence?]
Topics: Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Muscle Neoplasms; Pneumonectomy; Pneumothorax; Pyrimidines; Sarcoma; Sulfonamides | 2016 |
Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Fatigue; Female; Hemangiosarcoma; Humans; Indazoles; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2017 |
A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
Topics: Antineoplastic Agents; Female; Humans; Indazoles; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Sulfonamides; Tomography, X-Ray Computed; Uterine Neoplasms | 2016 |
Desmoplastic Small Round Cell Tumor of the Pleura Successfully Treated with a Lower Dose of Pazopanib.
Topics: Adult; Angiogenesis Inhibitors; Combined Modality Therapy; Desmoplastic Small Round Cell Tumor; Humans; Indazoles; Male; Pleural Neoplasms; Pyrimidines; Quality of Life; Sulfonamides | 2016 |
Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bridged-Ring Compounds; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hemangiosarcoma; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Skin Neoplasms; Sulfonamides; Taxoids | 2016 |
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Tumor Burden | 2017 |
Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma.
Topics: Adolescent; Angiogenesis Inhibitors; Female; Humans; Indazoles; Male; Pyrimidines; Recurrence; Sarcoma, Synovial; Sulfonamides | 2017 |
[Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma].
Topics: Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Paradoxical antitumor effects of pazopanib in a cutaneous angiosarcoma patient.
Topics: Aged; Angiogenesis Inhibitors; Disease Progression; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Indazoles; Male; Pyrimidines; Skin Neoplasms; Sulfonamides | 2017 |
Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Rate | 2017 |
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.
Topics: Adolescent; Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Crizotinib; Female; Humans; Indazoles; Intestinal Neoplasms; Liver Neoplasms; Male; Middle Aged; Neuroectodermal Tumors; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Vascular Endothelial Growth Factor A; Young Adult | 2016 |
Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors.
Topics: Apoptosis; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Indazoles; Indoles; Oncogenes; Pyrimidines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Rhabdoid Tumor; Sulfonamides; Sunitinib | 2016 |
An impressive response to pazopanib in a patient with metastatic endometrial carcinoma.
Topics: Abdominal Wall; Angiogenesis Inhibitors; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Hysterectomy; Indazoles; Intestinal Fistula; Middle Aged; Neoplasm Metastasis; Ovariectomy; Pyrimidines; Remission Induction; Salpingectomy; Soft Tissue Neoplasms; Sulfonamides | 2016 |
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Genetic Heterogeneity; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pharmacogenomic Testing; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Sunitinib | 2016 |
Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Sulfonamides; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
[Molecular mechanism of gastrointestinal stromal tumors and progress in drug research].
Topics: Benzimidazoles; Exons; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Indazoles; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinolones; Succinate Dehydrogenase; Sulfonamides | 2016 |
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study.
Topics: Aged; Antineoplastic Agents; Carcinosarcoma; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Uterine Neoplasms | 2017 |
Individualized Pazopanib Dosing-Letter.
Topics: Humans; Indazoles; Pyrimidines; Sulfonamides | 2016 |
Individualized Pazopanib Dosing-Response.
Topics: Humans; Indazoles; Pyrimidines; Sulfonamides | 2016 |
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Consciousness; Hemodynamics; Indazoles; Losartan; Male; Niacinamide; Phenylurea Compounds; Piperidines; Propranolol; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Regional Blood Flow; Sorafenib; Sulfonamides | 2017 |
Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemothera
Topics: Abdomen; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Dermatofibrosarcoma; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Humans; Ifosfamide; Indazoles; Male; Mesna; Middle Aged; Pyrimidines; Skin Neoplasms; Sulfonamides | 2017 |
Role of Molecular Profiling in Diagnosis of Papillary Renal-cell Cancer Presenting as Cancer of Unknown Primary Site.
Topics: Adult; Aged; Carcinoma, Renal Cell; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Pyrimidines; Sensitivity and Specificity; Sulfonamides; Treatment Outcome | 2017 |
The Significant Effects of Pazopanib on Multiple Pulmonary Metastatic Lesions of Alveolar Soft Part Sarcoma: A Case Report.
Topics: Child; Female; Humans; Indazoles; Lung Neoplasms; Pyrimidines; Sarcoma, Alveolar Soft Part; Sulfonamides; Treatment Outcome | 2017 |
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Indazoles; Infant; Male; Pyrimidines; Remission Induction; Sarcoma; Sulfonamides | 2017 |
Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Pazopanib, a promising option for the treatment of aggressive fibromatosis.
Topics: Adult; Female; Fibromatosis, Aggressive; Humans; Indazoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides | 2017 |
First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Indazoles; Italy; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome | 2017 |
Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity.
Topics: Acetaminophen; Cell Differentiation; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP1A2; Gene Expression Regulation; Glutathione; Hepatocytes; Humans; Indazoles; Induced Pluripotent Stem Cells; Iron; Organ Specificity; Oxidative Stress; Principal Component Analysis; Pyrimidines; Reactive Oxygen Species; RNA, Messenger; Sulfonamides; Transcription, Genetic | 2017 |
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; SEER Program; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagosomes; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Male; Melanoma; Mice, Nude; Microscopy, Fluorescence; Oximes; Phenylbutyrates; Pyridones; Pyrimidines; Pyrimidinones; RNA Interference; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2017 |
Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS).
Topics: Aged; Antineoplastic Agents; Female; France; Humans; Indazoles; Male; Middle Aged; Prospective Studies; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome | 2017 |
Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease-Free Survival; Humans; Indazoles; Indoles; Italy; Kidney Neoplasms; National Health Programs; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Analysis | 2017 |
Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Sunitinib | 2017 |
Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2017 |
Kidney cancer: Reversal of fortunes for TKI resistance.
Topics: Angiogenesis Inhibitors; Benzofurans; Histone Deacetylases; Humans; Hydroxamic Acids; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2017 |
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing | 2017 |
Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
Topics: Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 6; Female; Humans; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridones; Pyrimidines; Pyrimidinones; ras Proteins; Sarcoma, Synovial; Sulfonamides | 2017 |
Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.
Topics: Carcinoma, Basal Cell; DNA Mutational Analysis; DNA, Neoplasm; Humans; Indazoles; Male; Middle Aged; Mutation; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Young Adult | 2017 |
Heart Failure: A Paraneoplastic Manifestation of Renal Cell Carcinoma - Reversed With Pazopanib.
Topics: Carcinoma, Renal Cell; Drug Administration Schedule; Heart Failure; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Pyrimidines; Stroke Volume; Sulfonamides; Treatment Outcome | 2017 |
Pazopanib-associated posterior reversible encephalopathy syndrome with intracerebral haemorrhage.
Topics: Aged; Carcinoma, Renal Cell; Cerebral Hemorrhage; Decompressive Craniectomy; Female; Humans; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sulfonamides; Treatment Outcome | 2017 |
Prescriber Compliance With Liver Monitoring Guidelines for Pazopanib in the Postapproval Setting: Results From a Distributed Research Network.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indazoles; Liver; Male; Middle Aged; Practice Patterns, Physicians'; Pyrimidines; Retrospective Studies; Sulfonamides | 2019 |
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Disease Progression; Disease-Free Survival; Drug Eruptions; Exanthema; Female; Humans; Hypertension; Indazoles; Male; MAP Kinase Kinase Kinases; Middle Aged; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrimidinones; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Survival Rate; Thrombocytopenia | 2017 |
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Feasibility Studies; Female; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Tandem Mass Spectrometry; Treatment Outcome; Young Adult | 2017 |
Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Electromyography; Guillain-Barre Syndrome; Humans; Immunoglobulins, Intravenous; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Pyrimidines; Serologic Tests; Sulfonamides | 2017 |
Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Humans; Indazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Pyrimidines; Quinolines; Receptor, Platelet-Derived Growth Factor alpha; Sarcoma, Synovial; Signal Transduction; Sulfonamides; Thiourea; Xenograft Model Antitumor Assays | 2017 |
The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Indazoles; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nivolumab; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Sulfonamides; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Fatal heart failure in a young adult female sarcoma patient treated with pazopanib.
Topics: Adult; Chemical and Drug Induced Liver Injury; Fatal Outcome; Female; Heart Failure; Humans; Indazoles; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2017 |
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
Topics: Aged; Antineoplastic Agents; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2017 |
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Markov Chains; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Rate; United Kingdom | 2017 |
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cytokines; E-Selectin; Female; Hemoglobins; Hepatocyte Growth Factor; Humans; Indazoles; Interleukin-6; Interleukin-8; Kidney Neoplasms; L-Lactate Dehydrogenase; Leukocyte Count; Male; Middle Aged; Neutrophils; Osteopontin; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Time-to-Treatment; Tissue Inhibitor of Metalloproteinase-1; Tumor Burden; Vascular Endothelial Growth Factor A | 2017 |
Pazopanib for second recurrence of osteosarcoma in pediatric patients.
Topics: Adolescent; Angiogenesis Inhibitors; Bone Neoplasms; Child; Female; Humans; Indazoles; Liver Neoplasms; Lung Neoplasms; Male; Osteosarcoma; Pyrimidines; Sulfonamides | 2017 |
Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro.
Topics: Benzimidazoles; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Indazoles; Indoles; Male; Protein Kinase Inhibitors; Pyrimidines; Quinolones; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Sulfonamides | 2017 |
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
Topics: Angiogenesis Inhibitors; Compassionate Use Trials; Disease-Free Survival; Female; Hemangiosarcoma; Humans; Indazoles; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Solitary Fibrous Tumors; Sulfonamides; Survival Rate; Time Factors; Uterine Neoplasms | 2017 |
A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Choroidal Neovascularization; Disease Models, Animal; Fluorescein Angiography; Immunoconjugates; Indazoles; Intravitreal Injections; Pyrimidines; Sulfonamides; Swine; T-Lymphocytes, Cytotoxic; Vascular Endothelial Growth Factor A | 2017 |
Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region.
Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Rural Population; Sulfonamides; Sunitinib | 2017 |
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Disease-Free Survival; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Indoles; Insurance, Health; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Indazoles; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma, Alveolar Soft Part; Sulfonamides; Survival Rate; Trabectedin | 2018 |
[Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3].
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides | 2017 |
Treatment of succinate dehydrogenase B-associated renal cancer.
Topics: Adult; Antineoplastic Agents; Female; Germ-Line Mutation; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Succinate Dehydrogenase; Sulfonamides | 2017 |
Reply to M. Horiguchi et al.
Topics: Humans; Indazoles; Paclitaxel; Pyrimidines; Sulfonamides; Urologic Neoplasms | 2017 |
Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.
Topics: Humans; Indazoles; Paclitaxel; Pyrimidines; Sulfonamides; Urologic Neoplasms | 2017 |
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome | 2017 |
Renal cell carcinoma presenting as a cutaneous horn and nodules on the gingiva and scalp.
Topics: Acute Kidney Injury; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diagnosis, Differential; Fatal Outcome; Gingiva; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Scalp; Skin Neoplasms; Sulfonamides | 2017 |
Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.
Topics: Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Humans; Indazoles; Neoplasm Proteins; Neoplasms; Phosphoproteins; Pyrimidines; Signal Transduction; Sulfonamides | 2018 |
Pazopanib for advanced liposarcoma.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Humans; Indazoles; Liposarcoma; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Treatment Outcome | 2017 |
Favorable and Durable Response to Pazopanib in Metastatic Refractory Paraganglioma.
Topics: Angiogenesis Inhibitors; Biopsy; Humans; Indazoles; Male; Middle Aged; Paraganglioma; Pyrimidines; Retroperitoneal Neoplasms; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chondrosarcoma; Disease-Free Survival; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms, Connective and Soft Tissue; Pyrimidines; Ramucirumab; Retrospective Studies; Sulfonamides; Treatment Outcome | 2017 |
Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.
Topics: Animals; Astrocytes; Calcium-Binding Proteins; Cell Line, Tumor; Cognition; Collagen Type IV; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glial Fibrillary Acidic Protein; Indazoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; Motor Activity; Mutation; Neuroblastoma; Phosphorylation; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; RNA, Small Interfering; Silver Staining; Sulfonamides; tau Proteins; Tauopathies; Transfection; Treatment Outcome | 2017 |
Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Topics: Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dasatinib; Female; Humans; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyridines; Pyrimidines; Sarcoma, Alveolar Soft Part; src-Family Kinases; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases.
Topics: Angiogenesis Inhibitors; Animals; Apolipoprotein A-I; Cell-Penetrating Peptides; Choroidal Neovascularization; Coumarins; Drug Carriers; Indazoles; Lipoproteins, HDL; Liposomes; Male; Mice, Inbred C57BL; Mutation; Nanoparticles; Ophthalmic Solutions; Pyrimidines; Sulfonamides; Thiazoles | 2017 |
Individualized Pazopanib Dosing-Letter.
Topics: Angiogenesis Inhibitors; Humans; Indazoles; Pyrimidines; Sulfonamides | 2017 |
[Abnormal hair].
Topics: Carcinoma, Renal Cell; Female; Hair; Hair Color; Hair Diseases; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Pigmentation Disorders; Pyrimidines; Sulfonamides | 2019 |
Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Factors; Salvage Therapy; Sulfonamides; Tomography, X-Ray Computed | 2017 |
Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Cell-Free Nucleic Acids; Combined Modality Therapy; Disease-Free Survival; Everolimus; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Predictive Value of Tests; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2017 |
Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Neoplasm Recurrence, Local; Nephrectomy; Pyrimidines; Sulfonamides | 2017 |
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Female; Health Expenditures; Humans; Indazoles; Indoles; Insurance Claim Review; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medicare; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; United States | 2017 |
Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Leg Ulcer; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides | 2017 |
Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Blood Platelets; Cell Count; Disease-Free Survival; Female; Humans; Indazoles; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Proportional Hazards Models; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2018 |
Organic Cation Transporter 1 Is Responsible for Hepatocellular Uptake of the Tyrosine Kinase Inhibitor Pazopanib.
Topics: Administration, Intravenous; Animals; Cyclosporine; HEK293 Cells; Hepatocytes; Humans; Indazoles; Inhibitory Concentration 50; Liver; Male; Metformin; Mice; Mice, Inbred ICR; Octamer Transcription Factor-1; Protein Kinase Inhibitors; Pyrimidines; Quaternary Ammonium Compounds; Sulfonamides; Tissue Distribution; Transfection | 2018 |
Lingual alveolar soft part sarcoma responsive to pazopanib: A case report.
Topics: Antineoplastic Agents; Humans; Indazoles; Male; Pyrimidines; Sarcoma, Alveolar Soft Part; Sulfonamides; Tongue Neoplasms; Treatment Outcome; Young Adult | 2017 |
Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Disease Progression; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Temozolomide; Treatment Failure; Vascular Endothelial Growth Factor A; Young Adult | 2017 |
High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Discovery; Endoplasmic Reticulum Stress; High-Throughput Screening Assays; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Quaternary Ammonium Compounds; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Rhabdoid Tumor; SMARCB1 Protein; Sulfonamides | 2017 |
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Histone Deacetylase Inhibitors; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptor, ErbB-2; Sarcoma; Signal Transduction; Sulfonamides; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2017 |
Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model.
Topics: Angiogenesis Inhibitors; Animals; Arterial Pressure; Body Weight; Carcinoma, Renal Cell; Cardiac Output; Disease Models, Animal; Echocardiography; Electrocardiography; Heart; Hypertension; Indazoles; Kidney; Kidney Neoplasms; Mice; Myocardium; Pyrimidines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sulfonamides; Vascular Endothelial Growth Factor A | 2018 |
Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Salvage Therapy; Sarcoma; Sulfonamides; Survival Analysis; Uterine Neoplasms | 2018 |
Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Vesicles; Humans; Indazoles; Lamin Type A; LIM Domain Proteins; MicroRNAs; Pyrimidines; Sarcoma, Synovial; Sirtuin 3; Sulfonamides; Transcription Factors | 2018 |
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.
Topics: Drug Monitoring; Enzyme Inhibitors; Food-Drug Interactions; Humans; Indazoles; Indoles; Metabolic Clearance Rate; Phosphotransferases; Pyrimidines; Sorafenib; Sulfonamides; Vemurafenib | 2018 |
Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Decision-Making; Cost Sharing; Female; Health Expenditures; Health Services Accessibility; Humans; Indazoles; Kidney Neoplasms; Medicare Part D; Molecular Targeted Therapy; Patient Selection; Poverty; Pyrimidines; Retrospective Studies; Sulfonamides; Time Factors; United States | 2018 |
Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Desmoplastic Small Round Cell Tumor; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Salvage Therapy; Sulfonamides; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Pazopanib Sensitivity in a Patient With Breast Cancer and
Topics: Breast Neoplasms; Female; Gene Amplification; Humans; Indazoles; Middle Aged; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Sulfonamides | 2017 |
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Prospective Studies; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome | 2018 |
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Nivolumab; Probability; Prognosis; Proportional Hazards Models; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sex Factors; Sulfonamides; Sunitinib; Survival Rate; Thrombocytosis | 2018 |
Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.
Topics: Ammonium Hydroxide; Angiogenesis Inhibitors; Biological Assay; Chromatography, Liquid; Drug Monitoring; Humans; Indazoles; Pyrimidines; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry | 2018 |
Recurrent renal cell carcinoma presenting as a solitary left ventricular mass.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Heart Neoplasms; Heart Ventricles; Humans; Indazoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2017 |
Pazopanib-induced Endothelial Injury with Podocyte Changes.
Topics: Adult; Humans; Indazoles; Male; Nephrotic Syndrome; Podocytes; Proteinuria; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Rhabdomyosarcoma; Sulfonamides | 2018 |
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Czech Republic; Databases, Factual; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2018 |
Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy.
Topics: Aged, 80 and over; Humans; Indazoles; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Kaposi; Sulfonamides; Treatment Outcome | 2018 |
[Atrial flutter probably related to pazopanib: A case report].
Topics: Angiogenesis Inhibitors; Atrial Flutter; Carcinoma, Renal Cell; Electrocardiography; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Sarcoma; Sulfonamides | 2018 |
Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO Metabolites.
Topics: Administration, Oral; Aged; Carcinoma, Renal Cell; Cohort Studies; Denmark; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glomerular Filtration Rate; Hospitals, University; Humans; Hypertension; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitric Oxide; Prospective Studies; Pyrimidines; Risk Assessment; Sulfonamides; Time Factors | 2018 |
Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Nivolumab; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles.
Topics: Cell Line; Drug Approval; Hep G2 Cells; Hepatocytes; Humans; Indazoles; Molecular Docking Simulation; Pregnane X Receptor; Protein Binding; Pyrimidines; Sulfonamides; Tacrolimus | 2018 |
A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.
Topics: Adult; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indazoles; Liver; Neoplasm Recurrence, Local; Pyrimidines; Sarcoma, Endometrial Stromal; Sulfonamides | 2018 |
Pazopanib-Induced Hepatotoxicity in an Experimental Rat Model.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Bilirubin; Blood Chemical Analysis; Blood Glucose; Chemical and Drug Induced Liver Injury; Fatty Liver; Hemosiderin; Indazoles; Kupffer Cells; Liver; Male; Pyrimidines; Rats; Rats, Wistar; Sulfonamides | 2018 |
Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report.
Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Hemangioblastoma; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; von Hippel-Lindau Disease | 2018 |
Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib.
Topics: Aged; Ammonia; Anti-Bacterial Agents; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Indazoles; Middle Aged; Neurotoxicity Syndromes; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome; Withholding Treatment | 2019 |
A Case Report of Metastatic Primary Thyroid Leiomyosarcoma Treated with Pazopanib.
Topics: Aged; Antineoplastic Agents; Female; Humans; Indazoles; Leiomyosarcoma; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Thyroid Neoplasms | 2018 |
Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
Topics: Anemia, Iron-Deficiency; Angiogenesis Inhibitors; Bevacizumab; Epistaxis; Erythrocyte Transfusion; Hemoglobins; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic | 2018 |
Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report.
Topics: Carcinoma, Renal Cell; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Patient Admission; Pyrimidines; Sulfonamides; Tumor Lysis Syndrome | 2018 |
Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cell Line, Tumor; Combined Modality Therapy; Hemangiosarcoma; Humans; Immunohistochemistry; Immunotherapy, Adoptive; Indazoles; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Neoplasm Staging; Programmed Cell Death 1 Receptor; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
Development and Validation of a Simultaneous Quantification Method of Ruxolitinib, Vismodegib, Olaparib, and Pazopanib in Human Plasma Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Topics: Angiogenesis Inhibitors; Anilides; Chromatography, Liquid; Humans; Indazoles; Nitriles; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry | 2018 |
Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Analysis | 2018 |
Evaluation of Pazopanib Phase Behavior Following pH-Induced Supersaturation.
Topics: Crystallization; Hydrogen-Ion Concentration; Hypromellose Derivatives; Indazoles; Pyrimidines; Solubility; Sulfonamides | 2018 |
Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal Outcomes.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Administration, Oral; Antineoplastic Agents; Azetidines; Child; Chromatography, High Pressure Liquid; Humans; Imidazoles; Indazoles; Indoles; Limit of Detection; Linear Models; Oximes; Phenylurea Compounds; Piperidines; Pyridines; Pyridones; Pyrimidines; Pyrimidinones; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry; Vemurafenib | 2018 |
Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS.
Topics: Aged; Calibration; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Humans; Indazoles; Limit of Detection; Microsomes, Liver; Multicenter Studies as Topic; Pyrimidines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Tandem Mass Spectrometry | 2018 |
Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Solitary Fibrous Tumors; Sulfonamides; Treatment Outcome | 2018 |
Presurgical pazopanib for renal cell carcinoma with inferior vena caval thrombus: a single-institution study.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pyrimidines; Retrospective Studies; Sulfonamides; Vena Cava, Inferior; Venous Thrombosis | 2018 |
Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.
Topics: Adenoma, Oxyphilic; Administration, Oral; Combined Modality Therapy; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indazoles; Lung Neoplasms; Proteomics; Pyrimidines; Sulfonamides | 2018 |
Novel Insights for Inhibiting Mutant Heterodimer IDH1
Topics: Amino Acid Sequence; Antineoplastic Agents; Binding Sites; Dasatinib; Dihydroergotamine; Enzyme Inhibitors; Epirubicin; Gene Expression; High-Throughput Screening Assays; Humans; Indazoles; Indoles; Isocitrate Dehydrogenase; Molecular Docking Simulation; Mutation; Phenylcarbamates; Pivampicillin; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Protein Multimerization; Pyrimidines; Sulfonamides; Thermodynamics; Tosyl Compounds; User-Computer Interface | 2018 |
Pazopanib-induced crystal deposition in intestinal mucosa in a patient with retroperitoneal liposarcoma.
Topics: Adult; Antineoplastic Agents; Edema; Endoscopy, Gastrointestinal; Humans; Indazoles; Intestinal Diseases; Intestinal Mucosa; Kidney Neoplasms; Liposarcoma; Male; Neoplasm Recurrence, Local; Pyrimidines; Retroperitoneal Neoplasms; Sulfonamides; Tomography, X-Ray Computed | 2018 |
Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2018 |
Solubility and bioavailability improvement of pazopanib hydrochloride.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biological Availability; Drug Liberation; Excipients; Female; Humans; Indazoles; Male; Middle Aged; Neoplasms; Polyethylene Glycols; Polyvinyls; Pyrimidines; Solubility; Sulfonamides | 2018 |
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.
Topics: B7-H1 Antigen; beta Catenin; Biomarkers; Carcinoma, Renal Cell; Cell Line, Tumor; Cytokines; Dendritic Cells; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Humans; Immunophenotyping; Indazoles; Kidney Neoplasms; Phagocytosis; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Sulfonamides; T-Lymphocytes | 2018 |
Pazopanib efficacy in recurrent central nervous system hemangiopericytomas.
Topics: Adult; Angiogenesis Inhibitors; Central Nervous System Neoplasms; Female; Hemangiopericytoma; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Solitary Fibrous Tumors; Sulfonamides; Treatment Outcome | 2018 |
Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients.
Topics: Aged; Angiogenesis Inhibitors; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Merkel Cell; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Skin Neoplasms; Sulfonamides | 2018 |
Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Radiosurgery; Sulfonamides | 2018 |
Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Sectional Studies; Humans; Hypogonadism; Indazoles; Kidney Neoplasms; Luteinizing Hormone; Male; Middle Aged; Molecular Targeted Therapy; Prevalence; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib; Testosterone; Vascular Endothelial Growth Factor A | 2019 |
The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Female; Humans; Indazoles; Lung Neoplasms; Pyrimidines; Sarcoma, Ewing; Sulfonamides; Vaginal Neoplasms | 2018 |
Re: Randomized Phase III Trial of Adjuvant Pazopanib versus Placebo after Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Nephrectomy; Pyrimidines; Sulfonamides | 2018 |
Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kidney Neoplasms; Mice; Mice, SCID; Mice, Transgenic; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
Topics: Adenosine Triphosphate; Administration, Intravenous; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta, Thoracic; Cell Proliferation; Drug Evaluation, Preclinical; Epigenesis, Genetic; Histone Deacetylase Inhibitors; HT29 Cells; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Male; Mice, Inbred BALB C; Molecular Docking Simulation; Molecular Targeted Therapy; Pyrimidines; Rats, Sprague-Dawley; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2018 |
Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Health Care Costs; Health Resources; Humans; Indazoles; Indoles; Insurance Claim Review; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medicare; Patient Acceptance of Health Care; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Time Factors; Treatment Outcome; United States | 2018 |
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pyrimidines; Remission Induction; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sarcoma; Sulfonamides; Young Adult | 2018 |
Pazopanib induced unilateral posterior reversible encephalopathy syndrome.
Topics: Adult; Angiogenesis Inhibitors; Humans; Indazoles; Male; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sulfonamides; Testicular Neoplasms | 2017 |
A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Biomarkers; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Indazoles; Liver; Male; Metabolomics; Mice; Mice, Inbred C57BL; Multivariate Analysis; Oxidative Stress; Pyrimidines; Spectrometry, Mass, Electrospray Ionization; Sulfonamides | 2019 |
Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.
Topics: Adult; Aged; Asian People; Disease Progression; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Indazoles; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Taiwan; Treatment Outcome | 2018 |
A pneumoperitoneum due to intestinal cystic pneumatosis associated with a tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Pneumatosis Cystoides Intestinalis; Pneumoperitoneum; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed | 2018 |
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retreatment; Sulfonamides; Sunitinib; Survival Rate | 2019 |
Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged, 80 and over; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagus; Fatal Outcome; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Stomach; Stomach Neoplasms; Sulfonamides; Treatment Outcome | 2019 |
Long-term survival of a patient with neurofibromatosis type 1 diagnosed with multiple malignant peripheral nerve sheath tumors.
Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Humans; Indazoles; Magnetic Resonance Imaging; Middle Aged; Neoplasms, Second Primary; Nerve Sheath Neoplasms; Neurofibromatosis 1; Pyrimidines; Radiotherapy, Adjuvant; Skin; Skin Neoplasms; Sulfonamides; Time Factors; Treatment Outcome | 2019 |
Paclitaxel and Pazopanib in Ovarian Cancer.
Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides | 2018 |
Paclitaxel and Pazopanib in Ovarian Cancer-Reply.
Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides | 2018 |
Targeting VEGF and EGFR: a combination worth re-exploring?
Topics: Cetuximab; ErbB Receptors; Humans; Indazoles; Pyrimidines; Squamous Cell Carcinoma of Head and Neck; Sulfonamides; Vascular Endothelial Growth Factor A | 2018 |
Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Female; Humans; Indazoles; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Pyrimidines; Sulfonamides; Sunitinib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A; Young Adult | 2018 |
Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model.
Topics: Aged; Animals; Doxorubicin; Gene Amplification; Humans; Indazoles; Liposarcoma; Male; Mice; Mice, Nude; Neoplasm Proteins; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Xenograft Model Antitumor Assays | 2018 |
Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Italy; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides | 2018 |
Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic Metabolites.
Topics: Aldehydes; Amines; Catalysis; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Humans; Indazoles; Metalloporphyrins; Microsomes, Liver; Oxidation-Reduction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides; Sunitinib | 2018 |
Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON).
Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; Drug Therapy; Female; Humans; Indazoles; Male; Middle Aged; Middle East; Neoplasm Metastasis; Pyrimidines; Radiotherapy; Retrospective Studies; Sarcoma; Sulfonamides; Surgical Procedures, Operative | 2018 |
Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Indazoles; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Radiotherapy, Intensity-Modulated; Sorafenib; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2018 |
Rapid and life-threatening heart failure induced by pazopanib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Heart Failure; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides | 2018 |
Rapid hair depigmentation in patient treated with pazopanib.
Topics: Hair; Hair Color; Humans; Hypopigmentation; Indazoles; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2018 |
Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brazil; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2018 |
Pazopanib in relapsed osteosarcoma patients: report on 15 cases.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Child; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Progression-Free Survival; Pyrimidines; Salvage Therapy; Sulfonamides; Young Adult | 2019 |
Synthesis and characterization of four process impurities in pazopanib.
Topics: Angiogenesis Inhibitors; Drug Contamination; Indazoles; Magnetic Resonance Spectroscopy; Protein Kinase Inhibitors; Pyrimidines; Quality Control; Sulfonamides | 2018 |
Peritoneal epithelioid angiosarcoma: A case report.
Topics: Ascites; Hemangiosarcoma; Humans; Hypotension; Indazoles; Male; Middle Aged; Peritoneal Neoplasms; Postoperative Complications; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tomography, X-Ray Computed | 2018 |
The first prospective trial for von Hippel-Lindau disease: pazopanib.
Topics: Humans; Indazoles; Prospective Studies; Pyrimidines; Sulfonamides; von Hippel-Lindau Disease | 2018 |
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Autophagy; Autophagy-Related Proteins; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Liquid Biopsy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Polymorphism, Genetic; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate | 2018 |
Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Carcinoma, Renal Cell; Denosumab; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Humans; Hypocalcemia; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib | 2019 |
Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.
Topics: Adult; Aged; Case-Control Studies; Female; Humans; Indazoles; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pneumothorax; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Sarcoma; Sulfonamides | 2018 |
A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fibrosarcoma; Humans; Indazoles; Irinotecan; Male; Mice, Nude; Pyrimidines; Random Allocation; Salmonella Infections; Salmonella typhimurium; Sulfonamides; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Cyclopropane Modification of Trehalose Dimycolate Drives Granuloma Angiogenesis and Mycobacterial Growth through Vegf Signaling.
Topics: Angiogenesis Inhibitors; Animals; Bacterial Proteins; Cord Factors; Disease Models, Animal; Humans; Indazoles; Macrophages; Methyltransferases; Mycobacterium Infections, Nontuberculous; Mycobacterium marinum; Mycolic Acids; Neovascularization, Pathologic; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sulfonamides; Tuberculoma; Zebrafish | 2018 |
Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography: A CARE case report.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Fluorodeoxyglucose F18; Hemangioendothelioma, Epithelioid; Humans; Indazoles; Liver Neoplasms; Male; Positron Emission Tomography Computed Tomography; Pyrimidines; Radiopharmaceuticals; Sulfonamides; Treatment Outcome | 2018 |
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Soft Tissue Neoplasms; Sulfonamides; Young Adult | 2019 |
Total necrosis after sequential treatment with pazopanib followed by nivolumab in a patient with renal cell carcinoma involving the inferior vena cava.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Humans; Indazoles; Kidney; Kidney Neoplasms; Necrosis; Neoadjuvant Therapy; Neoplasm Invasiveness; Nephrectomy; Nivolumab; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior | 2019 |
Pazopanib-induced changes in protein expression signatures of extracellular vesicles in synovial sarcoma.
Topics: Cell Line, Tumor; Culture Media, Conditioned; Extracellular Vesicles; Humans; Indazoles; Neoplasm Proteins; Proteomics; Pyrimidines; Sarcoma, Synovial; Signal Transduction; Sulfonamides | 2018 |
Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels.
Topics: Aged; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Leiomyosarcoma; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Soft Tissue Neoplasms; Sulfonamides | 2018 |
Response to Pazopanib in Patients With Relapsed Osteosarcoma.
Topics: Adult; Bone Neoplasms; Female; Humans; Indazoles; Male; Neoplasm Recurrence, Local; Osteosarcoma; Pyrimidines; Sulfonamides | 2020 |
Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Carcinosarcoma; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Humans; Indazoles; Lung Neoplasms; Male; Meningeal Neoplasms; Neoplasm Staging; Pneumonectomy; Pyrimidines; Radiosurgery; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2018 |
Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib.
Topics: Aged; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2018 |
Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration.
Topics: Humans; Immunotherapy; Indazoles; Pyrimidines; Solitary Fibrous Tumors; Sulfonamides | 2019 |
Metastatic renal cell carcinoma presenting as a cardiac tumour.
Topics: Angiogenesis Inhibitors; Anticoagulants; Arrhythmias, Cardiac; Carcinoma, Renal Cell; Female; Heart Neoplasms; Heparin; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Palliative Care; Pyrimidines; Radiography, Thoracic; Sulfonamides; Tricuspid Valve Insufficiency; Tumor Burden | 2018 |
Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; ROC Curve; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
Topics: Aged; Amlodipine; Angiogenesis Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Diabetic Nephropathies; Dihydropyridines; Drug Substitution; Edema; Everolimus; Humans; Hypertension; Indazoles; Kidney Failure, Chronic; Lung Neoplasms; Male; Nephrotic Syndrome; Nivolumab; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pneumonectomy; Protein Kinase Inhibitors; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib | 2019 |
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Topics: Adult; Aged; Anilides; Antineoplastic Agents, Immunological; Axitinib; Carcinoma, Renal Cell; Female; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib; Treatment Failure | 2019 |
Pazopanib Confers a Progression-free Survival in a Patient with Ewing's Sarcoma/Primitive Neuroectodermal Tumor of the Lung.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fatal Outcome; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Pneumonectomy; Progression-Free Survival; Pyrimidines; Sarcoma, Ewing; Sulfonamides; Treatment Outcome | 2019 |
How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Topics: Deoxycytidine; Gemcitabine; Humans; Indazoles; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2019 |
Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Muscle, Skeletal; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Development of Ultrasound-Triggered and Magnetic-Targeted Nanobubble System for Dual-Drug Delivery.
Topics: A549 Cells; Administration, Inhalation; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Compounding; Drug Delivery Systems; Ferrosoferric Oxide; Humans; Indazoles; Injections, Intralesional; Liposomes; Lung Neoplasms; Magnetic Phenomena; Mice; Nanoparticles; Nebulizers and Vaporizers; Pemetrexed; Pyrimidines; Sulfonamides; Tissue Distribution; Tumor Burden; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2019 |
External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nomograms; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate | 2019 |
Prevention of tumor progression in Stewart-Treves syndrome with a low dose of pazopanib.
Topics: Aged; Amputation Stumps; Amputation, Surgical; Biopsy; Chemoradiotherapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemangiosarcoma; Humans; Indazoles; Leg; Lymphangiosarcoma; Neoplasm Recurrence, Local; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Skin; Skin Neoplasms; Sulfonamides | 2019 |
Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Area Under Curve; Dose-Response Relationship, Drug; Drug Interactions; Female; Glucuronosyltransferase; HEK293 Cells; Humans; Indazoles; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Male; Microsomes, Liver; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Topoisomerase I Inhibitors; Young Adult | 2019 |
Targeting the MAPK pathway in advanced BRAF wild-type melanoma.
Topics: Humans; Indazoles; Melanoma; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Sulfonamides | 2019 |
Pazopanib in the treatment of advanced solitary fibrous tumour.
Topics: Humans; Indazoles; Pyrimidines; Solitary Fibrous Tumors; Sulfonamides | 2019 |
Pazopanib in the treatment of advanced solitary fibrous tumour - Authors' reply.
Topics: Humans; Indazoles; Pyrimidines; Solitary Fibrous Tumors; Sulfonamides | 2019 |
Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome | 2019 |
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Pyrimidines; Quality of Life; Sulfonamides; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Promising effects of pazopanib with radiation on an advanced prostate leiomyosarcoma after failure of systemic chemotherapy.
Topics: Antineoplastic Agents; Combined Modality Therapy; Gamma Rays; Humans; Indazoles; Leiomyosarcoma; Male; Middle Aged; Prostate; Prostatic Neoplasms; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Noninvasive Contrast-Free 3D Evaluation of Tumor Angiogenesis with Ultrasensitive Ultrasound Microvessel Imaging.
Topics: Angiogenesis Inhibitors; Animals; Blood Flow Velocity; Carcinoma, Renal Cell; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Contrast Media; Humans; Image Interpretation, Computer-Assisted; Indazoles; Kidney Neoplasms; Microvessels; Models, Biological; Neovascularization, Pathologic; Phantoms, Imaging; Proof of Concept Study; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib; Ultrasonography | 2019 |
Evaluation of pazopanib cytotoxicity to normal vascular endothelial cells in vitro: A comment on Goto et al.
Topics: Angiogenesis Inhibitors; Apoptosis; Cell Line, Tumor; Cell Survival; Dermis; Endothelium, Vascular; Fibroblasts; Hemangiosarcoma; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Pyrimidines; Skin Neoplasms; Sulfonamides; Toxicity Tests | 2019 |
Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Molecular Targeted Therapy; Neutrophils; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate | 2019 |
Cardiotoxicity Monitoring in Patients Treated with Tyrosine Kinase Inhibitors.
Topics: Aged; Carcinoma, Renal Cell; Female; Heart Failure; Humans; Indazoles; Kidney Neoplasms; Leiomyosarcoma; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib | 2019 |
Case of Trichophyton tonsurans infection which emerged after using corticosteroid to treat herpetic encephalitis.
Topics: Adrenal Cortex Hormones; Encephalitis, Herpes Simplex; Humans; Indazoles; Pyrimidines; Sulfonamides; Tinea; Trichophyton | 2019 |
Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Multivariate Analysis; Neoplasm Metastasis; Outcome Assessment, Health Care; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom | 2019 |
ASO Author Reflections: Preoperative Pazopanib for High-Risk Soft Tissue Sarcoma: Better Patient Selection is Needed.
Topics: Humans; Indazoles; Patient Selection; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2019 |
Rare case of a giant duodenal ulcer penetrating the pancreas during antiangiogenic treatment.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Duodenal Ulcer; Electrocoagulation; Endoscopy; Gastrointestinal Hemorrhage; Gastroplasty; Humans; Indazoles; Melena; Middle Aged; Pancreas; Proton Pump Inhibitors; Pylorus; Pyrimidines; Sulfonamides; Syncope; Treatment Outcome | 2019 |
Pazopanib induced pigmented lesions of the scrotum and the face in a patient with metastatic renal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Face; Humans; Indazoles; Male; Middle Aged; Pigmentation Disorders; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Scrotum; Sulfonamides | 2019 |
Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Folic Acid; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome | 2019 |
Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model.
Topics: Animals; Doxorubicin; Drug Resistance, Neoplasm; Humans; Indazoles; Male; Mice; Mice, Nude; Middle Aged; Pyrimidines; Sarcoma, Synovial; Sulfonamides; Xenograft Model Antitumor Assays | 2019 |
Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.
Topics: Animals; Arterial Pressure; Disease Models, Animal; Drug Administration Schedule; Humans; Hypertension; Indazoles; Male; Piperidines; Pyrimidines; Quinazolines; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfonamides | 2019 |
Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Patient Safety; Prognosis; Prospective Studies; Pyrimidines; Risk Factors; Sulfonamides; Survival Rate; Young Adult | 2019 |
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Heterografts; Humans; Indazoles; Liposarcoma; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pyrimidines; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
FAILED LASER RETINOPEXY IN A PATIENT UNDERGOING PAZOPANIB THERAPY.
Topics: Aged; Humans; Indazoles; Laser Therapy; Male; Pyrimidines; Retinal Detachment; Retinal Perforations; Sulfonamides; Treatment Failure | 2021 |
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Everolimus; Female; Gemcitabine; Humans; Indazoles; International Agencies; Male; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Prognosis; Pyrimidines; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1 | 2019 |
Honing in on Subtypes to Guide More Individualized Treatment of Soft Tissue Sarcoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Gastric Acid; Humans; Indazoles; Molecular Targeted Therapy; Precision Medicine; Pyrimidines; Sarcoma; Sulfonamides | 2019 |
Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Precision Medicine; Pyrimidines; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study.
Topics: Aged; Antineoplastic Agents; Austria; Carcinoma, Renal Cell; Clinical Decision-Making; Electronic Health Records; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sex Characteristics; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2019 |
Effect of Acid-Suppressive Strategies on Pazopanib Efficacy in Patients With Soft-Tissue Sarcoma.
Topics: Aged; Female; Humans; Hypertension; Indazoles; Male; Middle Aged; Progression-Free Survival; Proton Pump Inhibitors; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome | 2019 |
Fusion gene-oriented precision medicine in soft tissue sarcoma.
Topics: Chondrosarcoma; Humans; Indazoles; Precision Medicine; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2019 |
The necessity for rigour in rare disease study design.
Topics: Drug Therapy, Combination; Fibromatosis, Aggressive; Humans; Indazoles; Methotrexate; Pyrimidines; Rare Diseases; Research Design; Sulfonamides; Vinblastine | 2019 |
Improved Prediction of in Vivo Supersaturation and Precipitation of Poorly Soluble Weakly Basic Drugs Using a Biorelevant Bicarbonate Buffer in a Gastrointestinal Transfer Model.
Topics: Administration, Oral; Animals; Bicarbonates; Buffers; Chemical Precipitation; Drug Delivery Systems; Drug Liberation; Female; Gastrointestinal Absorption; Gastrointestinal Tract; Hydrogen-Ion Concentration; Indazoles; Ketoconazole; Lapatinib; Methylcellulose; Models, Biological; Phosphates; Pyrimidines; Rats; Rats, Wistar; Solubility; Sulfonamides | 2019 |
Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Confidence Intervals; Female; Follow-Up Studies; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pyrimidines; Quality of Life; Radiosurgery; Regression Analysis; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate; Tomography, X-Ray Computed | 2019 |
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Sarcoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
[Cost-effectiveness between pazopanib and sunitinib for metastatic renal cancer from the perspective of the Brazilian Unified National Health System].
Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; National Health Programs; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome | 2019 |
Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Furans; Gemcitabine; Humans; Ifosfamide; Indazoles; Ketones; Liposarcoma; Middle Aged; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Trabectedin | 2019 |
CT-morphologic and CT-textural patterns of response in inoperable soft tissue sarcomas treated with pazopanib-a preliminary retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Deoxycytidine; Female; Gemcitabine; Heart Neoplasms; Humans; Indazoles; Male; Middle Aged; Prognosis; Progression-Free Survival; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Tunica Intima | 2020 |
Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; United States; United States Department of Veterans Affairs | 2019 |
Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Giant Cell Tumor of Tendon Sheath; Humans; Imatinib Mesylate; Indazoles; Pyrimidines; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2020 |
Pazopanib for progressive desmoid tumours: children, persistant effects, and cost.
Topics: Adult; Child; Drug Therapy, Combination; Fibromatosis, Aggressive; Humans; Indazoles; Methotrexate; Pyrimidines; Sulfonamides; Vinblastine | 2019 |
Pazopanib for progressive desmoid tumours: children, persistant effects, and cost - Author's reply.
Topics: Adult; Child; Drug Therapy, Combination; Fibromatosis, Aggressive; Humans; Indazoles; Methotrexate; Pyrimidines; Sulfonamides; Vinblastine | 2019 |
Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Dose-Response Relationship, Radiation; Doxorubicin; Female; Follow-Up Studies; Humans; Indazoles; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Pyrimidines; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms; Thyroidectomy; Tumor Burden | 2020 |
Case report of oxalate nephropathy in a patient with pancreatic metastases from renal carcinoma.
Topics: Acetates; Aged, 80 and over; Calcium Compounds; Carcinoma, Renal Cell; Exocrine Pancreatic Insufficiency; Gastrointestinal Agents; Humans; Indazoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Oxalates; Pancreatic Neoplasms; Pancrelipase; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Sulfonamides; Treatment Outcome | 2019 |
Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.
Topics: Aged; Carcinoma, Renal Cell; Disease Progression; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Latin America; Male; Middle Aged; Neoplasm Metastasis; Practice Patterns, Physicians'; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Time-to-Treatment | 2019 |
Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Function Tests; Longitudinal Studies; Male; Middle Aged; Polymorphism, Genetic; Progression-Free Survival; Prospective Studies; Pyrimidines; Retrospective Studies; Sulfonamides | 2020 |
Eyelashes depigmentation following treatment with pazopanib for metastatic renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Eyelashes; Female; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Pigmentation Disorders; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2019 |
Tumour-bowel fistula as a possible complication of pazopanib therapy in retroperitoneal leiomyosarcoma.
Topics: Angiogenesis Inhibitors; Diagnosis, Differential; Humans; Indazoles; Intestinal Fistula; Intestinal Perforation; Leiomyosarcoma; Male; Middle Aged; Pyrimidines; Retroperitoneal Neoplasms; Sulfonamides; Tomography, X-Ray Computed | 2019 |
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Time Factors | 2020 |
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomarkers, Tumor; Biopsy, Large-Core Needle; Cadherins; Carcinoma; Cell Line, Tumor; Cell Plasticity; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Indazoles; Male; Mice; Neoplastic Stem Cells; Paclitaxel; Pyrimidines; Sulfonamides; Vimentin; Xenograft Model Antitumor Assays | 2020 |
Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Renal Cell; Drug Therapy, Combination; Edema; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Sulfonamides; Synovitis | 2020 |
Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.
Topics: Angiogenesis Inhibitors; Animals; Choroidal Neovascularization; Crystallization; Disease Models, Animal; Drug Evaluation, Preclinical; Eye; Female; Humans; Indazoles; Macaca fascicularis; Macular Degeneration; Male; Nanoparticles; Ophthalmic Solutions; Particle Size; Phenylurea Compounds; Pyridines; Pyrimidines; Rabbits; Rats; Receptors, Vascular Endothelial Growth Factor; Species Specificity; Sulfonamides; Vascular Endothelial Growth Factor A | 2019 |
Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib | 2020 |
[Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions].
Topics: Adult; Age Factors; Antineoplastic Agents; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cross-Over Studies; Fibromatosis, Aggressive; Humans; Indazoles; Methotrexate; Proof of Concept Study; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Vinblastine | 2020 |
Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC).
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome | 2020 |
Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report.
Topics: Adolescent; Breast Neoplasms; Combined Modality Therapy; Endosonography; Female; Hemangiosarcoma; Humans; Indazoles; Mastectomy; Primary Ovarian Insufficiency; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Vagina | 2019 |
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report.
Topics: Humans; Indazoles; Kidney Neoplasms; Lung Abscess; Lung Neoplasms; Male; Middle Aged; Pyrimidines; Sulfonamides | 2020 |
Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Indazoles; Male; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib | 2020 |
Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era.
Topics: Adolescent; Adult; Age Factors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indazoles; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Sulfonamides; Sunitinib; Young Adult | 2020 |
Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Celecoxib; Cyclophosphamide; Drug Therapy; Etoposide; Female; Humans; Indazoles; India; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyrimidines; Recurrence; Sulfonamides | 2019 |
Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Renal Cell; Cell Line, Tumor; Chemokine CCL24; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Kidney Neoplasms; Male; Mice, Inbred NOD; Mice, SCID; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Pyrimidines; Receptors, CCR3; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Young Adult | 2020 |
Pazopanib as a choice for advanced solitary fibrous tumour.
Topics: Humans; Indazoles; Pyrimidines; Solitary Fibrous Tumors; Sulfonamides | 2020 |
Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Asian People; Carcinoma, Renal Cell; Drug Monitoring; Female; Humans; Indazoles; Japan; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2020 |
Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report.
Topics: Aged; Anilides; Carcinoma, Renal Cell; Cysts; Humans; Indazoles; Kidney Neoplasms; Liver Diseases; Male; Neoplasm Metastasis; Pyridines; Pyrimidines; Sulfonamides | 2020 |
Clinical response to pazopanib in a patient with endolymphatic sac tumor not associated with von Hippel-Lindau syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Ear Neoplasms; Endolymphatic Sac; Humans; Indazoles; Male; Prognosis; Pyrimidines; Sulfonamides; von Hippel-Lindau Disease | 2020 |
Hidradenitis suppurativa associated with pazopanib.
Topics: Hidradenitis Suppurativa; Humans; Indazoles; Pyrimidines; Sulfonamides | 2020 |
Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Pyrimidines; Retrospective Studies; Sulfonamides | 2020 |
Effectiveness of pazopanib for local and lung metastases in Stewart-Treves syndrome.
Topics: Aged; Angiogenesis Inhibitors; Duodenal Ulcer; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Hemangiosarcoma; Humans; Indazoles; Lung Neoplasms; Lymphangiosarcoma; Pyrimidines; Stomach Ulcer; Sulfonamides | 2020 |
Severe hyperglycaemia following pazopanib treatment: The role of drug-drug-gene interactions in a patient with metastatic renal cell carcinoma-A case report.
Topics: Aged; Carcinoma, Renal Cell; Drug Interactions; Humans; Hyperglycemia; Indazoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2020 |
Pazopanib as a potential chemotherapy for cutaneous angiosarcoma: A case series of 10 patients from a single institution.
Topics: Hemangiosarcoma; Humans; Indazoles; Pyrimidines; Skin Neoplasms; Sulfonamides | 2020 |
Importance of Therapeutic Drug Monitoring to Detect Drug Interaction between Pazopanib and Warfarin: A Case Report.
Topics: Administration, Oral; Aged; Carcinoma, Renal Cell; Drug Interactions; Drug Monitoring; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; Warfarin | 2020 |
Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
Topics: Adult; Female; Humans; Indazoles; Leiomyosarcoma; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Survival Analysis | 2021 |
A case of alveolar rhabdomyosarcoma showing concurrent responsive bone marrow lesions and refractory pancreatic lesions to pazopanib monotherapy.
Topics: Adolescent; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Neoplasms; Fluorodeoxyglucose F18; Forkhead Box Protein O1; Humans; Indazoles; Oncogene Proteins, Fusion; Paired Box Transcription Factors; Pancreatic Neoplasms; PAX3 Transcription Factor; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Rhabdomyosarcoma, Alveolar; Sulfonamides; Tumor Microenvironment; Zoledronic Acid | 2020 |
Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome | 2020 |
Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Histamine H2 Antagonists; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate; Time Factors; Treatment Outcome | 2020 |
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel; Doxorubicin; Female; Humans; Ifosfamide; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Uterine Neoplasms | 2020 |
Vastus lateralis myocutaneous flap for ischial skin wound following the treatment of epithelioid sarcoma using pazopanib.
Topics: Adult; Angiogenesis Inhibitors; Buttocks; Combined Modality Therapy; Female; Humans; Indazoles; Magnetic Resonance Imaging; Myocutaneous Flap; Pyrimidines; Quadriceps Muscle; Sarcoma; Sulfonamides; Treatment Outcome; Wound Healing | 2020 |
Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers; Exome Sequencing; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sarcoma; Sulfonamides | 2020 |
Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome | 2020 |
Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Child; Female; Humans; Indazoles; Inflammation; Kidney Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Platelet Count; Prognosis; Pyrimidines; Sulfonamides; Sunitinib; Young Adult | 2020 |
CORR Insights®: Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Topics: Biomarkers; Humans; Indazoles; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2020 |
Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Topics: Angiogenesis Inhibitors; Cohort Studies; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Republic of Korea; Retrospective Studies; Sarcoma; Sulfonamides; Survival Analysis | 2020 |
Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation.
Topics: Anilides; Antineoplastic Agents; Arylsulfotransferase; Axitinib; Carcinoma, Renal Cell; Carrier Proteins; Cell Line, Tumor; Chromogranins; Computer Simulation; Cyclin E; DNA Copy Number Variations; Drug Resistance, Neoplasm; GTP-Binding Protein alpha Subunits, Gs; Humans; Indazoles; Kidney Neoplasms; Oncogene Proteins; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib | 2020 |
Synergistic effects of pazopanib and hyperthermia against uterine leiomyosarcoma growth mediated by downregulation of histone acetyltransferase 1.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; CLOCK Proteins; Female; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Hyperthermia, Induced; Indazoles; Leiomyosarcoma; Pyrimidines; Sulfonamides; Uterine Neoplasms | 2020 |
Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Lung Diseases, Interstitial; Male; Pyrimidines; Sulfonamides | 2020 |
Successful long-term treatment with pazopanib after prior interleukin-2 therapy in patients with metastatic cutaneous angiosarcoma of the scalp.
Topics: Hemangiosarcoma; Humans; Indazoles; Interleukin-2; Pyrimidines; Scalp; Skin Neoplasms; Sulfonamides | 2020 |
A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Indazoles; Male; Middle Aged; Paclitaxel; Prognosis; Pyrimidines; Research Design; Salvage Therapy; Skin Neoplasms; Sulfonamides; Young Adult | 2020 |
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Molecular Targeted Therapy; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom; Young Adult | 2020 |
Stereotactic radiosurgery as a primary treatment for metastatic skull base alveolar soft part sarcoma: a case report.
Topics: Angiogenesis Inhibitors; Female; Humans; Indazoles; Pyrimidines; Radiosurgery; Sarcoma, Alveolar Soft Part; Skull Base Neoplasms; Sulfonamides; Temporal Bone; Young Adult | 2021 |
Long-term multidisciplinary treatment including proton therapy for a recurrent low-grade endometrial stromal sarcoma and pathologically prominent epithelial differentiation: an autopsy case report.
Topics: Adult; Autopsy; Drainage; Endometrial Neoplasms; Fatal Outcome; Female; Humans; Indazoles; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proton Therapy; Pyrimidines; Sarcoma, Endometrial Stromal; Sepsis; Sulfonamides; Young Adult | 2020 |
Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Nivolumab; Patient Selection; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Sunitinib | 2020 |
HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Child; Disease-Free Survival; Female; Genotype; HLA-A Antigens; Humans; Indazoles; Loss of Heterozygosity; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Sarcoma, Synovial; Sulfonamides; T-Lymphocytes; Treatment Outcome; Young Adult | 2020 |
Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bile Duct Diseases; Bile Ducts, Intrahepatic; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; Syndrome | 2020 |
Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study).
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemokine CXCL12; Disease Progression; Drug Resistance, Neoplasm; E-Selectin; Female; Hepatocyte Growth Factor; Humans; Indazoles; Interleukin-6; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Osteopontin; Progression-Free Survival; Prospective Studies; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Survival Rate; Translational Research, Biomedical; Vascular Endothelial Growth Factor A | 2020 |
MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets.
Topics: Carcinoma, Renal Cell; Female; Gene Expression Profiling; Humans; Indazoles; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Pyrimidines; RNA, Messenger; Sulfonamides; Sunitinib; Survival Analysis | 2020 |
Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients.
Topics: Benzazepines; Humans; Indazoles; Pyrimidines; Sarcoma; Sulfonamides | 2020 |
Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
Topics: Animals; Biomarkers, Tumor; Drug Resistance, Neoplasm; Exome Sequencing; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Indazoles; Mice; Microtubule-Associated Proteins; Middle Aged; Molecular Targeted Therapy; Mutation; Precision Medicine; Prognosis; Protein Interaction Maps; Protein Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Geriatric Assessment; Humans; Indazoles; Kidney Neoplasms; Male; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2021 |
Pazopanib-induced mixed liver injury in a patient with soft-tissue sarcoma, but without the UGT1A1*28 mutation: a case report.
Topics: Aged; Humans; Indazoles; Liver; Male; Mutation; Pyrimidines; Sarcoma; Sulfonamides | 2021 |
Development of a High-Throughput Quantification Method for Pazopanib Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry and Its Clinical Application in Patients With Soft Tissue Tumors.
Topics: Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Indazoles; Pyrimidines; Reproducibility of Results; Soft Tissue Neoplasms; Sulfonamides; Tandem Mass Spectrometry | 2021 |
Pharmacokinetically guided dosing has the potential to improve real-world outcomes of pazopanib.
Topics: Drug Monitoring; Humans; Indazoles; Prospective Studies; Pyrimidines; Sulfonamides | 2021 |
Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
Topics: Angiogenesis Inhibitors; Diagnosis, Differential; Female; Humans; Indazoles; Magnetic Resonance Imaging; Middle Aged; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sarcoma; Sulfonamides; Uterine Neoplasms | 2021 |
Overexpression of NDRG2 promotes the therapeutic effect of pazopanib on ovarian cancer.
Topics: Apoptosis; Biomarkers, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2021 |
An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy.
Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indazoles; Italy; Kidney Neoplasms; Pyrimidines; Quality-Adjusted Life Years; State Medicine; Sulfonamides; Sunitinib | 2020 |
Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Female; Furans; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Ketones; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Survival Analysis; Trabectedin; Treatment Outcome | 2020 |
Scrotal Erythema: First Sign of a Cutaneous Drug Reaction to Pazopanib.
Topics: Erythema; Humans; Indazoles; Male; Pharmaceutical Preparations; Pyrimidines; Sulfonamides | 2021 |
An autopsy case of severe acute pancreatitis induced by administration of pazopanib following nivolumab.
Topics: Aged; Fatal Outcome; Female; Humans; Indazoles; Methylprednisolone; Nivolumab; Pancreatitis; Pyrimidines; Sulfonamides | 2021 |
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States | 2020 |
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Topics: Adult; Aged; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indazoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Protective effects of taxifolin on pazopanib-induced liver toxicity: an experimental rat model.
Topics: Animals; Chemical and Drug Induced Liver Injury; Indazoles; Liver; Male; Protective Agents; Pyrimidines; Quercetin; Rats; Rats, Wistar; Sulfonamides | 2021 |
Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.
Topics: Antineoplastic Agents; Axitinib; Caspases; HMGB1 Protein; Humans; Indazoles; Indoles; Inflammasomes; Interleukin-1beta; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; THP-1 Cells | 2021 |
Scrotal erythema and geographic tongue subsequent to multikinase inhibiting therapy with Pazopanib.
Topics: Erythema; Glossitis, Benign Migratory; Humans; Indazoles; Pyrimidines; Sulfonamides | 2021 |
Postmarketing observational study of pazopanib in patients with metastatic soft tissue sarcoma in Japan.
Topics: Adolescent; Adult; Aged; Female; Humans; Incidence; Indazoles; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome; Young Adult | 2021 |
Panniculitis in a patient with metastatic renal cell carcinoma on a tyrosine kinase inhibitor.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Panniculitis; Pyrimidines; Sulfonamides | 2021 |
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Female; Gemcitabine; Health Records, Personal; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Treatment Outcome; United States; Young Adult | 2021 |
Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
Topics: Adult; Aged; Appetite; Fatigue; Female; Humans; Indazoles; Lebanon; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Tertiary Care Centers; Young Adult | 2021 |
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Indazoles; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Pyrimidines; Retrospective Studies; Skin Neoplasms; Sulfonamides; Survival Rate | 2021 |
Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Carcinoma, Renal Cell; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Karnofsky Performance Status; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nephrectomy; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2021 |
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Female; Humans; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinolines; Retrospective Studies; Sulfonamides; Survival Rate; Treatment Outcome | 2021 |
Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma.
Topics: Cost-Benefit Analysis; Humans; Indazoles; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2022 |
Is there association between clinically relevant toxicities of pazopanib and sunitinib with the use of weak CYP3A4 and P-gp inhibitors?
Topics: Cytochrome P-450 CYP3A; Humans; Indazoles; Pyrimidines; Sulfonamides; Sunitinib | 2021 |
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; B7-H1 Antigen; Female; Humans; Indazoles; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides | 2021 |
Symptomatic Sinus Bradycardia in a Patient with Solitary Fibrous Tumor/Hemangiopericytoma Treated with Pazopanib.
Topics: Bradycardia; Hemangiopericytoma; Humans; Indazoles; Male; Neoplasm Recurrence, Local; Pyrimidines; Solitary Fibrous Tumors; Sulfonamides | 2021 |
Biomolecular interaction mechanism of an anticancer drug, pazopanib with human serum albumin: a multi-spectroscopic and computational approach.
Topics: Antineoplastic Agents; Binding Sites; Circular Dichroism; Diazepam; Humans; Indazoles; Molecular Docking Simulation; Phenylbutazone; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Serum Albumin, Human; Spectrometry, Fluorescence; Sulfonamides; Thermodynamics; Warfarin | 2022 |
[RENAL CELL CARCINOMA METASTASIS TO BLADDER DURING MOLECULAR TARGETED THERAPY WITH PAZOPANIB: REPORT OF TWO CASES].
Topics: Aged; Carcinoma, Renal Cell; Combined Modality Therapy; Cystectomy; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Pyrimidines; Sulfonamides; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
Topics: Adolescent; Animals; Antibiotics, Antineoplastic; Bone Neoplasms; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Everolimus; Female; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Osteosarcoma; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; TOR Serine-Threonine Kinases | 2021 |
Targeted therapy in Xp11 translocation renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Crizotinib; Disease Progression; Everolimus; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Nivolumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib; Tomography, X-Ray Computed | 2021 |
Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021;79:33
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Nephrectomy; Pyrimidines; Sulfonamides; Survival Analysis | 2021 |
Pazopanib-associated secondary adrenal insufficiency in a patient with malignant solitary fibrous tumor.
Topics: Adrenal Insufficiency; Aged; Humans; Indazoles; Male; Pyrimidines; Solitary Fibrous Tumors; Sulfonamides | 2021 |
Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation.
Topics: Aged; Esthesioneuroblastoma, Olfactory; Female; Fumarate Hydratase; Humans; Indazoles; Mutation; Nasal Cavity; Neoplasm Recurrence, Local; Nose Neoplasms; Pyrimidines; Remission Induction; Retreatment; Sulfonamides; Time Factors | 2021 |
Inhibition of Lipid Accumulation and Cyclooxygenase-2 Expression in Differentiating 3T3-L1 Preadipocytes by Pazopanib, a Multikinase Inhibitor.
Topics: 3T3-L1 Cells; Adenylate Kinase; Adipocytes; Adipogenesis; Animals; CCAAT-Enhancer-Binding Protein-alpha; Cell Death; Cell Differentiation; Cell Proliferation; Cyclooxygenase 2; Fatty Acid Synthases; Glycerol; Indazoles; Leptin; Lipid Metabolism; Mice; Perilipin-1; Phosphorylation; PPAR gamma; Protein Kinase Inhibitors; Pyrimidines; Resistin; RNA, Messenger; STAT3 Transcription Factor; Sterol Esterase; Sulfonamides; Triglycerides; Tumor Necrosis Factor-alpha | 2021 |
Switching on prodrugs using radiotherapy.
Topics: Animals; Antineoplastic Agents; Azides; Doxorubicin; Female; Fluorescent Dyes; Gamma Rays; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oxidation-Reduction; Prodrugs; Proof of Concept Study; Pyrimidines; Sulfonamides; X-Rays; Xenograft Model Antitumor Assays | 2021 |
Radiation recall myositis caused by pazopanib in a patient with refractory osteosarcoma.
Topics: Humans; Indazoles; Myositis; Osteosarcoma; Pyrimidines; Sulfonamides | 2021 |
Use of Physiologically Based Pharmacokinetic Modeling for Predicting Drug-Food Interactions: Recommendations for Improving Predictive Performance of Low Confidence Food Effect Models.
Topics: Administration, Oral; Area Under Curve; Benzilates; Biological Availability; Computer Simulation; Food-Drug Interactions; Gastric Emptying; Healthy Volunteers; Humans; Indazoles; Intestinal Absorption; Models, Biological; Nortropanes; Piperazines; Pyrimidines; Solubility; Sulfonamides; Thiazoles | 2021 |
EHA 2021 Virtual Congress.
Topics: Activin Receptors, Type II; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; beta-Thalassemia; Graft vs Host Disease; Hematologic Diseases; Humans; Immunoglobulin Fc Fragments; Indazoles; Interleukin-1 Receptor-Associated Kinases; Internet; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Multiple Myeloma; Protein Kinase Inhibitors; Pyrimidines; Recombinant Fusion Proteins; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic | 2021 |
Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib.
Topics: Adult; Carcinoma, Renal Cell; Chromosomes, Human, X; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; Translocation, Genetic | 2021 |
Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Immunomodulation; Indazoles; Kidney Neoplasms; Male; Myeloid-Derived Suppressor Cells; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Transcriptome; Tumor Cells, Cultured; Tumor Microenvironment | 2021 |
Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2021 |
[Capillary and cutaneous hypopigmentation secondary to pazopanib].
Topics: Humans; Hypopigmentation; Indazoles; Pyrimidines; Sulfonamides | 2022 |
[Pneumothorax during Pazopanib Therapy in a Patient with Soft Tissue Sarcoma].
Topics: Aged; Humans; Indazoles; Kidney Neoplasms; Male; Pneumothorax; Pyrimidines; Sarcoma; Sulfonamides | 2021 |
Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Incidence; Indazoles; Lung; Lung Neoplasms; Male; Middle Aged; Pleura; Pneumothorax; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Soft Tissue Neoplasms; Sulfonamides; Time Factors | 2021 |
Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia.
Topics: Anemia; Epistaxis; Humans; Indazoles; Pyrimidines; Retrospective Studies; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic | 2022 |
Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line.
Topics: Aged; Carcinoma, Renal Cell; Cardiovascular Agents; Disease-Free Survival; Humans; Indazoles; Indoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2021 |
Pazopanib-induced chylothorax in a patient with renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Chylothorax; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides | 2022 |
Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Design; Histone Deacetylase Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; Hydroxamic Acids; Indazoles; Mice; Microsomes, Liver; Pyrimidines; Rats; Rats, Sprague-Dawley; Sulfonamides; Vascular Endothelial Growth Factors; Vorinostat | 2022 |
Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disseminated Intravascular Coagulation; Humans; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nivolumab; Pyrimidines; Sulfonamides | 2022 |
Sensitive quantification of free pazopanib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and assessment of clinical application.
Topics: Chromatography, High Pressure Liquid; Humans; Indazoles; Pyrimidines; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry | 2021 |
PTCH1-GLI1 Fusion-Positive Ovarian Tumor: Report of a Unique Case With Response to Tyrosine Kinase Inhibitor Pazopanib.
Topics: Female; Gene Fusion; Hedgehog Proteins; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Zinc Finger Protein GLI1 | 2021 |
Dangerous interaction of bitter melon (
Topics: Acute Disease; Aged; Herb-Drug Interactions; Humans; Indazoles; Male; Momordica charantia; Pancreatitis; Plant Extracts; Pyrimidines; Sulfonamides | 2022 |
Leptomeningeal Dissemination of Low-Grade Neuroepithelial Tumor with FGFR1_TACC1 Fusion with Clinical and Radiographic Response to Pazopanib and Topotecan.
Topics: Fetal Proteins; Humans; Indazoles; Male; Microtubule-Associated Proteins; Neoplasms, Neuroepithelial; Nuclear Proteins; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Sulfonamides; Topotecan | 2022 |
Novel Bile Acid-Dependent Mechanisms of Hepatotoxicity Associated with Tyrosine Kinase Inhibitors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; Bile Acids and Salts; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cholesterol 7-alpha-Hydroxylase; Dasatinib; Hepatocytes; Humans; Indazoles; Organic Anion Transporters, Sodium-Dependent; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Symporters | 2022 |
Pazopanib-induced severe acute liver injury: A case report.
Topics: Bilirubin; Biopsy; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Female; Hepatitis B; Humans; Indazoles; Jaundice; Kidney Neoplasms; Middle Aged; Nausea; Pyrimidines; Steroids; Sulfonamides; Tomography, X-Ray Computed; Ultrasonography; United States; Vomiting | 2021 |
Binding Mechanism between Acetylcholinesterase and Drugs Pazopanib and Lapatinib: Biochemical and Biophysical Studies.
Topics: Acetylcholinesterase; Binding Sites; Indazoles; Lapatinib; Pharmaceutical Preparations; Protein Binding; Pyrimidines; Sulfonamides; Thermodynamics | 2021 |
Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites.
Topics: Aged; Ascites; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Humans; Indazoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome | 2022 |
Improvement of Cutaneous Hereditary Hemorrhagic Telangiectasia With Pazopanib-A Multikinase Inhibitor.
Topics: Humans; Indazoles; Pyrimidines; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic | 2022 |
Prognostic Importance of Inflammatory Indexes in Patients Treated by Pazopanib for Soft Tissue Sarcoma.
Topics: Humans; Indazoles; Lymphocytes; Neutrophils; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides | 2022 |
Efficacy of Pazopanib in the Treatment of Metastatic Malignant Giant Cell Tumor of Soft Tissue: A Case Report.
Topics: Aged; Female; Giant Cell Tumors; Humans; Indazoles; Pyrimidines; Sulfonamides | 2022 |
Gene expression-based prediction of pazopanib efficacy in sarcoma.
Topics: Gene Expression; Humans; Indazoles; Prospective Studies; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Young Adult | 2022 |
Pazopanib restricts small cell lung cancer proliferation via reactive oxygen species-mediated endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum Stress; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Pyrimidines; Reactive Oxygen Species; Small Cell Lung Carcinoma; Sulfonamides | 2022 |
Pazopanib Is a Potential Treatment for Coronavirus-Induced Lung Injuries.
Topics: Animals; COVID-19 Drug Treatment; Indazoles; Lung; Lung Injury; Mice; Murine hepatitis virus; Pyrimidines; Sulfonamides | 2022 |
Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety.
Topics: Amino Acids; Antineoplastic Agents; Carcinoma, Renal Cell; Glycerophospholipids; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2022 |
Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.
Topics: Anilides; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Nerve Growth Factors; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinolines; src-Family Kinases; Sulfonamides; Sunitinib | 2022 |
Bilateral Significant Pneumotorax During Pazopanib Treatment.
Topics: Humans; Indazoles; Pyrimidines; Sulfonamides | 2023 |
Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response.
Topics: Humans; Indazoles; Pyrimidines; Sarcoma; Sulfonamides | 2023 |
[Pilonidal sinus disease and hidradenitis suppurativa due to Pazopanib].
Topics: Hidradenitis Suppurativa; Humans; Indazoles; Pilonidal Sinus; Pyrimidines | 2023 |
Small Bowel Lipomatosis: An Unusual Radiological Finding in Patients With Renal Cell Cancer on Pazopanib.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Lipomatosis; Protein Kinase Inhibitors; Sunitinib | 2023 |
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; East Asian People; Humans; Indazoles; Kidney Neoplasms; Sarcoma; Soft Tissue Neoplasms | 2023 |
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |
Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib | 2023 |
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
Topics: Adult; Female; Humans; Indazoles; Leiomyosarcoma; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Turkey | 2023 |
Right ventricular myocarditis and rapid fibrosis induced by pazopanib.
Topics: Fibrosis; Humans; Indazoles; Myocarditis; Myocardium | 2023 |
Pharmacist-Urologist Collaborative Management for Patients with Renal Cell Carcinoma Receiving Pazopanib Monotherapy.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pharmacists; Retrospective Studies; Treatment Outcome; Urologists | 2023 |
Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer.
Topics: Carcinoma, Renal Cell; Humans; Immune Checkpoint Inhibitors; Indazoles; Kidney Neoplasms | 2023 |